

Approved



Kenya
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		869,556		869,556	1,106,681	1,976,237
USAID		228,843,873		228,843,873	33,334,209	262,178,082
DOD		3,671,865		3,671,865	12,291,863	15,963,728
HHS/CDC	3,320,000	170,558,758		173,878,758	3,770,926	177,649,684
HHS/HRSA		2,088,269		2,088,269	0	2,088,269
State/SGAC		35,480,000		35,480,000	10,000,000	45,480,000
State/AF				0	144,000	144,000
Total	3,320,000	441,512,321	0	444,832,321	60,647,679	505,480,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							Total
	State	DOD	HHS/CDC	HHS/HRSA	State/AF	State/SGAC	USAID	
CIRC		142,194	9,996,408	0	0	5,000,000	3,459,149	18,597,751
HBHC		18,046	0	0	0	0	6,143,664	6,161,710
HKID		519,185	4,764,870	412,753	0	0	26,747,954	32,444,762
HLAB		83,779	8,763,938	281,979	0	0	1,142,510	10,272,206
HMBL		0	1,446,947	0	0	0	12,774	1,459,721
HMIN		0	1,324,642	0	0	0	12,774	1,337,416
HTXD		0	0	0	0	0	71,640,788	71,640,788
HTXS		1,084,101	66,585,850	0	0	18,288,000	59,314,242	145,272,193
HVAB		0	977,346	282,445	0	0	2,476,711	3,736,502
HVCT		164,631	20,365,591	0	0	12,192,000	11,385,792	44,108,014
HVMS	869,556	471,788	6,543,585				8,929,190	16,814,119

Approved



HVOP		431,450	19,062,909	573,450	0	0	13,866,659	33,934,468
HVSI		435,527	10,085,541	450,000	0	0	3,659,615	14,630,683
HVTB		22,060	7,436,690	0	0	0	2,587,703	10,046,453
IDUP		0	989,147	0	0	0	655,525	1,644,672
MTCT		175,740	7,415,171	0	0	0	8,402,997	15,993,908
OHSS		0	1,818,235	87,642	0	0	2,633,646	4,539,523
PDCS		18,491	0	0	0	0	1,399,140	1,417,631
PDTX		104,873	6,301,888	0	0	0	4,373,040	10,779,801
	869,556	3,671,865	173,878,758	2,088,269	0	35,480,000	228,843,873	444,832,321



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	5,846,013
HKID	31,795,843
HVTB	9,951,460
PDCS	1,098,936
Total Technical Area Planned Funding:	48,692,252

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	9,576,662
HVSI	13,408,548
OHSS	4,010,300
Total Technical Area Planned Funding:	26,995,510

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	18,037,456
HMBL	1,339,140
HMIN	1,216,835
HVAB	3,560,210
HVCT	42,888,510
HVOP	32,976,827
IDUP	1,404,521
MTCT	15,436,055
Total Technical Area Planned Funding:	116,859,554

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	71,501,549
HTXS	141,748,276
PDTX	10,408,375
Total Technical Area Planned Funding:	223,658,200

Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	98 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,150,747
	Number of new ANC and L&D clients	1,177,861
	By Age (Denominator): <10	30
	By Age (Denominator): 10-14	4,272
	By Age (Denominator): <15-19	152,730
	By Age (Denominator): 20-24	405,744
	By Age (Denominator): 50+	3,862
	By Number of known positives: 10-14	34
	By Number of known positives: 15-19	2,330
	By Number of known positives: 20-24	10,515
	By Number of known positives: 50+	10
	By Number of new positives: 10-14	47
	By Number of new positives: 15-19	2,951
	By Number of new positives: 20-24	7,647
	By Number of new positives: 50+	35
By Number of new negative: <10	13	
By Number of new negative: 10-14	2,532	



	By Number of new negative: 15-19	132,507
	By Number of new negative: 20-24	370,535
	By Number of new negative: 50+	2,580
	By Age (Numerator): <10	13
	By Age (Numerator): 10-14	2,607
	By Age (Numerator): 15-19	138,302
	By Age (Numerator): 20-24	389,592
	By Age (Numerator): 50+	2,662
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	153,981
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	154,024
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	153,600
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	149,618
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	7,543
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	146,624
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	2,694
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	7,524
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	147,411
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	2,695



	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	7,531
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	142,680
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	2,690
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	7,433
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	142,087
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	2,689
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	157,686
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	157,709
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	153,319
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	152,542
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	98 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	42,143



	Number of new ANC and L&D clients	43,055
	By Age (Denominator): 10-14	6
	By Age (Denominator): 15-19	7,691
	By Age (Denominator): 20-24	13,023
	By Age (Denominator): 50+	5
	By known positives: 15-19	6
	By known positives: 20-24	35
	By new positives: 15-19	35
	By new positives: 20-24	72
	By new positives: 50+	1
	By new negatives: 10-14	11
	By new negatives: 15-19	3,817
	By new negatives: 20-24	8,046
	By new negatives: 50+	79
	By Age (Numerator): 10-14	11
	By Age (Numerator): : 15-19	3,861
	By Age (Numerator): 20-24	8,138
	By Age (Numerator): 50+	80
	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	5,561
	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	5,561
	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	5,601
	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	5,607
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Known at Entry Positive	43
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Negative	7,476



PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Positive	56
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Known at Entry Positive	43
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Negative	7,503
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Positive	55
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Known at Entry Positive	43
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Negative	7,536
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Positive	55
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Known at Entry Positive	43
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Newly Identified Negative	7,253
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Newly Identified Positive	54
PMTCT_STAT_N_TA_Age_Sex 25-29, Female	7,564
PMTCT_STAT_N_TA_Age_Sex 30-34, Female	7,568
PMTCT_STAT_N_TA_Age_Sex	7,619



	35-39, Female	
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	7,342
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	59,790
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,150,747
	New on ART	19,769
	Already on ART at beginning of current pregnancy	40,021
	PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy
Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy		560
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		42,143
New on ART		327



	Already on ART at beginning of current pregnancy	233
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	8,249
	Sex: Male	6,398
	Sex: Female	1,851
	Sum of Sex disaggregates	8,249
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	300,051
	By Age: 0-60 days	4,145
	By Age: 2 months - 9 years	1,182
	By Age: 10-14	177,862
	By Age: 15-19	78,363
	By Age: 20-24	25,846
	By Age: 25-29	12,619
	By Age: 50+	312
	By circumcision technique: Surgical VMMC	272,635
	By circumcision technique: Device-based VMMC	2,031
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	507
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	507
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	507



PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	31,001
	Male 15-19	302
	Male 20-24	1,807
	Male 50+	602
	Female 15-19	3,659
	Female 20-24	12,703
	Female 50+	606
	FSW	4,791
	MSM	2,205
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	2,125
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	922
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	1,556
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	1,263
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	1,535
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	1,234
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	1,538
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	920



PrEP_NEW_TA	PrEP_NEW_TA Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	46
	Male 20-24	2
	Female 15-19	6
	Female 20-24	19
	FSW	6
	MSM	2
	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	2
	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	2
	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	1
	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	2
	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	1
	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	2
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population	325,522



	who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	
	Age/sex: 10-14 Male	4,732
	Age/sex: 15-19 Male	18,327
	Age/sex: 20-24 Male	25,644
	Age/sex: 50+ Male	5,317
	Age/sex: 10-14 Female	36,244
	Age/sex: 15-19 Female	63,301
	Age/sex: 20-24 Female	48,868
	Age/sex: 50+ Female	4,708
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	10,031
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	18,725
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	10,072
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	17,370
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	10,096
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	16,325
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	10,072
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	16,325
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a



	<p>Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required</p>	<p>294,784</p>
	<p>By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>17,902</p>
	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>12,417</p>
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>186,575</p>
	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are</p>	<p>14,576</p>



	based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,476
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	61,838
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	718
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions	250



	that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	468
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	103,037
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,302
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	28
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,306
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	29
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	505
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	516
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	9
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,064
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	41



	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,765
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	31
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	83
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	67
	Service Delivery Point (Facility) Inpatient: <1, Negative	26
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	714
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	13
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	71
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	65
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	246
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	3
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	206



	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	3
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	8
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	7
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	196
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	3
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	165
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,497
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	63
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,699
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	93
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	10,594
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	313



	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	8,166
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	211
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	264
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	7
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	501
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	12
	Service Delivery Point (Facility) Other PITC: <1, Negative	374
	Service Delivery Point (Facility) Other PITC: <1, Positive	1
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	808
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	3
	Service Delivery Point (Facility) Pediatric : <5 Negative	14
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	60
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	6
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	54
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	6
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	87
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	10



Service Delivery Point (Facility) TB: 15-19, Male, Negative	111
Service Delivery Point (Facility) TB: 15-19, Male, Positive	12
Service Delivery Point (Facility) TB: 20-24, Female, Negative	89
Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
Service Delivery Point (Facility) TB: 20-24, Male, Negative	110
Service Delivery Point (Facility) TB: 20-24, Male, Positive	14
Service Delivery Point (Facility) TB: 50+, Female, Negative	69
Service Delivery Point (Facility) TB: 50+, Female, Positive	10
Service Delivery Point (Facility) TB: 50+, Male, Negative	117
Service Delivery Point (Facility) TB: 50+, Male, Positive	16
Service Delivery Point (Facility) TB: 1-9, Negative	44
Service Delivery Point (Facility) TB: 1-9, Positive	6
Service Delivery Point (Facility) VMC: 10-14, Negative	123
Service Delivery Point (Facility) VMC: 15-19, Negative	185
Service Delivery Point (Facility) VMC: 20-24, Negative	185
Service Delivery Point (Facility) Index: 10-14, Female, Negative	62
Service Delivery Point (Facility) Index: 10-14, Male, Negative	26



Service Delivery Point (Facility) Index: 15-19, Female, Negative	193
Service Delivery Point (Facility) Index: 15-19, Female, Positive	52
Service Delivery Point (Facility) Index: 15-19, Male, Negative	101
Service Delivery Point (Facility) Index: 15-19, Male, Positive	33
Service Delivery Point (Facility) Index: 20-24, Female, Negative	649
Service Delivery Point (Facility) Index: 20-24, Female, Positive	179
Service Delivery Point (Facility) Index: 20-24, Male, Negative	650
Service Delivery Point (Facility) Index: 20-24, Male, Positive	114
Service Delivery Point (Facility) Index: 50+, Female, Negative	28
Service Delivery Point (Facility) Index: 50+, Female, Positive	8
Service Delivery Point (Facility) Index: 50+, Male, Negative	9
Service Delivery Point (Facility) Index: <1, Negative	32
Service Delivery Point (Facility) Index: 1-9, Negative	218
Service Delivery Point (Facility) Index: 1-9, Positive	2
By Key Population: FSW, Negative	463
By Key Population: FSW, Positive	7
By Key Population: MSM, Negative	2
Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1
Service Delivery Point (Facility)	18



	ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 15-19, Negative	7,359
	Service Delivery Point (Facility) ANC: 15-19, Positive	29
	Service Delivery Point (Facility) ANC: 20-24, Negative	13,794
	Service Delivery Point (Facility) ANC: 20-24, Positive	130
	Service Delivery Point (Facility) ANC: 50+, Negative	228
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	104
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	19
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,662
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	31
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,042
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	24
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	6,105
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	107
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3,569
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	78
	Service Delivery Point (Facility)	309



VCT: 50+, Female, Negative	
Service Delivery Point (Facility)	3
VCT: 50+, Female, Positive	
Service Delivery Point (Facility)	161
VCT: 50+, Male, Negative	
Service Delivery Point (Facility)	3
VCT: 50+, Male, Positive	
Service Delivery Point (Facility)	33
VCT: <1, Negative	
Service Delivery Point (Facility)	151
VCT: 1-9, Negative	
Service Delivery Point (Facility)	2
VCT: 1-9, Positive	
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Negative	234
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Positive	64
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Negative	38
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Positive	11
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Negative	261
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Positive	70
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Negative	48
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Positive	9
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Negative	71
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Positive	14
HTS_TST_N_TA_Index_Age_Sex_	45



	Result 35-39, Male, Negative	
	HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Positive	10
	HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Negative	68
	HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Positive	13
	HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Negative	16
	HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Positive	5
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Negative	633
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Positive	10
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Negative	309
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Positive	3
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Negative	608
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Positive	11
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Negative	360
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Positive	5
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Negative	147
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Positive	2
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Negative	373
	HTS_TST_N_TA_Inpat_Age_Sex_	5



	Result 35-39, Male, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Negative	156
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Positive	1
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Negative	118
	HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Positive	1
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 25-29, Female, Negative	58
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 25-29, Female, Positive	1
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 25-29, Male, Negative	35
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 30-34, Female, Negative	67
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 30-34, Female, Positive	1
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 30-34, Male, Negative	42
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 35-39, Female, Negative	16
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 35-39, Male, Negative	42
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 40-49, Female, Negative	16
	HTS_TST_N_TA_MbMod_Age_Sex_ Result 40-49, Male, Negative	14
	HTS_TST_N_TA_NdxMod_Age_Sex_ Result 30-34, Male, Negative	1
	HTS_TST_N_TA_NdxMod_Age_Sex_ Result 35-39, Male, Negative	1
	HTS_TST_N_TA_OtPITC_Age_Sex_	1,298



x_Result 25-29, Female, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	27
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	3,015
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	72
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,500
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	33
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	3,584
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	99
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	547
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	14
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,868
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	71
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	549
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	15
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	950
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	20
HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	9,309
HTS_TST_N_TA_PMTCT_Age_Sex	107



	x_Result 25-29, Female, Positive	
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	8,060
	x_Result 30-34, Female, Negative	
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	52
	x_Result 30-34, Female, Positive	
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	6,386
	x_Result 35-39, Female, Negative	
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	46
	x_Result 35-39, Female, Positive	
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	4,751
	x_Result 40-49, Female, Negative	
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	11
	x_Result 40-49, Female, Positive	
	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	128
	x_Result 15-19, Female, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	74
	x_Result 15-19, Male, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	476
	x_Result 20-24, Female, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	260
	x_Result 20-24, Male, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	124
	x_Result 25-29, Female, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	56
	x_Result 25-29, Male, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	145
	x_Result 30-34, Female, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	68
	x_Result 30-34, Male, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	31
	x_Result 35-39, Female, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	65
	x_Result 35-39, Male, Negative	
	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	30



	result 40-49, Female, Negative	
	HTS_TST_N_TA_STI_Age_Sex_R result 40-49, Male, Negative	17
	HTS_TST_N_TA_STI_Age_Sex_R result 50+, Female, Negative	13
	HTS_TST_N_TA_STI_Age_Sex_R result 50+, Male, Negative	7
	HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Female, Negative	89
	HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Female, Positive	10
	HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Male, Negative	110
	HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Male, Positive	14
	HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Negative	79
	HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Positive	10
	HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Negative	118
	HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Positive	15
	HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Negative	96
	HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Positive	13
	HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Negative	171
	HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Positive	21
	HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Female, Negative	72
	HTS_TST_N_TA_TBC_Age_Sex_	11



	Result 40-49, Female, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	145
	Result 40-49, Male, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	20
	Result 40-49, Male, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	2,303
	Result 25-29, Female, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	43
	Result 25-29, Female, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	834
	Result 25-29, Male, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	12
	Result 25-29, Male, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	2,667
	Result 30-34, Female, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	45
	Result 30-34, Female, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	994
	Result 30-34, Male, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	15
	Result 30-34, Male, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	595
	Result 35-39, Female, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	9
	Result 35-39, Female, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	975
	Result 35-39, Male, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	16
	Result 35-39, Male, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	627
	Result 40-49, Female, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	8
	Result 40-49, Female, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	330



	Result 40-49, Male, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	4
	Result 40-49, Male, Positive	
	HTS_TST_N_TA_VMMC_Age_Sex_	123
	Result 25-29, Male, Negative	
HTS_SELF_TA	HTS_SELF_N_TA	1,254
	HTS_SELF_N_TA_Age_Sex_HIVS	
	elfTest 15-19, Female, Directly-Assisted	67
	HTS_SELF_N_TA_Age_Sex_HIVS	
	elfTest 15-19, Female, Unassisted	67
	HTS_SELF_N_TA_Age_Sex_HIVS	
	elfTest 15-19, Male, Directly-Assisted	22
	HTS_SELF_N_TA_Age_Sex_HIVS	
	elfTest 15-19, Male, Unassisted	22
	HTS_SELF_N_TA_Age_Sex_HIVS	
	elfTest 20-24, Female, Directly-Assisted	66
	HTS_SELF_N_TA_Age_Sex_HIVS	
	elfTest 20-24, Female, Unassisted	66
HTS_SELF_N_TA_Age_Sex_HIVS		
elfTest 20-24, Male, Directly-Assisted	22	
HTS_SELF_N_TA_Age_Sex_HIVS		
elfTest 20-24, Male, Unassisted	22	
HTS_SELF_N_TA_Age_Sex_HIVS		
elfTest 25-29, Female, Directly-Assisted	66	
HTS_SELF_N_TA_Age_Sex_HIVS		
elfTest 25-29, Female, Unassisted	66	
HTS_SELF_N_TA_Age_Sex_HIVS		
elfTest 25-29, Male, Directly-Assisted	22	



HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Male, Unassisted	21
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Female, Directly-Assisted	66
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Female, Unassisted	66
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Male, Directly-Assisted	22
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Male, Unassisted	21
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Female, Directly-Assisted	66
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Female, Unassisted	66
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Male, Directly-Assisted	22
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Male, Unassisted	21
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Female, Directly-Assisted	66
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Female, Unassisted	66
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Male, Directly-Assisted	22
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Male, Unassisted	21
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 50+, Female, Directly-Assisted	66



	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	66
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	22
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	22
	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	627
	HTS_SELF_N_TA_HIVSelfTest Unassisted	627
	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	65
	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	316
	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	252
	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	866
	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	192
	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	76
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	58,851
	Total number of registered new and relapsed TB cases, during the reporting period.	59,112



	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,535
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32,308
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,701
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21,299
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,509
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	32,666
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,777
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	21,171



TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	99 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,235
	Total number of registered new and relapsed TB cases, during the reporting period.	1,247
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	296
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	196
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	444
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	302
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	196
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered	301



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	296
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	436
HTS_SELF_DSD	HTS_SELF_N_DSD	393,312
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	201
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Unassisted	26
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	21,081
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	21,060
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	6,989
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	7,008
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	20,962
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female,	21,048



	Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	6,998
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	7,017
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	21,070
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	21,051
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	6,993
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	7,014
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	21,078
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	21,060
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	7,008
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	7,026
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	21,094
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	21,073
	HTS_SELF_N_DSD_Age_Sex_HI	6,993



	VSelfTest 35-39, Male, Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	7,012
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	21,072
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	21,050
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	6,994
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	7,012
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	21,076
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	21,056
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	6,994
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	7,228
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	196,817
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	196,495
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Other	19,763
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	98,342
	HTS_SELF_N_DSD_HIVSelfTestU	78,906



	ser Unassisted - Sex Partner	
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Directly-Assisted	261,897
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	73
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Directly-Assisted	58,580
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest People in prisons and other enclosed settings, Unassisted	30
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest PWID, Directly-Assisted	23,148
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,021,094
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,522
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	19
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,219
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	13
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	34,519
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	600
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	22,136
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	405
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	118,829



	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2,170
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	70,827
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1,290
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	4,140
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	75
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,712
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	56
	Service Delivery Point (Facility) Inpatient: <1, Negative	5,121
	Service Delivery Point (Facility) Inpatient: <1, Positive	47
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	12,577
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	103
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	12,433
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	239
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	9,154
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	189



	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	42,816
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	806
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	29,467
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	599
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	926
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	5
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,580
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	27
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	28,141
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	312
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	25,014
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	225
	Service Delivery Point (Facility) Other PITC: 15-19, Female,	237,118



	Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	4,720
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	345,876
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	6,920
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,164,325
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	23,359
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	783,172
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	15,571
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	35,950
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	724
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	42,946
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	738
	Service Delivery Point (Facility)Other PITC: <1, Negative	50,245
	Service Delivery Point (Facility) Other PITC: <1, Positive	405
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	129,710
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,249



	Service Delivery Point (Community) Other: 15-19, Female, Negative	2,396
	Service Delivery Point (Community) Other: 15-19, Female, Positive	19
	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,953
	Service Delivery Point (Community) Other: 15-19, Male, Positive	16
	Service Delivery Point (Community) Other: 20-24, Female, Negative	8,250
	Service Delivery Point (Community) Other: 20-24, Female, Positive	65
	Service Delivery Point (Community) Other: 20-24, Male, Negative	6,265
	Service Delivery Point (Community) Other: 20-24, Male, Positive	50
	Service Delivery Point (Community) Other: 50+, Female, Negative	11
	Service Delivery Point (Community) Other: 50+, Male, Negative	308
	Service Delivery Point (Community) Other: 50+, Male, Positive	2
	Service Delivery Point (Facility) Pediatric : <5 Negative	54,116
	Service Delivery Point (Facility) Pediatric : <5 Positive	232
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1,417
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	290
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1,306
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	274



	Service Delivery Point (Facility) TB: 15-19, Female, Negative	2,107
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	442
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	2,584
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	546
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2,104
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	458
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2,592
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	551
	Service Delivery Point (Facility) TB: 50+, Female, Negative	1,685
	Service Delivery Point (Facility) TB: 50+, Female, Positive	343
	Service Delivery Point (Facility) TB: 50+, Male, Negative	3,009
	Service Delivery Point (Facility) TB: 50+, Male, Positive	650
	Service Delivery Point (Facility) TB: 1-9, Negative	1,155
	Service Delivery Point (Facility) TB: 1-9, Positive	232
	Service Delivery Point (Facility) VMC: 10-14, Negative	34,773
	Service Delivery Point (Facility) VMC: 10-14, Positive	72
	Service Delivery Point (Facility) VMC: 15-19, Negative	55,398



	Service Delivery Point (Facility) VMMC: 15-19, Positive	109
	Service Delivery Point (Facility) VMMC: 20-24, Negative	55,373
	Service Delivery Point (Facility) VMMC: 20-24, Positive	115
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	8,905
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	118
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	6,606
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	79
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	11,857
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2,517
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	8,544
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1,839
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	40,964
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	8,426
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	39,444
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	6,085
	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,289
	Service Delivery Point (Facility) Index: 50+, Female, Positive	281



	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,330
	Service Delivery Point (Facility) Index: 50+, Male, Positive	258
	Service Delivery Point (Facility) Index: <1, Negative	8,766
	Service Delivery Point (Facility) Index: <1, Positive	140
	Service Delivery Point (Facility) Index: 1-9, Negative	30,245
	Service Delivery Point (Facility) Index: 1-9, Positive	414
	By Key Population: FSW, Negative	114,577
	By Key Population: FSW, Positive	3,912
	By Key Population: MSM, Negative	13,287
	By Key Population: MSM, Positive	597
	By Key Population: People in prisons and other enclosed settings, Negative	58,863
	By Key Population: People in prisons and other enclosed settings, Positive	2,055
	By Key Population: PWID, Negative	5,500
	By Key Population: PWID, Positive	109
	By Key Population: TG, Negative	1
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	236
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	171
	Service Delivery Point (Community)	1,916



	Index Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	96
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,202
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	64
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	6,571
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	331
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3,862
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	204
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	151
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	4
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	162
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	9
	Service Delivery Point (Community) Index Mod: <1, Negative	212
	Service Delivery Point (Community) Index Mod: <1, Positive	1
	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,026
	Service Delivery Point (Community) Index Mod: 1-9, Positive	4
	Service Delivery Point (Facility)	4,245



	ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	19
	Service Delivery Point (Facility) ANC: 15-19, Negative	133,304
	Service Delivery Point (Facility) ANC: 15-19, Positive	1,368
	Service Delivery Point (Facility) ANC: 1-9, Negative	13
	Service Delivery Point (Facility) ANC: 20-24, Negative	369,776
	Service Delivery Point (Facility) ANC: 20-24, Positive	6,731
	Service Delivery Point (Facility) ANC: 50+, Negative	2,566
	Service Delivery Point (Facility) ANC: 50+, Positive	36
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	5,077
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	98
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	3,870
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	74
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	108,252
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	2,338
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	72,672
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1,668
	Service Delivery Point (Facility)	372,426



	VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility)	8,067
	VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility)	232,236
	VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility)	5,312
	VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility)	11,791
	VCT: 50+, Female, Negative	
	Service Delivery Point (Facility)	280
	VCT: 50+, Female, Positive	
	Service Delivery Point (Facility)	12,138
	VCT: 50+, Male, Negative	
	Service Delivery Point (Facility)	237
	VCT: 50+, Male, Positive	
	Service Delivery Point (Facility)	3,510
	VCT: <1, Negative	
	Service Delivery Point (Facility)	62
	VCT: <1, Positive	
	Service Delivery Point (Facility)	14,574
	VCT: 1-9, Negative	
	Service Delivery Point (Facility)	265
	VCT: 1-9, Positive	
	Service Delivery Point (Community)	1,398
	VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community)	12
	VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community)	1,041
	VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community)	16
	VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community)	4,819
	VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community)	108



VCT Mod: 20-24, Female, Positive	
Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	3,395
Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	65
Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	291
Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	2
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	83
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	9,028
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	1,985
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	6,793
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	1,446
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	10,329
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	2,257
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	8,142
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	1,725
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	2,568
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	563
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	8,144
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	1,726



x_Result 35-39, Male, Positive	
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	2,575
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	564
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	2,693
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	528
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	29,062
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	558
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	18,068
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	306
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	33,311
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	633
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	21,707
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	368
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	8,384
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	151
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	21,697
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	367
HTS_TST_N_DSD_Inpat_Age_Sex	8,339



	_Result 40-49, Female, Negative	
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	154
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	7,258
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	113
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	6,470
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	82
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	7,906
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	152
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	7,396
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	94
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	9,497
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	183
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	1,842
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	22
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	9,497



	Sex_Result 35-39, Male, Negative	
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Male, Positive	183
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Female, Negative	1,842
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Female, Positive	22
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Male, Negative	3,168
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Male, Positive	61
	HTS_TST_N_DSD_MN_Age_Sex_ Result <5, Unknown Sex, Negative	6,531
	HTS_TST_N_DSD_MN_Age_Sex_ Result <5, Unknown Sex, Positive	100
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Negative	1,034
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Positive	54
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Male, Negative	872
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Male, Positive	52
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Negative	1,181
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Positive	61
	HTS_TST_N_DSD_NdxMod_Age_	1,044



	Sex_Result 30-34, Male, Negative	
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Male, Positive	58
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Negative	293
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Positive	13
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Male, Negative	1,044
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Male, Positive	58
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Female, Negative	293
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Female, Positive	13
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Male, Negative	349
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Male, Positive	17
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Female, Negative	170,487
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Female, Positive	3,610
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Negative	277,283
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Positive	5,482
	HTS_TST_N_DSD_OtPITC_Age_	190,171



	Sex_Result 30-34, Female, Negative	
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive	4,040
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative	333,096
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive	6,600
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Negative	72,184
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive	1,468
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative	239,245
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive	4,671
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative	72,295
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Positive	1,473
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Negative	80,556
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Positive	1,533
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Negative	75
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Negative	1,536



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	13
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	87
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	1,845
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	15
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	21
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	1,845
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	15
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	21
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	614
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	5
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	142,375
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	9,798
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	142,130
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,598



HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	141,665
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1,353
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	141,542
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	891
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	7,196
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	17
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	4,369
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	11
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	24,897
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	76
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	13,971
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	49
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	4,593
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	17
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	4,280



HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	7
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	5,261
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	21
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	5,127
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	10
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	1,296
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	2
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	5,134
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	10
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	1,290
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	2
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	1,675
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	613
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	784
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	1,989



HTS_TST_N_DSD_TBC_Age_Sex _Result 25-29, Female, Positive	418
HTS_TST_N_DSD_TBC_Age_Sex _Result 25-29, Male, Negative	2,628
HTS_TST_N_DSD_TBC_Age_Sex _Result 25-29, Male, Positive	554
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Negative	1,801
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Positive	363
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Negative	2,847
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	594
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	2,219
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	453
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	3,972
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	847
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	1,779
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	356
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	3,685
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	782
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	81,655
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	2,040



HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	57,076
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	1,188
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	93,619
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	2,319
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	68,663
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	1,447
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	23,681
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	569
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	68,559
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	1,444
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	23,654
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	568
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	23,027
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	476
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	2,044
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	34



HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	414
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	12
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	2,338
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	39
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	500
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	13
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	586
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	11
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	500
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	13
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	586
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	11
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	167
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	4



	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	36,934
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	68
GEND_GBV_DSD	Number of people receiving post-GBV care	253,255
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	126,617
	By type of service: Sexual Violence (Post-Rape Care)	126,636
	By PEP service provision (related to sexual violence services provided)	74,723
	<10, Female, Physical and/or Emotional Violence	2,518
	<10, Female, Sexual Violence (Post-Rape Care)	2,517
	<10, Male, Physical and/or Emotional Violence	2,516
	<10, Male, Sexual Violence (Post-Rape Care)	2,513
	10-14, Female, Physical and/or Emotional Violence	7,622
	10-14, Female, Sexual Violence (Post-Rape Care)	7,654
	10-14, Male, Physical and/or Emotional Violence	2,514
	10-14, Male, Sexual Violence (Post-Rape Care)	2,514
	15-19, Female, Physical and/or Emotional Violence	25,293
	15-19, Female, Sexual Violence (Post-Rape Care)	25,390



	15-19, Male, Physical and/or Emotional Violence	2,517
	15-19, Male, Sexual Violence (Post-Rape Care)	2,518
	20-24, Female, Physical and/or Emotional Violence	35,410
	20-24, Female, Sexual Violence (Post-Rape Care)	35,385
	20-24, Male, Physical and/or Emotional Violence	2,520
	20-24, Male, Sexual Violence (Post-Rape Care)	2,516
	50+, Female, Physical and/or Emotional Violence	2,523
	50+, Female, Sexual Violence (Post-Rape Care)	2,517
	50+, Male, Physical and/or Emotional Violence	2,519
	50+, Male, Sexual Violence (Post-Rape Care)	2,504
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	7,568
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	7,563
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	2,519
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	2,517
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female,	7,960



	Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	7,808
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	2,520
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	2,516
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	7,562
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	7,553
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	2,523
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	2,515
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	7,536
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	7,534
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	2,520
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	2,517
GEND_GBV_TA	Number of people receiving	469



	post-GBV care	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	236
	By type of service: Sexual Violence (Post-Rape Care)	234
	By PEP service provision (related to sexual violence services provided)	221
	<10, Female, Physical and/or Emotional Violence	3
	<10, Female, Sexual Violence (Post-Rape Care)	3
	<10, Male, Physical and/or Emotional Violence	3
	<10, Male, Sexual Violence (Post-Rape Care)	3
	10-14, Female, Physical and/or Emotional Violence	14
	10-14, Female, Sexual Violence (Post-Rape Care)	14
	10-14, Male, Physical and/or Emotional Violence	3
	10-14, Male, Sexual Violence (Post-Rape Care)	3
	15-19, Female, Physical and/or Emotional Violence	48
	15-19, Female, Sexual Violence (Post-Rape Care)	48
	15-19, Male, Physical and/or Emotional Violence	3
	15-19, Male, Sexual Violence (Post-Rape Care)	3
	20-24, Female, Physical and/or	64



	Emotional Violence	
	20-24, Female, Sexual Violence (Post-Rape Care)	64
	20-24, Male, Physical and/or Emotional Violence	3
	20-24, Male, Sexual Violence (Post-Rape Care)	3
	50+, Female, Physical and/or Emotional Violence	3
	50+, Female, Sexual Violence (Post-Rape Care)	3
	50+, Male, Physical and/or Emotional Violence	3
	50+, Male, Sexual Violence (Post-Rape Care)	3
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	14
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	14
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	3
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	3
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	14
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	14
	GEND_GBV_N_TA_Age_Sex_Viol	3



	enceType_v3 30-34, Male, Physical and/or Emotional Violence	
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	3
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Female, Physical and/or Emotional Violence	14
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	14
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Male, Physical and/or Emotional Violence	3
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	3
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 40-49, Female, Physical and/or Emotional Violence	14
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	14
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 40-49, Male, Physical and/or Emotional Violence	3
	GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	3
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	794,950
	Age/Sex: 10-14 Male	106,263
	Age/Sex: 15-17 Male	70,745



	By: Age/sex: Male 18-24	49,629
	By: Age/sex: Male 25+	560
	Age/Sex: 10-14 Female	154,424
	Age/Sex: 15-17 Female	141,027
	By: Age/sex: 18-24 Female	90,959
	By: Age/sex: 25+ Female	5,941
	Sum of Age/Sex disaggregates	472,459
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	15,747
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	46,709
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	21,733
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	2
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1,295
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	6,937
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	513
	Required only for DREAMS countries - By service, age and	16,728



	sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	7,015
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	748
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	2,640
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	3,190
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	2,418
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	728
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	66
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,746
	Required only for DREAMS	4,933



	countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	4,924
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	1,856
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	581
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	304
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	1,331
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	5,728
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	10,726
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	689
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male	434



	15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	296
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	43,031
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	79,211
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	55,989
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	465
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	2,136
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1,546
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	604
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	11
	Age/Sex: <1	2,642
	Age/Sex: 1-9	170,495
	Program Completion: Active	789,284
	Program Completion: Graduation	5,666
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of	78 %



	orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	616,354
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	794,950
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	19,240
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10,350
	Aggregated Age/Sex: Female <15	22



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8,884
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	202
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	78
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	122



TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	84 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	153,099
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	181,859
	By Age/Sex (Denominator): <15, Female	8,962
	By Age/Sex (Denominator): <15, Male	13,159
	By Age/Sex (Denominator): 15+, Female	109,026
	By Age/Sex (Denominator): 15+, Male	50,392
	By Age/Sex (Numerator): <15, Female	7,898
	By Age/Sex (Numerator): <15, Male	10,519
	By Age/Sex (Numerator): 15+, Female	91,347
	By Age/Sex (Numerator): 15+, Male	42,955
	TB_PREV_D_DSD_TherapyType_ NewExArt_HIV Alternative TPT	3,116



	Regimen, Life-long ART, Already, Positive	
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2,102
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,745
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	173,898
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	2,927
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,959
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,042
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	13,634
TB_PREV_TA	TB_PREV_TA TB_PREV_TA	85 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	355
	The number of ART patients who were newly started on TB	418



	preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	20
	By Age/Sex (Denominator): <15, Male	10
	By Age/Sex (Denominator): 15+, Female	177
	By Age/Sex (Denominator): 15+, Male	211
	By Age/Sex (Numerator): <15, Female	17
	By Age/Sex (Numerator): <15, Male	8
	By Age/Sex (Numerator): 15+, Female	152
	By Age/Sex (Numerator): 15+, Male	180
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	418
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	1,266,654
	Denominator: By Aggregated Age/Sex: <15, Female	53,719



	Denominator: By Aggregated Age/Sex: <15, Male	73,953
	Denominator: By Aggregated Age/Sex:15+, Female	787,076
	Denominator: By Aggregated Age/Sex:15+, Male	351,601
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	68,165
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	8,433
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	57,128
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	7,004
	Denominator: By Aggregated Age/Sex: <15, Female	1,225
	Denominator: By Aggregated Age/Sex: <15, Male	590
	Denominator: By Aggregated Age/Sex: 15+, Female	3,576
	Denominator: By Aggregated Age/Sex: 15+, Male	1,620
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,334
	Denominator: By Diagnostic Test	200



	[Subdisagg of Specimen Sent]: Smear Only	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,067
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	8,530
	By infants who received a virologic test within 2 months of birth	305
	By infants who received their first virologic HIV test between 2 and 12 months of age	8,225
	Sum of Infant Age disaggregates	8,530
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	70
	By infants who received their first virologic HIV test between 2 and 12 months of age	70
	Sum of Infant Age disaggregates	70
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,266,615
	Age/Sex: 15-19 Male	19,994
	Age/Sex: 15-19 Female	35,910



	Age/Sex: <1	1,587
	Age/Sex: <1-9	47,587
	Age/Sex: 10-14 Male	20,917
	Age/Sex: 10-14 Female	22,610
	Age/Sex: 20-24 Male	26,602
	Age/Sex: 50+ Male	30,805
	Age/Sex: 20-24 Female	99,378
	Age/Sex: 50+ Female	79,254
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	192,631
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	52,774
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	145,468
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	82,395
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	145,446
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	82,139
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	99,060
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	82,143
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,006
	Age/Sex: 15-19 Male	216
	Age/Sex: 15-19 Female	295
	Sum of Age/Sex disaggregations	511
	Age/Sex: <1	53
	Age/Sex: 1-9	127
	Age/Sex: 10-14 Male	422



	Age/Sex: 10-14 Female	392
	Age/Sex: 20-24 Male	292
	Age/Sex: 50+ Male	95
	Age/Sex: 20-24 Female	819
	Age/Sex: 50+ Female	388
	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	946
	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	175
	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	716
	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	276
	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	715
	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	276
	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	486
	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	276
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	182,480
	By Age/Sex: <1	2,197
	By Age/Sex: 1-9	2,881
	By Age/Sex: 10-14 Male	630
	By Age/Sex: 15-19 Male	10,432
	By Age/Sex: 20-24 Male	33,879
	By Age/Sex: 50+ Male	1,845
	By Age/Sex: 10-14 Female	807
	By Age/Sex: 15-19 Female	13,838
	By Age/Sex: 20-24 Female	48,220



	By Age/Sex: 50+ Female	2,151
	Pregnancy status	15,372
	Breastfeeding status	3,044
	FSW	1,169
	MSM	334
	People in prisons and other enclosed settings	1,252
	TG	41
	By Key populations: People who inject drugs (PWID)	41
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	11,553
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	8,648
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	12,628
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	10,472
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	4,203
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	10,414
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	3,744
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	3,755
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	368
	By Age/Sex: <1	14
	By Age/Sex: 1-9	26
	By Age/Sex: 10-14 Male	31
	By Age/Sex: 15-19 Male	41



	By Age/Sex: 20-24 Male	134
	By Age/Sex: 10-14 Female	31
	By Age/Sex: 15-19 Female	9
	By Age/Sex: 20-24 Female	29
	By Age/Sex: 50+ Female	1
	Sum of Age/Sex disaggregates	276
	Pregnancy status	23
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	14
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	3
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	18
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	3
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	4
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	3
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	4
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,244,317
	<15, Undocumented Test	571



	Indication, Female	
	<15, Undocumented Test Indication, Male	221
	15+, Undocumented Test Indication, Female	2,857
	15+, Undocumented Test Indication, Male	1,109
	Undocumented Test Indication	2,671
	Denominator: Indication: Routine	847,482
	Denominator: Indication: Targeted	79,005
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	3,744
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	38,103
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	5,976
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	68,188
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	32,135
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	313,111
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	40,093
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	641,695
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART	7,118



	patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	245,591
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	273,031
	Numerator by Status: Pregnant	4,458
	Numerator by Status: Breastfeeding	5,663
	Denominator by Status: Pregnant	20,531
	Denominator by Status: Breastfeeding	6,104
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,301
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58,461
	Aggregated Age/Sex: <15 Female	2,017



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	101,568
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,579
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86,274
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,091
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated	173,683



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	89 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,813
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,048
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	129
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	575

Approved



	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,262



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7139	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	1,048,800
7305	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development		
9108	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	1,638,269
9110	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	637,707
11406	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs		
12054	CHF International	NGO	U.S. Agency for International Development	GHP-State	298,047
12056	Ananda Marga Universal Relief	NGO	U.S. Agency for International		



	Teams		Development		
12540	University of North Carolina	University	U.S. Agency for International Development		
13340	FHI 360	NGO	U.S. Agency for International Development		
13346	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
13588	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development		
13636	JHPIEGO	University	U.S. Agency for International Development		
13701	Kenya Medical Supplies Agency	Host Country Government Agency	U.S. Agency for International Development	GHP-State	96,250,358
13868	New Partner	TBD	U.S. Agency for International Development	GHP-State	2,302,684
13882	Children of God Relief Institute	FBO	U.S. Agency for International Development	GHP-State	1,807,295
13919	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	337,339



			Control and Prevention		
14009	FHI 360	NGO	U.S. Agency for International Development	GHP-State	754,000
14012	Moi Teaching and Referral Hospital	Parastatal	U.S. Agency for International Development	GHP-State	11,867,930
14015	IntraHealth International, Inc	NGO	U.S. Agency for International Development		
14022	African Medical and Research Foundation	NGO	U.S. Agency for International Development	GHP-State	1,661,297
14034	Equity Group Foundation	NGO	U.S. Agency for International Development		
16450	Kenya Community Development Foundation	NGO	U.S. Agency for International Development		
16670	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	539,775
16679	International Business & Technical Consultants Inc.	Private Contractor	U.S. Agency for International Development		
16684	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	522,485



			for Disease Control and Prevention		
16687	Health Strat Kenya	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,269,717
16705	United Nations Office on Drug and Crime (UNODC)	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	783,826
16709	Center for Health Solutions (CHS)	NGO	U.S. Agency for International Development		
16710	Equity Group Foundation	NGO	U.S. Agency for International Development		
17190	Life Skills Promoters	NGO	U.S. Agency for International Development		
17191	Reformed Church of East Africa	FBO	U.S. Agency for International Development		
17707	PLAN International	NGO	U.S. Agency for International Development	GHP-State	2,782,682
17709	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	1,021,170
17711	National Blood Transfusion Service, Kenya	Host Country Government Agency	U.S. Department of Health and Human	GHP-State	740,000



			Services/Centers for Disease Control and Prevention		
17712	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,590,000
17718	Interchurch Medical Assistance	FBO	U.S. Agency for International Development	GHP-State	6,509,000
17719	Pathfinder International	NGO	U.S. Agency for International Development	GHP-State	8,110,320
17944	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,721,058
17945	mHealth Kenya	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	825,000
17947	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,516,997
17948	African Society for Laboratory	NGO	U.S. Department of Health and	GHP-State	60,000



	Medicine		Human Services/Centers for Disease Control and Prevention		
17950	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,021,492
17951	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,285,257
17954	Global Implementation Solutions	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,695,640
17956	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	349,729
17958	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	1,053,546



17959	University of Nairobi	University	U.S. Agency for International Development	GHP-State	1,155,255
17960	Population Council	NGO	U.S. Agency for International Development		
17964	University of North Carolina	University	U.S. Agency for International Development		
18203	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	15,822,446
18204	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,792,880
18205	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,364,493
18206	Kenya Conference of Catholic Bishops	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	9,722,497



			Prevention		
18207	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,078,035
18208	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,275,144
18209	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,382,617
18213	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,427,832
18214	Palladium Group	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,726,177



18215	Coptic Hospital	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,977,262
18216	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
18217	County Government of Siaya	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,911,377
18223	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,823,335
18260	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	450,000
18262	UNAIDS - Joint	Multi-lateral	U.S. Department	GHP-State	100,000



	United Nations Programme on HIV/AIDS	Agency	of Health and Human Services/Centers for Disease Control and Prevention		
18281	Chemonics. Inc	Private Contractor	U.S. Agency for International Development	GHP-State	951,693
18283	TBD	TBD	Redacted	Redacted	Redacted
18284	TBD	TBD	Redacted	Redacted	Redacted
18285	Catholic Relief Services	FBO	U.S. Agency for International Development		
18318	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	1,271,939
18493	TBD	TBD	Redacted	Redacted	Redacted
18494	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	19,711,347
18495	FHI 360	NGO	U.S. Agency for International Development	GHP-State	10,278,236
18496	JHPIEGO	University	U.S. Agency for International Development	GHP-State	7,551,081
18497	TBD	TBD	Redacted	Redacted	Redacted
18499	TBD	TBD	Redacted	Redacted	Redacted
18504	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	9,399,645



			Control and Prevention		
18505	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	13,282,082
18506	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,286,800
18507	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,225,453
18508	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,107,493
18509	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	2,363,795



			Prevention		
18511	Christian Health Association of Kenya	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,654,026
18512	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,682,803
18513	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,727,557
18514	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,598,213
18515	Eastern Deanery AIDS Relief Program	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,737,135



18516	Mkomani Society Clinic	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,162,707
18517	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
18670	TBD	TBD	Redacted	Redacted	Redacted
18678	TBD	TBD	Redacted	Redacted	Redacted
70108	TBD	TBD	Redacted	Redacted	Redacted
70109	TBD	TBD	Redacted	Redacted	Redacted
70110	TBD	TBD	Redacted	Redacted	Redacted
70111	TBD	TBD	Redacted	Redacted	Redacted
70112	TBD	TBD	Redacted	Redacted	Redacted
70150	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	500,000
80036	Task Force for Global Health Inc.	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	259,680



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7139		Mechanism Name: HP Plus	
Funding Agency: USAID		Procurement Type: Contract	
Prime Partner Name: Palladium Group			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	
Total All Funding Sources: 1,048,800		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 1,048,800			
Funding Source		Funding Amount	
GHP-State		1,048,800	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 7139 Mechanism Name: HP Plus Prime Partner Name: Palladium Group		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	973,800
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	75,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7305	Mechanism Name: Applying Science to Strengthen and Improve Systems-ASSIST
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 7305 Mechanism Name: Applying Science to Strengthen and Improve Systems-ASSIST Prime Partner Name: University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9108	Mechanism Name: AIHA
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,638,269	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,638,269	
Funding Source	Funding Amount
GHP-State	1,638,269

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	1,268,648
Human Resources for Health	200,000



Budget Code Information

Mechanism ID: 9108		
Mechanism Name: AIHA		
Prime Partner Name: American International Health Alliance Twinning Center		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	412,753
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	281,979
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	87,642
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	282,445
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	573,450
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	9,663



	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 10-14 Female	4,984
PP_PREV_DSD	Age/sex: 15-19 Female	3,003
PP_PREV_DSD	Age/sex: 20-24 Female	1,680
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,667
GEND_GBV_DSD	Number of people receiving post-GBV care	642
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	325
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	317
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	62
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	96
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	169
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	105
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	84
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	19,410
OVC_SERV_DSD	Age/Sex: 10-14 Female	9,703
OVC_SERV_DSD	Age/Sex: 15-17 Female	7,226
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,481
OVC_SERV_DSD	Sum of Age/Sex disaggregates	16,929
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,450
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	4,364
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	3,031
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	3,405
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	497
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	426



	and sex: Social Protection Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	840
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	559
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	9,703
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	7,226
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	2,481
OVC_SERV_DSD	Program Completion: Active	19,410
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	18,431
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	19,410

Implementing Mechanism Details

Mechanism ID: 9110	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 637,707	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 637,707	
Funding Source	Funding Amount
GHP-State	637,707



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9110 Mechanism Name: APHL Prime Partner Name: Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	457,967
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	121,725
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	58,015
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11406	Mechanism Name: Community Grants Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11406		
Mechanism Name: Community Grants Program		
Prime Partner Name: U.S. Department of State		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12054	Mechanism Name: Healthy Outcomes through Prevention Education (HOPE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CHF International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 298,047	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 620,747	
Total All Funding Sources and Applied Pipeline Amount: 918,794	
Funding Source	Funding Amount
GHP-State	298,047

Cross-Cutting Budget Attribution(s)

Gender: GBV	59,720
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Adolescent Girls and Young Women (AGYW)	298,047
---	---------

Budget Code Information

Mechanism ID: 12054		
Mechanism Name: Healthy Outcomes through Prevention Education (HOPE)		
Prime Partner Name: CHF International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	275,782
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	22,265
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on	187



	oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	2
PrEP_NEW_DSD	Male 20-24	11
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	22
PrEP_NEW_DSD	Female 20-24	77
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_DSD	FSW	26
PrEP_NEW_DSD	MSM	13
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	13
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	6
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,350
PP_PREV_DSD	Age/sex: 10-14 Male	32
PP_PREV_DSD	Age/sex: 15-19 Male	432
PP_PREV_DSD	Age/sex: 20-24 Male	105
PP_PREV_DSD	Age/sex: 50+ Male	2
PP_PREV_DSD	Age/sex: 10-14 Female	488
PP_PREV_DSD	Age/sex: 15-19 Female	1,144
PP_PREV_DSD	Age/sex: 20-24 Female	913
PP_PREV_DSD	Age/sex: 50+ Female	9
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,125
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	43
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	9



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	43
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	9
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	43
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	9
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	43
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	9
GEND_GBV_DSD	Number of people receiving post-GBV care	2,850
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,425
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,425
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	352
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	29
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	29
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	86
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	29
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	285
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	285
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	29
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	399
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	399
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	29
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	29
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	29
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	29



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	29
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,018



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,171
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	377
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	46
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	62
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	19
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	430
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	124
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	234
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	100
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	84
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	40
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	214
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	239
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	5



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	98
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	252
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	327
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,615
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,292
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,980
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	81
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	152
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	127
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	15
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	2

Implementing Mechanism Details



Mechanism ID: 12056	Mechanism Name: Inuka Community Based OVC Project (ICOP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ananda Marga Universal Relief Teams	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12056		
Mechanism Name: Inuka Community Based OVC Project (ICOP)		
Prime Partner Name: Ananda Marga Universal Relief Teams		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12540	Mechanism Name: MEASURE Evaluation
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 12540 Mechanism Name: MEASURE Evaluation Prime Partner Name: University of North Carolina		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13340	Mechanism Name: APHIAPlus Rift Valley
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13340		
Mechanism Name: APHIAPlus Rift Valley		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13346	Mechanism Name: Support Services for HIV Pandemic
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	350,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	10,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building



Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 13346		
Mechanism Name: Support Services for HIV Pandemic		
Prime Partner Name: World Health Organization		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	40,090
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	99,940
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	49,970
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	102,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	58,000

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13588	Mechanism Name: APHIAplus Nyanza/Western
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13588		
Mechanism Name: APHIAplus Nyanza/Western		
Prime Partner Name: Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13636	Mechanism Name: APHIAplus Central/Eastern
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13636 Mechanism Name: APHIAplus Central/Eastern Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13701	Mechanism Name: KEMSA Medical Commodities Program
----------------------------	--



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Kenya Medical Supplies Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 96,250,358	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 14,611,340	
Total All Funding Sources and Applied Pipeline Amount: 110,861,698	
Funding Source	Funding Amount
GHP-State	96,250,358

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13701		
Mechanism Name: KEMSA Medical Commodities Program		
Prime Partner Name: Kenya Medical Supplies Agency		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	5,846,013
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,275,725
Strategic Area	Budget Code	Planned Amount



Care	PDCS	1,098,936
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	250,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	70,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	616,171
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	71,501,549
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	15,591,964
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13868	Mechanism Name: Health Communication & Marketing
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,302,684	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,174,440	
Total All Funding Sources and Applied Pipeline Amount: 3,477,124	
Funding Source	Funding Amount
GHP-State	2,302,684

Cross-Cutting Budget Attribution(s)

Condom programming	439,654
--------------------	---------



Budget Code Information

Mechanism ID: 13868 Mechanism Name: Health Communication & Marketing Prime Partner Name: New Partner		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	238,268
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	25,990
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	415,336
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	83,324
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	412,277
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,116,545
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	10,944

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	567



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,092
PMTCT_ART_DSD	New on ART	313
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	254
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	102
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,259
PMTCT_ART_TA	New on ART	102
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,092
PMTCT_STAT_DSD	Number of new ANC and L&D clients	27,838
PMTCT_STAT_DSD	By Age (Denominator): 10-14	29
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,445
PMTCT_STAT_DSD	By Age (Denominator): 20-24	9,433
PMTCT_STAT_DSD	By Age (Denominator): 50+	179
PMTCT_STAT_DSD	By Number of known positives: 15-19	6
PMTCT_STAT_DSD	By Number of known positives: 20-24	58
PMTCT_STAT_DSD	By Number of new positives: 15-19	30
PMTCT_STAT_DSD	By Number of new positives: 20-24	110
PMTCT_STAT_DSD	By Number of new negative: 10-14	12
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,852
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,635
PMTCT_STAT_DSD	By Number of new negative: 50+	34
PMTCT_STAT_DSD	By Age (Numerator): 10-14	12
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,889
PMTCT_STAT_DSD	By Age (Numerator): 20-24	7,807
PMTCT_STAT_DSD	By Age (Numerator): 50+	35



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3,938
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,938
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	3,938
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,938
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	3,232
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	46
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,232
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	46
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	3,232
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	46
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	3,232
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	46
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3,335
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,335
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,335
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,335
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	5,259



	their results)	
PMTCT_STAT_TA	Number of new ANC and L&D clients	5,228
PMTCT_STAT_TA	By Age (Denominator): 10-14	4
PMTCT_STAT_TA	By Age (Denominator): 15-19	684
PMTCT_STAT_TA	By Age (Denominator): 20-24	1,875
PMTCT_STAT_TA	By Age (Denominator): 50+	5
PMTCT_STAT_TA	By known positives: 20-24	6
PMTCT_STAT_TA	By new positives: 15-19	12
PMTCT_STAT_TA	By new positives: 20-24	35
PMTCT_STAT_TA	By new negatives: 10-14	11
PMTCT_STAT_TA	By new negatives: 15-19	679
PMTCT_STAT_TA	By new negatives: 20-24	1,660
PMTCT_STAT_TA	By new negatives: 50+	2
PMTCT_STAT_TA	By Age (Numerator): 10-14	11
PMTCT_STAT_TA	By Age (Numerator): : 15-19	692
PMTCT_STAT_TA	By Age (Numerator): 20-24	1,702
PMTCT_STAT_TA	By Age (Numerator): 50+	2
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	665
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	665
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	665
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	665
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	668
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	15
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	668
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	15



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	668
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	15
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	668
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	15
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	687
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	687
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	687
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	687
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	225
PrEP_NEW_DSD	Male 15-19	2
PrEP_NEW_DSD	Male 20-24	14
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	25
PrEP_NEW_DSD	Female 20-24	92
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_DSD	FSW	31
PrEP_NEW_DSD	MSM	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	8
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	8



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	6
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	77,299
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,016
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	598
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	2



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,545
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,237
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,979
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	158
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,612
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	170
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	520
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	201
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1,	58



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	288
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male,	11



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,712
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	6,872
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,743
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male,	821



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	6,001
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	160
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,631
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	307
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	7

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	316
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	75
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	75
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,694
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,978
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,959
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	73



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,436
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,044
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,217
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,044
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	405
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,827
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,827
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,827
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,827

HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	137
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	8



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,149
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	47



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	558
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,454
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	668
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	612
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	668
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	612
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	221
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	84,074
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male,	6



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	269
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	379
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	927
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,215
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	49
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	23
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14,	89



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,561
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	73
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	4,025
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	106
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	12,165
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	337
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	9,772
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	262
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	363
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	660
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	77
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9,	346



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	27
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	123
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	185
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	185
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	11
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	1,185
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	3,045
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	45
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	976
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	882



HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,374
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	82
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,836
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	83
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	238
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	180
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	183
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male,	1



	Negative	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	191
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	274
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	220
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	316
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	56
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	326
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	56
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	109
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 25-29,	15



	Male, Negative	
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 30-34, Male, Negative	18
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 35-39, Male, Negative	18
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 40-49, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,901
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	42
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	3,960
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	97
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,125
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	46
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,766
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	118
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	731
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,967
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	95



	Male, Positive	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	731
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,321
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	26
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,268
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	56
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,268
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,268
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,268
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	66
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	54
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	254
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	183
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female,	58



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	62
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	69
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	75
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	16
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	75
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	22
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	12
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	22



	Negative	
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	1,682
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	908
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	1,917
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	53
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	1,088
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	480
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	1,088
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	480
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	364
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29,	123



	Male, Negative	
HTS_SELF_TA	HTS_SELF_N_TA	224
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	3



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	112
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	112
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	12
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	56
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	46
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	150
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM,	31



	Directly-Assisted	
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	12
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	271
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	278
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	159
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	98
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	167
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	98
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3

TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	115
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	71
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	15
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	15
PMTCT_EID_DSD	Sum of Infant Age disaggregates	15
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,816
TX_CURR_DSD	Age/Sex: 15-19 Male	108
TX_CURR_DSD	Age/Sex: 15-19 Female	187
TX_CURR_DSD	Sum of age/sex disaggregates	295
TX_CURR_DSD	Age/Sex: <1-9	66



TX_CURR_DSD	Age/Sex: 10-14 Male	29
TX_CURR_DSD	Age/Sex: 10-14 Female	39
TX_CURR_DSD	Age/Sex: 20-24 Male	139
TX_CURR_DSD	Age/Sex: 50+ Male	219
TX_CURR_DSD	Age/Sex: 20-24 Female	551
TX_CURR_DSD	Age/Sex: 50+ Female	516
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,304
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	369
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	940
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	571
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	940
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	571
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	636
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	571
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,754
TX_NEW_DSD	By Age/Sex: <1	8
TX_NEW_DSD	By Age/Sex: 1-9	7
TX_NEW_DSD	By Age/Sex: 15-19 Male	141
TX_NEW_DSD	By Age/Sex: 20-24 Male	479
TX_NEW_DSD	By Age/Sex: 50+ Male	10
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	137
TX_NEW_DSD	By Age/Sex: 20-24 Female	484
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,252



TX_NEW_DSD	Pregnancy status	144
TX_NEW_DSD	Breastfeeding status	15
TX_NEW_DSD	FSW	15
TX_NEW_DSD	MSM	7
TX_NEW_DSD	People in prisons and other enclosed settings	16
TX_NEW_DSD	TG	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	14
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	110
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	18
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	129
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	128
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	34
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,194
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	36
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	46
TX_PVLS_DSD	Undocumented Test Indication	82
TX_PVLS_DSD	Denominator: Indication: Routine	4,562
TX_PVLS_DSD	Denominator: Indication: Targeted	53
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	43
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	4



	Female Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	51
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	15
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,701
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	45
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,982
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,173
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,571
TX_RET_DSD	Numerator by Status: Breastfeeding	12
TX_RET_DSD	Denominator by Status: Pregnant	124
TX_RET_DSD	Denominator by Status: Breastfeeding	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	504
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,024
HTS_SELF_DSD	HTS_SELF_N_DSD	649



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	34



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	325
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	32
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	163
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	130
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	435
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	99

HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	39
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	838
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	581
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	23
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	20
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	369
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	166
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	31
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	32
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	555
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	221
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	581
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	7,816
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	297
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	287
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	4,696
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	2,537
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	249
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	42



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	192
-----------	---	-----

Implementing Mechanism Details

Mechanism ID: 13882	Mechanism Name: Integrated Program for both HIV infected and affected children and their households
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Children of God Relief Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,807,295	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,807,295	
Funding Source	Funding Amount
GHP-State	1,807,295

Cross-Cutting Budget Attribution(s)

Economic Strengthening	259,794
Education	194,845
Food and Nutrition: Commodities	129,897

Budget Code Information

Mechanism ID:	13882
Mechanism Name:	Integrated Program for both HIV infected and affected children and their households
Prime Partner Name:	Children of God Relief Institute



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	649,484
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	17,080
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	51,191
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	422,670
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	666,870

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	21
PrEP_NEW_DSD	Male 20-24	1
PrEP_NEW_DSD	Female 15-19	3
PrEP_NEW_DSD	Female 20-24	9
PrEP_NEW_DSD	FSW	3
PrEP_NEW_DSD	MSM	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	1



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	1
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,936
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	3



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	244
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	840
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	396
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	31



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	104
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	41



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	37
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	37
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	15
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,419
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,566
OVC_SERV_DSD	Age/Sex: 15-17 Male	909
OVC_SERV_DSD	By: Age/sex: Male 18-24	589
OVC_SERV_DSD	By: Age/sex: Male 25+	7
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,719
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,999
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,401



OVC_SERV_DSD	By: Age/sex: 25+ Female	23
OVC_SERV_DSD	Sum of Age/Sex disaggregates	7,193
OVC_SERV_DSD	Age/Sex: <1	151
OVC_SERV_DSD	Age/Sex: 1-9	4,070
OVC_SERV_DSD	Program Completion: Active	13,269
OVC_SERV_DSD	Program Completion: Graduation	150
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	11,943
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,419
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	37
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	158
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	158
PMTCT_EID_DSD	Sum of Infant Age disaggregates	158
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,750
TX_CURR_DSD	Age/Sex: 15-19 Male	25
TX_CURR_DSD	Age/Sex: 15-19 Female	45
TX_CURR_DSD	Sum of age/sex disaggregates	70
TX_CURR_DSD	Age/Sex: <1	32



TX_CURR_DSD	Age/Sex: <1-9	1,023
TX_CURR_DSD	Age/Sex: 10-14 Male	530
TX_CURR_DSD	Age/Sex: 10-14 Female	572
TX_CURR_DSD	Age/Sex: 20-24 Male	34
TX_CURR_DSD	Age/Sex: 50+ Male	45
TX_CURR_DSD	Age/Sex: 20-24 Female	127
TX_CURR_DSD	Age/Sex: 50+ Female	115
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	251
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	81
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	190
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	122
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	190
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	122
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	122
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	159
TX_NEW_DSD	By Age/Sex: <1	33
TX_NEW_DSD	By Age/Sex: 1-9	19
TX_NEW_DSD	By Age/Sex: 10-14 Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	16
TX_NEW_DSD	By Age/Sex: 50+ Male	1
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	16



TX_NEW_DSD	By Age/Sex: 20-24 Female	37
TX_NEW_DSD	Sum of Age/Sex disaggregates	80
TX_NEW_DSD	Pregnancy status	12
TX_NEW_DSD	Breastfeeding status	1
TX_NEW_DSD	FSW	2
TX_NEW_DSD	MSM	1
TX_NEW_DSD	People in prisons and other enclosed settings	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	6
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,237
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	1,285
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,241
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	838
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	873

TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	333
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	368
TX_RET_DSD	Numerator by Status: Breastfeeding	6
TX_RET_DSD	Denominator by Status: Pregnant	31
TX_RET_DSD	Denominator by Status: Breastfeeding	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	88
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	151
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	250
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	537



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	22
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	23
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	318
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	174
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	11
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	13
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	148
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	78
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	537
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,729
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	95
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	93
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	2,406
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,138
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	122
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	35
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	83

Implementing Mechanism Details

Mechanism ID: 13919	Mechanism Name: Laboratory Regulatory Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 337,339	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 337,339	
Funding Source	Funding Amount
GHP-State	337,339

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13919		
Mechanism Name: Laboratory Regulatory Support		
Prime Partner Name: Clinical and Laboratory Standards Institute		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	337,339



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14009	Mechanism Name: Kenya Nutrition and HIV Program Plus
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 754,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 963,542	
Total All Funding Sources and Applied Pipeline Amount: 1,717,542	
Funding Source	Funding Amount
GHP-State	754,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14009



Mechanism Name: Kenya Nutrition and HIV Program Plus		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	754,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14012	Mechanism Name: AMPATHplus
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Moi Teaching and Referral Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 11,867,930	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,020,175	
Total All Funding Sources and Applied Pipeline Amount: 12,888,105	
Funding Source	Funding Amount
GHP-State	11,867,930

Cross-Cutting Budget Attribution(s)

Gender: GBV	207,690
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Education	39,782
Adolescent Girls and Young Women (AGYW)	571,167
Food and Nutrition: Commodities	39,782

Budget Code Information

Mechanism ID: 14012		
Mechanism Name: AMPATHplus		
Prime Partner Name: Moi Teaching and Referral Hospital		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	442,027
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	362,827
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,152,830
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,557,676
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,820,370
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	532,200

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,041
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	153,071
PMTCT_ART_DSD	New on ART	1,714
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,327
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	13
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	936



PMTCT_ART_TA	New on ART	13
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	153,071
PMTCT_STAT_DSD	Number of new ANC and L&D clients	156,485
PMTCT_STAT_DSD	By Age (Denominator): 10-14	368
PMTCT_STAT_DSD	By Age (Denominator): <15-19	16,774
PMTCT_STAT_DSD	By Age (Denominator): 20-24	55,676
PMTCT_STAT_DSD	By Age (Denominator): 50+	63
PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	80
PMTCT_STAT_DSD	By Number of known positives: 20-24	340
PMTCT_STAT_DSD	By Number of new positives: 10-14	11
PMTCT_STAT_DSD	By Number of new positives: 15-19	222
PMTCT_STAT_DSD	By Number of new positives: 20-24	514
PMTCT_STAT_DSD	By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Number of new negative: <10	13
PMTCT_STAT_DSD	By Number of new negative: 10-14	900
PMTCT_STAT_DSD	By Number of new negative: 15-19	17,234
PMTCT_STAT_DSD	By Number of new negative: 20-24	42,867
PMTCT_STAT_DSD	By Number of new negative: 50+	212
PMTCT_STAT_DSD	By Age (Numerator): <10	13
PMTCT_STAT_DSD	By Age (Numerator): 10-14	912
PMTCT_STAT_DSD	By Age (Numerator): 15-19	17,545
PMTCT_STAT_DSD	By Age (Numerator): 20-24	43,735
PMTCT_STAT_DSD	By Age (Numerator): 50+	217
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	20,901
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	20,901
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	20,901
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	20,901
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	472



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	21,928
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	246
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	472
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	21,928
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	246
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	472
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	21,928
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	246
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	472
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	21,928
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	246
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	22,668
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	22,668
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	22,668
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	22,668
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	936
PMTCT_STAT_TA	Number of new ANC and L&D clients	955
PMTCT_STAT_TA	By Age (Denominator): 10-14	2
PMTCT_STAT_TA	By Age (Denominator): 15-19	96
PMTCT_STAT_TA	By Age (Denominator): 20-24	333
PMTCT_STAT_TA	By known positives: 20-24	1



PMTCT_STAT_TA	By new positives: 15-19	3
PMTCT_STAT_TA	By new positives: 20-24	4
PMTCT_STAT_TA	By new negatives: 15-19	182
PMTCT_STAT_TA	By new negatives: 20-24	273
PMTCT_STAT_TA	By Age (Numerator): : 15-19	184
PMTCT_STAT_TA	By Age (Numerator): 20-24	277
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	131
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	131
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	131
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	131
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	112
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	112
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	112
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	112
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	2



	40-49, Female, Newly Identified Positive	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	116
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	116
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	116
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	116
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,954
PrEP_NEW_DSD	Male 15-19	18
PrEP_NEW_DSD	Male 20-24	118
PrEP_NEW_DSD	Male 50+	39
PrEP_NEW_DSD	Female 15-19	234
PrEP_NEW_DSD	Female 20-24	801
PrEP_NEW_DSD	Female 50+	39
PrEP_NEW_DSD	FSW	274
PrEP_NEW_DSD	MSM	137
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	137
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	57
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	98
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	77
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	98
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	77
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	98
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	57
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	468
KP_PREV_TA	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	468



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	692,786
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,988
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,684
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	13,734
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	284
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	8,586
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	181
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	590
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	414
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	8



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,143
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,539
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,613
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	753
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	19,994
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	414
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	33,032
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	680
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	103,064
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,135
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	73,935
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,516
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,025
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	2,586



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	13,359
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	162
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	14,935
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	201
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	716
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	154
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	229
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	281
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	229
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	281



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	328
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	294
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	948
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	215
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	726
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	165
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,262
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	716
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,145



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	556
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	1,521
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,765
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	38
HTC_TST_DSD	By Key Population: FSW, Negative	703
HTC_TST_DSD	By Key Population: FSW, Positive	21
HTC_TST_DSD	By Key Population: MSM, Negative	7
HTC_TST_DSD	By Key Population: PWID, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	120
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	80
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	415
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	256
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	14



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	906
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	17,342
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	43,145
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	337
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	217
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	134
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	4,502
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,880
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	15,507
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	321
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,212
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female,	596



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	372
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	366
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	615
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,015
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	217
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,158
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	248
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	536
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	290
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	536
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	112



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	290
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	4,127
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,068
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	4,716
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,481
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,178
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,481
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49,	1,178



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	827
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	19,900
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	405
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	21,186
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	428
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	22,041
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	448
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	25,655
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	517
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	8,046
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	15,518
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	315
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	8,046
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49,	5,175

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	22,087
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	968
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	22,087
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	172
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	22,087
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	22,087
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	602
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	419
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	2,072
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,341
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	8



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	514
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	258
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	589
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	309
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	309
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	47



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	290
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	199
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	311
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	435
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	196
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	398
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4,179
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,862



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	4,777
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,235
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,194
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,235
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,194
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	746
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,695
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	68
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	147
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	197
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	292
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	295
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	36
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	70
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	5
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	40
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	67
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	46
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	75
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	19
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	47
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49,	19



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	46
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	46
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	46
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	46
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	2
HTS_SELF_TA	HTS_SELF_N_TA	26
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	1
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	13
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	13
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	1
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	7
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	5
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	18
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM,	4



	Directly-Assisted	
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,856
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,852
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	373
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,909
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	368
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,215
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	358
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,017
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	355
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,148
GEND_GBV_DSD	Number of people receiving post-GBV care	12,213
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6,100



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,098
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	4,879
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	121
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	121
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	366
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	366
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	121
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,221
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,222
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	121
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,744
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,744
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	121
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	121
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	121
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	366
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	366
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	121
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	366



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	366
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	121
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	366
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	366
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	121
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	366
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	366
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	121
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	121
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,935
OVC_SERVDSD	Age/Sex: 10-14 Male	1,347
OVC_SERVDSD	Age/Sex: 15-17 Male	1,047
OVC_SERVDSD	By: Age/sex: Male 18-24	834
OVC_SERVDSD	By: Age/sex: Male 25+	23
OVC_SERVDSD	Age/Sex: 10-14 Female	1,372
OVC_SERVDSD	Age/Sex: 15-17 Female	1,103
OVC_SERVDSD	By: Age/sex: 18-24 Female	850
OVC_SERVDSD	By: Age/sex: 25+ Female	73
OVC_SERVDSD	Sum of Age/Sex disaggregates	4,869



OVC_SERV_DSD	Age/Sex: <1	1
OVC_SERV_DSD	Age/Sex: 1-9	2,283
OVC_SERV_DSD	Program Completion: Active	8,313
OVC_SERV_DSD	Program Completion: Graduation	622
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	7,161
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,935
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,386
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	760
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	624
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	660
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	660
PMTCT_EID_DSD	Sum of Infant Age disaggregates	660
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	96,971
TX_CURR_DSD	Age/Sex: 15-19 Male	1,346
TX_CURR_DSD	Age/Sex: 15-19 Female	2,436
TX_CURR_DSD	Sum of age/sex disaggregates	3,782
TX_CURR_DSD	Age/Sex: <1	89
TX_CURR_DSD	Age/Sex: <1-9	4,210
TX_CURR_DSD	Age/Sex: 10-14 Male	1,771



TX_CURR_DSD	Age/Sex: 10-14 Female	2,064
TX_CURR_DSD	Age/Sex: 20-24 Male	1,794
TX_CURR_DSD	Age/Sex: 50+ Male	2,183
TX_CURR_DSD	Age/Sex: 20-24 Female	6,791
TX_CURR_DSD	Age/Sex: 50+ Female	6,267
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	15,140
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,882
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	11,485
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6,066
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	11,485
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	6,066
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	7,831
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,066
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,442
TX_NEW_DSD	By Age/Sex: <1	181
TX_NEW_DSD	By Age/Sex: 1-9	463
TX_NEW_DSD	By Age/Sex: 10-14 Male	34
TX_NEW_DSD	By Age/Sex: 15-19 Male	898
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,872
TX_NEW_DSD	By Age/Sex: 50+ Male	109
TX_NEW_DSD	By Age/Sex: 10-14 Female	73
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,208
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,156
TX_NEW_DSD	By Age/Sex: 50+ Female	170



TX_NEW_DSD	Sum of Age/Sex disaggregates	9,520
TX_NEW_DSD	Pregnancy status	1,339
TX_NEW_DSD	Breastfeeding status	245
TX_NEW_DSD	FSW	59
TX_NEW_DSD	MSM	7
TX_NEW_DSD	People in prisons and other enclosed settings	241
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,186
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	543
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,356
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	651
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	341
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	651
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	341
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	217
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	94,979
TX_PVLS_DSD	Denominator: Indication: Routine	80,448
TX_PVLS_DSD	Denominator: Indication: Targeted	14,531
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	587
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,102
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	625
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	9,217



	Female Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,391
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	23,283
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,587
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	50,187
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,986
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	16,878
TX_RET_DSD	Numerator by Status: Breastfeeding	405
TX_RET_DSD	Denominator by Status: Pregnant	1,275
TX_RET_DSD	Denominator by Status: Breastfeeding	387
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	382
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,094
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,150
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,068



HTS_SELF_DSD	HTS_SELF_N_DSD	3,569
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	192



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,785
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,784
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	178
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	892
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	714
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	2,390
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM,	535



	Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	214
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,964
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	16,511
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	583
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	4,195
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	10,320
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,103
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	564
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	2,963
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	7,960
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,215
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	16,511
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	374
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	96,989
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,942
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	19,385
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	60,674
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	12,975
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB	4,590



	disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	728
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	3,289

Implementing Mechanism Details

Mechanism ID: 14015		Mechanism Name: FUNZO Kenya	
Funding Agency: USAID		Procurement Type: Cooperative Agreement	
Prime Partner Name: IntraHealth International, Inc			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

Total All Funding Sources: 0		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source		Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14015		
Mechanism Name: FUNZO Kenya		
Prime Partner Name: IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14022	Mechanism Name: APHIAplus Imarisha
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,661,297	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,661,297	
Funding Source	Funding Amount



GHP-State	1,661,297
-----------	-----------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14022		
Mechanism Name: APHIAplus Imarisha		
Prime Partner Name: African Medical and Research Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	308,466
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	498,298
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	793,368
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	61,165

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	471
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,739
PMTCT_ART_TA	New on ART	238
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	233
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,739
PMTCT_STAT_TA	Number of new ANC and L&D clients	38,565
PMTCT_STAT_TA	By Age (Denominator): 15-19	7,136
PMTCT_STAT_TA	By Age (Denominator): 20-24	11,405
PMTCT_STAT_TA	By known positives: 15-19	6
PMTCT_STAT_TA	By known positives: 20-24	32
PMTCT_STAT_TA	By new positives: 15-19	23
PMTCT_STAT_TA	By new positives: 20-24	44
PMTCT_STAT_TA	By new positives: 50+	1
PMTCT_STAT_TA	By new negatives: 15-19	3,181
PMTCT_STAT_TA	By new negatives: 20-24	6,616
PMTCT_STAT_TA	By new negatives: 50+	77
PMTCT_STAT_TA	By Age (Numerator): : 15-19	3,221
PMTCT_STAT_TA	By Age (Numerator): 20-24	6,700
PMTCT_STAT_TA	By Age (Numerator): 50+	78
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	5,006
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	5,006
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	5,006
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	5,006
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	39



	25-29, Female, Known at Entry Positive	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	6,932
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	43
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	39
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	6,932
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	43
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	39
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	6,932
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	43
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	39
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	6,648
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	42
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	7,014
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	7,014
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	7,014
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	6,732
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	46
PrEP_NEW_TA	Male 20-24	2
PrEP_NEW_TA	Female 15-19	6
PrEP_NEW_TA	Female 20-24	19
PrEP_NEW_TA	FSW	6



PrEP_NEW_TA	MSM	2
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	2
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	2
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	1
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	2
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	1
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	2
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	42,269
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,287
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,296
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	641
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	95
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	94
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	23
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	38



HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	55
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	55
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	72
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	5,952
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	9,708



HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	87
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	165
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	62
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	7,529
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	43
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,280
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	35
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,606
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	32
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,971
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	54
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	9



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	70
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	48
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	75
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	58
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	105
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	42
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	87
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	17
HTS_SELF_TA	HTS_SELF_N_TA	452
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male,	8



	Directly-Assisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	8



	Unassisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	8
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	226
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	226
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	24
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	113
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	90
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	304
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	68
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	27
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,232
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,244



TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	294
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	195
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	444
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	302
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	195
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	301
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	294
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	436
GEND_GBV_TA	Number of people receiving post-GBV care	469
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	236
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	234
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	221
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	3
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	3



GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	14
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	48
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	48
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	64
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	64
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	3
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	14
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	14
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39,	14

	Female, Physical and/or Emotional Violence	
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	14
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	3
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	202
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	78
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	122
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	70
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	70
PMTCT_EID_TA	Sum of Infant Age disaggregates	70
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,006
TX_CURR_TA	Age/Sex: 15-19 Male	216



TX_CURR_TA	Age/Sex: 15-19 Female	295
TX_CURR_TA	Sum of Age/Sex disaggregations	511
TX_CURR_TA	Age/Sex: <1	53
TX_CURR_TA	Age/Sex: 1-9	127
TX_CURR_TA	Age/Sex: 10-14 Male	422
TX_CURR_TA	Age/Sex: 10-14 Female	392
TX_CURR_TA	Age/Sex: 20-24 Male	292
TX_CURR_TA	Age/Sex: 50+ Male	95
TX_CURR_TA	Age/Sex: 20-24 Female	819
TX_CURR_TA	Age/Sex: 50+ Female	388
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	946
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	175
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	716
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	276
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	715
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	276
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	486
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	276
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	368
TX_NEW_TA	By Age/Sex: <1	14
TX_NEW_TA	By Age/Sex: 1-9	26
TX_NEW_TA	By Age/Sex: 10-14 Male	31
TX_NEW_TA	By Age/Sex: 15-19 Male	41
TX_NEW_TA	By Age/Sex: 20-24 Male	134



TX_NEW_TA	By Age/Sex: 10-14 Female	31
TX_NEW_TA	By Age/Sex: 15-19 Female	9
TX_NEW_TA	By Age/Sex: 20-24 Female	29
TX_NEW_TA	By Age/Sex: 50+ Female	1
TX_NEW_TA	Sum of Age/Sex disaggregates	276
TX_NEW_TA	Pregnancy status	23
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	14
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	3
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	18
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	3
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	3
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	4
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,118
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,813
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,048
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	129

	treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	575
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,262
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	355
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	418
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	20
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	10
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	177
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	211
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	17
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	8
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	152
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	180
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	418
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	7,004



TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,225
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	590
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	3,576
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	1,620
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,334
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	200
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,067

Implementing Mechanism Details

Mechanism ID: 14034	Mechanism Name: The OVC Scholarship and Leadership Program
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14034		
Mechanism Name: The OVC Scholarship and Leadership Program		
Prime Partner Name: Equity Group Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16450	Mechanism Name: Global Give Back Circle
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Community Development Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16450		
Mechanism Name: Global Give Back Circle		
Prime Partner Name: Kenya Community Development Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16670	Mechanism Name: HIV Fellowship Program
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 539,775	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 539,775	
Funding Source	Funding Amount
GHP-State	539,775

Cross-Cutting Budget Attribution(s)

Human Resources for Health	344,250
----------------------------	---------

Budget Code Information

Mechanism ID:	16670
----------------------	--------------



Mechanism Name: HIV Fellowship Program		
Prime Partner Name: University of Nairobi		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	539,775
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16679	Mechanism Name: Program Support Services
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: International Business & Technical Consultants Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16679		
Mechanism Name: Program Support Services		
Prime Partner Name: International Business & Technical Consultants Inc.		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16684	Mechanism Name: Kenya Disciplined Services ZUIA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 522,485	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 522,485	
Funding Source	Funding Amount
GHP-State	522,485

Cross-Cutting Budget Attribution(s)

Renovation	25,000
------------	--------

Budget Code Information

Mechanism ID:	16684
Mechanism Name:	Kenya Disciplined Services ZUIA
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	9,975
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	50,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	107,392
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	130,060
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	9,940
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	200,156
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	14,962

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	339
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,780
PMTCT_ART_DSD	New on ART	164
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	175
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	6,780



	their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,874
PMTCT_STAT_DSD	By Age (Denominator): 10-14	10
PMTCT_STAT_DSD	By Age (Denominator): <15-19	808
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,357
PMTCT_STAT_DSD	By Age (Denominator): 50+	12
PMTCT_STAT_DSD	By Number of known positives: 15-19	7
PMTCT_STAT_DSD	By Number of known positives: 20-24	46
PMTCT_STAT_DSD	By Number of new positives: 15-19	22
PMTCT_STAT_DSD	By Number of new positives: 20-24	62
PMTCT_STAT_DSD	By Number of new negative: 10-14	10
PMTCT_STAT_DSD	By Number of new negative: 15-19	756
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,252
PMTCT_STAT_DSD	By Number of new negative: 50+	5
PMTCT_STAT_DSD	By Age (Numerator): 10-14	11
PMTCT_STAT_DSD	By Age (Numerator): 15-19	781
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,349
PMTCT_STAT_DSD	By Age (Numerator): 50+	6
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	923
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	920
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	921
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	923
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	852
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	22
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	864



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	22
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	843
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	22
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	845
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	22
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	911
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	920
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	902
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	900
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	143
PrEP_NEW_DSD	Male 20-24	11
PrEP_NEW_DSD	Male 50+	1
PrEP_NEW_DSD	Female 15-19	16
PrEP_NEW_DSD	Female 20-24	59
PrEP_NEW_DSD	Female 50+	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	17
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	8
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	6



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	2
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	38,635
PP_PREV_DSD	Age/sex: 10-14 Male	374
PP_PREV_DSD	Age/sex: 15-19 Male	2,674
PP_PREV_DSD	Age/sex: 20-24 Male	1,757
PP_PREV_DSD	Age/sex: 50+ Male	379
PP_PREV_DSD	Age/sex: 10-14 Female	4,357
PP_PREV_DSD	Age/sex: 15-19 Female	11,078
PP_PREV_DSD	Age/sex: 20-24 Female	9,517
PP_PREV_DSD	Age/sex: 50+ Female	251
PP_PREV_DSD	Sum of Age/Sex disaggregates	30,387
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	974
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,088
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	974
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,088
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	974
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,088
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	974
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,088
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	66,127
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	642
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	500
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	1,829



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,252
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	8,827
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	283
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,855
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	133
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	376
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	474
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,738
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	775
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,319
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	6



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,352
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,734
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	8,097
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,541
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,892
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,758
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,115



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,110
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	747
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	747
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	411
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	885
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	885
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	885
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	11



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	885
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	186
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	7



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,291
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	9

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	816
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,476
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	982
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	368
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	982
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	368
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	250
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	253
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	136

TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	98
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	137
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	100
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	51
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	42
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	42
PMTCT_EID_DSD	Sum of Infant Age disaggregates	42
TX_CURR_DSD	Number of adults and children receiving antiretroviral	4,157



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	77
TX_CURR_DSD	Age/Sex: 15-19 Female	129
TX_CURR_DSD	Sum of age/sex disaggregates	206
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	93
TX_CURR_DSD	Age/Sex: 10-14 Male	54
TX_CURR_DSD	Age/Sex: 10-14 Female	58
TX_CURR_DSD	Age/Sex: 20-24 Male	103
TX_CURR_DSD	Age/Sex: 50+ Male	95
TX_CURR_DSD	Age/Sex: 20-24 Female	360
TX_CURR_DSD	Age/Sex: 50+ Female	265
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	638
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	171
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	490
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	276
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	481
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	267
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	331
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	267
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,095
TX_NEW_DSD	By Age/Sex: <1	7
TX_NEW_DSD	By Age/Sex: 1-9	14
TX_NEW_DSD	By Age/Sex: 10-14 Male	5



TX_NEW_DSD	By Age/Sex: 15-19 Male	54
TX_NEW_DSD	By Age/Sex: 20-24 Male	220
TX_NEW_DSD	By Age/Sex: 50+ Male	6
TX_NEW_DSD	By Age/Sex: 10-14 Female	7
TX_NEW_DSD	By Age/Sex: 15-19 Female	94
TX_NEW_DSD	By Age/Sex: 20-24 Female	313
TX_NEW_DSD	By Age/Sex: 50+ Female	8
TX_NEW_DSD	Sum of Age/Sex disaggregates	707
TX_NEW_DSD	Pregnancy status	94
TX_NEW_DSD	Breastfeeding status	18
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	60
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	55
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	81
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	60
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	26
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	53
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	14
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	18
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,105
TX_PVLS_DSD	Denominator: Indication: Routine	2,959
TX_PVLS_DSD	Denominator: Indication: Targeted	146
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	1



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	45
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	98
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	75
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	886
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	86
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,912
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,523
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,574
TX_RET_DSD	Numerator by Status: Breastfeeding	27
TX_RET_DSD	Denominator by Status: Pregnant	97
TX_RET_DSD	Denominator by Status: Breastfeeding	25
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	487
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	979

	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	504
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,013
HTS_SELF_DSD	HTS_SELF_N_DSD	343
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	4



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	4

	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	172
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	171
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	16
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	86
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	68
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	228
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,327
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,372
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	61
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	148
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	834
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	329



TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	59
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	144
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	806
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	318
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	793
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,984
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	150
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	164
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	2,398
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,272
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	225
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	33
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	183

Implementing Mechanism Details

Mechanism ID: 16687	Mechanism Name: Kenya Prison Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Strat Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,269,717	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,269,717	
Funding Source	Funding Amount



GHP-State	1,269,717
-----------	-----------

Cross-Cutting Budget Attribution(s)

Gender: GBV	3,854
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	3,854
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	287,771
Renovation	32,271

Budget Code Information

Mechanism ID: 16687		
Mechanism Name: Kenya Prison Services		
Prime Partner Name: Health Strat Kenya		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	26,942
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	84,025
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	149,370
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	611,072
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	100,645
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	273,318
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	24,345

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	382
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,246
PMTCT_ART_DSD	New on ART	188
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	194
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,246
PMTCT_STAT_DSD	Number of new ANC and L&D clients	8,266
PMTCT_STAT_DSD	By Age (Denominator): 10-14	10
PMTCT_STAT_DSD	By Age (Denominator): <15-19	839
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,872
PMTCT_STAT_DSD	By Age (Denominator): 50+	25
PMTCT_STAT_DSD	By Number of known positives: 15-19	6



PMTCT_STAT_DSD	By Number of known positives: 20-24	46
PMTCT_STAT_DSD	By Number of new positives: 15-19	22
PMTCT_STAT_DSD	By Number of new positives: 20-24	68
PMTCT_STAT_DSD	By Number of new negative: 10-14	8
PMTCT_STAT_DSD	By Number of new negative: 15-19	777
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,694
PMTCT_STAT_DSD	By Number of new negative: 50+	15
PMTCT_STAT_DSD	By Age (Numerator): 10-14	8
PMTCT_STAT_DSD	By Age (Numerator): 15-19	805
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,808
PMTCT_STAT_DSD	By Age (Numerator): 50+	15
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	1,130
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,130
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,130
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,130
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,083
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,093
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,083
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	28



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,083
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	1,150
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,160
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,150
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,150
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	332
PrEP_NEW_DSD	Male 15-19	1
PrEP_NEW_DSD	Male 20-24	18
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	38
PrEP_NEW_DSD	Female 20-24	136
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	8
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	27
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	24
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	13
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	8
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	61,838
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations	61,838



	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	109,592
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	58



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	58,636
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	2,049
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	779
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,700
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	195



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	137
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,197
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	281
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	5,871
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	28,224
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	972
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	18,792
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	692
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,041
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	682
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	204
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	635
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	31

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,083
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,083
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,083
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,083
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	4



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	7,288
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	236
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	3,421

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	125
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	8,329
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	276
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,106
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	150
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,080
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	4,106
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	150
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,080
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,370
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	49
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,104
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,123
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	42
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	635

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	38
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	409
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	47
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	630
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	44
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	413
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	235
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	128
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	107
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	17
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	17



PMTCT_EID_DSD	Sum of Infant Age disaggregates	17
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,646
TX_CURR_DSD	Age/Sex: 15-19 Male	174
TX_CURR_DSD	Age/Sex: 15-19 Female	289
TX_CURR_DSD	Sum of age/sex disaggregates	463
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	123
TX_CURR_DSD	Age/Sex: 10-14 Male	54
TX_CURR_DSD	Age/Sex: 10-14 Female	57
TX_CURR_DSD	Age/Sex: 20-24 Male	233
TX_CURR_DSD	Age/Sex: 50+ Male	238
TX_CURR_DSD	Age/Sex: 20-24 Female	810
TX_CURR_DSD	Age/Sex: 50+ Female	630
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,520
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	423
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,136
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	711
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	664
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	787
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	662
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,585
TX_NEW_DSD	By Age/Sex: <1	6



TX_NEW_DSD	By Age/Sex: 1-9	12
TX_NEW_DSD	By Age/Sex: 10-14 Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	185
TX_NEW_DSD	By Age/Sex: 20-24 Male	601
TX_NEW_DSD	By Age/Sex: 50+ Male	15
TX_NEW_DSD	By Age/Sex: 10-14 Female	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	197
TX_NEW_DSD	By Age/Sex: 20-24 Female	678
TX_NEW_DSD	By Age/Sex: 50+ Female	24
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,707
TX_NEW_DSD	Pregnancy status	228
TX_NEW_DSD	Breastfeeding status	47
TX_NEW_DSD	People in prisons and other enclosed settings	40
TX_NEW_DSD	TG	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	180
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	90
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	220
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	129
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	48
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	108
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	49
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	36
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,253



TX_PVLS_DSD	Denominator: Indication: Routine	10,253
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	123
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,186
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	154
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,790
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,852
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,909
TX_RET_DSD	Numerator by Status: Breastfeeding	31
TX_RET_DSD	Denominator by Status: Pregnant	151
TX_RET_DSD	Denominator by Status: Breastfeeding	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	628
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,224
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	642
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,267



HTS_SELF_DSD	HTS_SELF_N_DSD	395
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	42



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	198
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	197
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	18
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	99
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	79
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	264
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM,	57



	Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	22
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,533
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,758
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	116
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	118
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,663
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	861
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	107
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	100
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,542
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	784
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,758
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	187
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	9,633
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	388
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	463
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	5,685
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	3,097
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB	473



	disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	65
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	386

Implementing Mechanism Details

Mechanism ID: 16705	Mechanism Name: IDU - HIV Combination Prevention
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 783,826	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 308,979	
Total All Funding Sources and Applied Pipeline Amount: 1,092,805	
Funding Source	Funding Amount
GHP-State	783,826

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16705		
Mechanism Name: IDU - HIV Combination Prevention		
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	275,208
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	508,618
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	5,549
KP_MAT_DSD	Sex: Male	4,748
KP_MAT_DSD	Sex: Female	801
KP_MAT_DSD	Sum of Sex disaggregates	5,549
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,153
KP_PREV_DSD	By key population type: Males who inject drugs (Male	2,851



	PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	302
GEND_GBV_DSD	Number of people receiving post-GBV care	6,842
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,417
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,422
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	3,089
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	68
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	205
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	205
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	683
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	683
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	956
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	956
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	68
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	68



GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	205
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	68



HTS_SELF_DSD	HTS_SELF_N_DSD	784
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	42



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	392
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	392
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	39
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	196
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	157
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	525
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM,	118



	Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	47

Implementing Mechanism Details

Mechanism ID: 16709	Mechanism Name: Accelerating Progress Against TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16709		
Mechanism Name: Accelerating Progress Against TB		
Prime Partner Name: Center for Health Solutions (CHS)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16710	Mechanism Name: Expanding Health Insurance Coverage
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16710 Mechanism Name: Expanding Health Insurance Coverage Prime Partner Name: Equity Group Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17190	Mechanism Name: Wezesha Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Life Skills Promoters	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17190		
Mechanism Name: Wezesha Project		
Prime Partner Name: Life Skills Promoters		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17191	Mechanism Name: Watoto Wazima Initiative)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Reformed Church of East Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17191 Mechanism Name: Watoto Wazima Initiative) Prime Partner Name: Reformed Church of East Africa		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17707	Mechanism Name: Nilinde Project
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: PLAN International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,782,682	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 4,208,711	
Total All Funding Sources and Applied Pipeline Amount: 6,991,393	
Funding Source	Funding Amount
GHP-State	2,782,682

Cross-Cutting Budget Attribution(s)

Gender: GBV	490,329
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Economic Strengthening	430,663
Education	193,304
Adolescent Girls and Young Women (AGYW)	245,606

Budget Code Information



Mechanism ID: 17707 Mechanism Name: Nilinde Project Prime Partner Name: PLAN International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,782,682
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	192
PrEP_NEW_DSD	Male 15-19	2
PrEP_NEW_DSD	Male 20-24	12
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	23



PrEP_NEW_DSD	Female 20-24	79
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_DSD	FSW	27
PrEP_NEW_DSD	MSM	13
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	13
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	8
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	8
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	6
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	133,945
OVC_SERV_DSD	Age/Sex: 10-14 Male	18,611
OVC_SERV_DSD	Age/Sex: 15-17 Male	9,869
OVC_SERV_DSD	By: Age/sex: Male 18-24	6,095
OVC_SERV_DSD	By: Age/sex: Male 25+	119
OVC_SERV_DSD	Age/Sex: 10-14 Female	25,990
OVC_SERV_DSD	Age/Sex: 15-17 Female	16,924
OVC_SERV_DSD	By: Age/sex: 18-24 Female	10,468
OVC_SERV_DSD	By: Age/sex: 25+ Female	201
OVC_SERV_DSD	Sum of Age/Sex disaggregates	71,394
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	502
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	577
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	186
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	31



	and sex: Education Support Male 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	430
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	124
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	234
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	100
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	84
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	18
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	97
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	109
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	910
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,292
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,117
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	46



	and sex: Other Services Female 25+	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	86
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	72
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	1
OVC_SERV_DSD	Age/Sex: <1	1,172
OVC_SERV_DSD	Age/Sex: 1-9	44,502
OVC_SERV_DSD	Program Completion: Active	133,675
OVC_SERV_DSD	Program Completion: Graduation	270
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	117,038
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	133,945

Implementing Mechanism Details

Mechanism ID: 17709	Mechanism Name: HRH Kenya
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,021,170	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 2,175,810	
Total All Funding Sources and Applied Pipeline Amount: 3,196,980	
Funding Source	Funding Amount
GHP-State	1,021,170



Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,021,170
----------------------------	-----------

Budget Code Information

Mechanism ID: 17709 Mechanism Name: HRH Kenya Prime Partner Name: IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	518,370
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	502,800
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17711	Mechanism Name: Implementation and expansion of blood safety
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Blood Transfusion Service, Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 740,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 740,000	
Funding Source	Funding Amount
GHP-State	740,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	369,750
----------------------------	---------

Budget Code Information

Mechanism ID: 17711		
Mechanism Name: Implementation and expansion of blood safety		
Prime Partner Name: National Blood Transfusion Service, Kenya		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	740,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17712	Mechanism Name: Strengthening Strategic Information in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,590,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,590,000	
Funding Source	Funding Amount



GHP-State	3,590,000
-----------	-----------

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	322,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Human Resources for Health	1,021,200
Adolescent Girls and Young Women (AGYW)	90,000

Budget Code Information

Mechanism ID: 17712		
Mechanism Name: Strengthening Strategic Information in Kenya		
Prime Partner Name: University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	3,500,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	90,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17718	Mechanism Name: Afya Jijini
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Interchurch Medical Assistance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,509,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,509,000	
Funding Source	Funding Amount
GHP-State	6,509,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	59,720
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	150,000
Adolescent Girls and Young Women (AGYW)	729,904

Budget Code Information

Mechanism ID: 17718 Mechanism Name: Afya Jijini Prime Partner Name: Interchurch Medical Assistance		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	271,266
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	231,881
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	519,154
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	499,680
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	771,099
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,071,036
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	144,884

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,914
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,232
PMTCT_ART_DSD	New on ART	1,325
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,589
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,232
PMTCT_STAT_DSD	Number of new ANC and L&D clients	65,840
PMTCT_STAT_DSD	By Age (Denominator): 10-14	38
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,525
PMTCT_STAT_DSD	By Age (Denominator): 20-24	22,189
PMTCT_STAT_DSD	By Number of known positives: 15-19	46
PMTCT_STAT_DSD	By Number of known positives: 20-24	296
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	108
PMTCT_STAT_DSD	By Number of new positives: 20-24	492
PMTCT_STAT_DSD	By Number of new negative: 10-14	44
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,952
PMTCT_STAT_DSD	By Number of new negative: 20-24	22,054
PMTCT_STAT_DSD	By Number of new negative: 50+	5
PMTCT_STAT_DSD	By Age (Numerator): 10-14	45
PMTCT_STAT_DSD	By Age (Numerator): 15-19	5,109
PMTCT_STAT_DSD	By Age (Numerator): 20-24	22,837
PMTCT_STAT_DSD	By Age (Numerator): 50+	5
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	9,522
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	9,522



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	9,522
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	9,522
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	328
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	9,077
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	201
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	328
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	9,077
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	201
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	328
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	9,077
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	201
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	328
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	9,077
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	201
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	9,606
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	9,606
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	9,606
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	9,606
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,232
VMMC_CIRC_DSD	By Age: 10-14	3,729



VMMC_CIRC_DSD	By Age: 15-19	1,908
VMMC_CIRC_DSD	By Age: 20-24	323
VMMC_CIRC_DSD	By Age: 25-29	263
VMMC_CIRC_DSD	By Age: 50+	9
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	5,969
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	6,232
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,091
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	141
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,166
PrEP_NEW_DSD	Male 15-19	11
PrEP_NEW_DSD	Male 20-24	71
PrEP_NEW_DSD	Male 50+	25
PrEP_NEW_DSD	Female 15-19	138
PrEP_NEW_DSD	Female 20-24	480
PrEP_NEW_DSD	Female 50+	25
PrEP_NEW_DSD	FSW	163
PrEP_NEW_DSD	MSM	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	36
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	56
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	56
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	56
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	36
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,145
PP_PREV_DSD	Age/sex: 10-14 Male	10
PP_PREV_DSD	Age/sex: 15-19 Male	145



PP_PREV_DSD	Age/sex: 20-24 Male	36
PP_PREV_DSD	Age/sex: 50+ Male	1
PP_PREV_DSD	Age/sex: 10-14 Female	170
PP_PREV_DSD	Age/sex: 15-19 Female	395
PP_PREV_DSD	Age/sex: 20-24 Female	314
PP_PREV_DSD	Age/sex: 50+ Female	3
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,074
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	15
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	15
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	15
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	3
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	15
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	222,449
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	717
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	342
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	2,466



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,091
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	4,079
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	120
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	4,091
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	19,061
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	563



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	8,434
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	481
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	160
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	436
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	237
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	72
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	42



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	212
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	320
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	319
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female,	2



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	141
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,021
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	134
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	995
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	275
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	44



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	5,038
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	22,420
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	430
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	9,995
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	310
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4,761
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	147
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	34,439
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,060
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	15,238
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	472
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	293
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	868
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	27



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	270
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	129
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	51



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	311
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	374
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	374
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	4



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,147
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,402
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,310
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,885
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,885
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	961
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29,	9,229



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	9,229
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	222
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	9,229
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	223
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	9,234
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	223
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male,	10



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	143
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	82



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	189
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,072
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,346
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	134
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,368
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	5,213
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	164
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	592
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	5,213
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	164
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	592

	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,736
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	213
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,506
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,574
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	172
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,513
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	142
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,675
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	177
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,552
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total	153



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,688
GEND_GBV_DSD	Number of people receiving post-GBV care	9,658
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,831
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4,831
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,192
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	98
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	289
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	289
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	965
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	965
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,352
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,352
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	98
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	289



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	289
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	289
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	289
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	289
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	289
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	289
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	289
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	98
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	516
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	594



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	191
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	32
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	22
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	116
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	130
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	98
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	252
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	327
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	704
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	999



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	66
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	55
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,137
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	630
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	506
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	840
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	840
PMTCT_EID_DSD	Sum of Infant Age disaggregates	840
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	46,304
TX_CURR_DSD	Age/Sex: 15-19 Male	625
TX_CURR_DSD	Age/Sex: 15-19 Female	1,164
TX_CURR_DSD	Sum of age/sex disaggregates	1,789
TX_CURR_DSD	Age/Sex: <1	26



TX_CURR_DSD	Age/Sex: <1-9	770
TX_CURR_DSD	Age/Sex: 10-14 Male	397
TX_CURR_DSD	Age/Sex: 10-14 Female	420
TX_CURR_DSD	Age/Sex: 20-24 Male	831
TX_CURR_DSD	Age/Sex: 50+ Male	1,263
TX_CURR_DSD	Age/Sex: 20-24 Female	3,243
TX_CURR_DSD	Age/Sex: 50+ Female	2,980
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	7,203
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,234
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	5,467
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,494
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	5,467
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,494
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,725
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,494
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,168
TX_NEW_DSD	By Age/Sex: <1	48
TX_NEW_DSD	By Age/Sex: 1-9	29
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	228
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,025
TX_NEW_DSD	By Age/Sex: 50+ Male	85
TX_NEW_DSD	By Age/Sex: 10-14 Female	7
TX_NEW_DSD	By Age/Sex: 15-19 Female	709



TX_NEW_DSD	By Age/Sex: 20-24 Female	2,678
TX_NEW_DSD	By Age/Sex: 50+ Female	32
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,769
TX_NEW_DSD	Pregnancy status	842
TX_NEW_DSD	Breastfeeding status	55
TX_NEW_DSD	FSW	168
TX_NEW_DSD	MSM	76
TX_NEW_DSD	People in prisons and other enclosed settings	41
TX_NEW_DSD	TG	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	237
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	454
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	275
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	536
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	57
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	536
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	57
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	176
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	41,410
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,470
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,928



TX_RET_DSD	Numerator by Status: Breastfeeding	180
TX_RET_DSD	Denominator by Status: Pregnant	917
TX_RET_DSD	Denominator by Status: Breastfeeding	162
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,400
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,347
HTS_SELF_DSD	HTS_SELF_N_DSD	2,748
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	49



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	49



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,374
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,374
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	139
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	690
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	548
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	1,843
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	412
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	167
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,020
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	8,989
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	315



TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	342
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,317
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,019
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	265
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	298
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,753
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,694
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	8,989
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	46,303
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,131
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,099
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	29,828
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	14,246
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,517
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	457
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,000

Implementing Mechanism Details

Mechanism ID: 17719	Mechanism Name: APHIAPlus Pwani
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 8,110,320	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,110,320	
Funding Source	Funding Amount
GHP-State	8,110,320

Cross-Cutting Budget Attribution(s)

Gender: GBV	113,471
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Adolescent Girls and Young Women (AGYW)	815,735

Budget Code Information

Mechanism ID: 17719		
Mechanism Name: APHIAPlus Pwani		
Prime Partner Name: Pathfinder International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	150,897
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	250,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	263,582
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	440,043
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	536,067
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,159,755
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,949,736
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	360,240

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,351
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	98,110
PMTCT_ART_DSD	New on ART	1,995
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,356
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	98,110
PMTCT_STAT_DSD	Number of new ANC and L&D clients	98,551
PMTCT_STAT_DSD	By Age (Denominator): 10-14	84
PMTCT_STAT_DSD	By Age (Denominator): <15-19	10,835
PMTCT_STAT_DSD	By Age (Denominator): 20-24	31,168
PMTCT_STAT_DSD	By Age (Denominator): 50+	500
PMTCT_STAT_DSD	By Number of known positives: 15-19	51



PMTCT_STAT_DSD	By Number of known positives: 20-24	417
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	212
PMTCT_STAT_DSD	By Number of new positives: 20-24	667
PMTCT_STAT_DSD	By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Number of new negative: 10-14	36
PMTCT_STAT_DSD	By Number of new negative: 15-19	9,585
PMTCT_STAT_DSD	By Number of new negative: 20-24	30,510
PMTCT_STAT_DSD	By Number of new negative: 50+	225
PMTCT_STAT_DSD	By Age (Numerator): 10-14	40
PMTCT_STAT_DSD	By Age (Numerator): 15-19	9,834
PMTCT_STAT_DSD	By Age (Numerator): 20-24	31,601
PMTCT_STAT_DSD	By Age (Numerator): 50+	225
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	13,991
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	13,991
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	13,991
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	13,991
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	462
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	13,519
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	276
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	462
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	13,519
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	276
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	462
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	13,519



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	276
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	462
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	13,519
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	276
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	14,300
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	14,300
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	14,300
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	14,300
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,141
PrEP_NEW_DSD	Male 15-19	11
PrEP_NEW_DSD	Male 20-24	69
PrEP_NEW_DSD	Male 50+	23
PrEP_NEW_DSD	Female 15-19	137
PrEP_NEW_DSD	Female 20-24	468
PrEP_NEW_DSD	Female 50+	23
PrEP_NEW_DSD	FSW	159
PrEP_NEW_DSD	MSM	80
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	80
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	34
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	56
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	56
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	56
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	34
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	267,399



	months	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	360
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	2,145



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,567
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,336
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	4,186
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	9,296
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	12,231
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	291
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,422
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	785
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	869
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	22



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,347
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	8,133
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	115
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	28



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,465
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	850
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	205
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	511
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	376
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	148
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	13



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	682
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,284
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	8
HTC_TST_DSD	By Key Population: FSW, Negative	653
HTC_TST_DSD	By Key Population: FSW, Positive	7
HTC_TST_DSD	By Key Population: MSM, Negative	94
HTC_TST_DSD	By Key Population: PWID, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	113
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	8,232



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	27,207
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	561
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	235
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,423
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,856
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,372
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	6,017
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	187
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	8,173
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	259
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	19,252
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	586
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	929
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	213



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	982
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	5,076
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	463
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	171
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	536
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	203
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	203
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	33



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	129
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	9



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	3,093
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,196
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	178
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	6,753
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	162

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	7,873
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	193
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	8,301
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	204
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,855
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,730
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,855
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,574
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	11,988
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	996
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	11,988
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	182
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	11,988



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	11,988
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	158
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	271
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	311
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	103



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	97
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	97



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	6,513
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	204
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,078
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	7,442
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	229
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,297
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,864
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,297
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,864
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	59



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	432
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	14
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,363
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,365
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	129
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,938
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	153
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,136
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	129
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,951
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	144
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,148
GEND_GBV_DSD	Number of people receiving post-GBV care	11,282
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5,641



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5,641
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	5,086
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	113
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	338
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	338
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,128
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,128
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,579
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,579
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	121
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	338
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	338
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	338



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	338
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	113
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	338
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	338
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	113
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	113
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	338
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	338
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	113
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	113
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	883
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	530
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	375
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within	491



	12 months of birth during the reporting period	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	491
PMTCT_EID_DSD	Sum of Infant Age disaggregates	491
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	55,500
TX_CURR_DSD	Age/Sex: 15-19 Male	1,390
TX_CURR_DSD	Age/Sex: 15-19 Female	1,677
TX_CURR_DSD	Sum of age/sex disaggregates	3,067
TX_CURR_DSD	Age/Sex: <1	50
TX_CURR_DSD	Age/Sex: <1-9	1,594
TX_CURR_DSD	Age/Sex: 10-14 Male	1,687
TX_CURR_DSD	Age/Sex: 10-14 Female	1,728
TX_CURR_DSD	Age/Sex: 20-24 Male	1,852
TX_CURR_DSD	Age/Sex: 50+ Male	1,009
TX_CURR_DSD	Age/Sex: 20-24 Female	4,684
TX_CURR_DSD	Age/Sex: 50+ Female	3,552
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	8,584
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,803
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	6,505
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,815
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	6,505
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,815
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4,442
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,814



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,542
TX_NEW_DSD	By Age/Sex: <1	121
TX_NEW_DSD	By Age/Sex: 1-9	329
TX_NEW_DSD	By Age/Sex: 10-14 Male	121
TX_NEW_DSD	By Age/Sex: 15-19 Male	544
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,782
TX_NEW_DSD	By Age/Sex: 50+ Male	45
TX_NEW_DSD	By Age/Sex: 10-14 Female	169
TX_NEW_DSD	By Age/Sex: 15-19 Female	270
TX_NEW_DSD	By Age/Sex: 20-24 Female	962
TX_NEW_DSD	By Age/Sex: 50+ Female	115
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,008
TX_NEW_DSD	Pregnancy status	543
TX_NEW_DSD	Breastfeeding status	38
TX_NEW_DSD	FSW	10
TX_NEW_DSD	MSM	1
TX_NEW_DSD	People in prisons and other enclosed settings	63
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	805
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	239
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	922
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	288
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	227
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	287
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	229



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	92
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	54,885
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,341
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,448
TX_RET_DSD	Numerator by Status: Breastfeeding	32
TX_RET_DSD	Denominator by Status: Pregnant	505
TX_RET_DSD	Denominator by Status: Breastfeeding	127
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	301
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	606
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,854
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,553
HTS_SELF_DSD	HTS_SELF_N_DSD	5,707
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	307



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	291
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	307



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	2,852
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,855
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	286
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	1,428
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,143
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	3,826
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	857
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	342

TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,506
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,965
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	254
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	224
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,878
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,608
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	247
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	215
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,534
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,510
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,965
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	55,578
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,526
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,334
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	33,985
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	16,743
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,171
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	173
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	913



Implementing Mechanism Details

Mechanism ID: 17944	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,721,058	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 800,550	
Total All Funding Sources and Applied Pipeline Amount: 4,521,608	
Funding Source	Funding Amount
GHP-State	3,721,058

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	2,604,742
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	1,116,317
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID: 17944 Mechanism Name: Linkages Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	71,231
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	3,649,827
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	212
PP_PREV_DSD	Age/sex: 10-14 Male	5
PP_PREV_DSD	Age/sex: 15-19 Male	20
PP_PREV_DSD	Age/sex: 20-24 Male	71
PP_PREV_DSD	Age/sex: 10-14 Female	18
PP_PREV_DSD	Sum of Age/Sex disaggregates	114
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	21
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	21
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	21
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	21
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	86,695
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,740
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,913
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	72,966



	interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	76
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	250
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	53,443
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,390
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,570
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	11,669
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	5,196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	79



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	631
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	214
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	2
HTC_TST_DSD	By Key Population: FSW, Negative	33,119
HTC_TST_DSD	By Key Population: FSW, Positive	1,188
HTC_TST_DSD	By Key Population: MSM, Negative	5,428
HTC_TST_DSD	By Key Population: MSM, Positive	158
HTC_TST_DSD	By Key Population: PWID, Negative	272
HTC_TST_DSD	By Key Population: PWID, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,052
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	737
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	3,625
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	2,421
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	223
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	1

HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	4,401
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,078
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	5,026
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,304
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,255
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,304
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,255
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	9

HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	1,568
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	368
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	1,793
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	450
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	450
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12	795



	months	
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	67
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	58
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	232
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	183
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	4
HTC_TST_TA	By Key Population: FSW, Negative	463
HTC_TST_TA	By Key Population: FSW, Positive	7
HTC_TST_TA	By Key Population: MSM, Negative	2
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 25-29, Female, Negative	58
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 25-29, Male, Negative	20
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 30-34, Female, Negative	67
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 30-34, Female, Positive	1



HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 30-34, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 35-39, Female, Negative	16
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 35-39, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_TA	HTS_TST_N_TA_MbMod_Age_Sex_Result 40-49, Male, Negative	8
HTS_SELF_TA	HTS_SELF_N_TA	598
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	11



	Unassisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	299



HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	299
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	30
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	150
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	120
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	401
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	90
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD	141,404
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	7,487
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	7,575



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	7,575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male,	2,526



	Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	2,526
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	70,702
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	70,702
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	7,069
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	35,349
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	28,283
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	94,740
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	21,209
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	8,485

Implementing Mechanism Details

Mechanism ID: 17945	Mechanism Name: mHealth
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: mHealth Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 825,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 825,000	
Funding Source	Funding Amount
GHP-State	825,000



Cross-Cutting Budget Attribution(s)

Renovation	32,271
------------	--------

Budget Code Information

Mechanism ID: 17945 Mechanism Name: mHealth Prime Partner Name: mHealth Kenya		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	825,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17947	Mechanism Name: Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,516,997	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,516,997	
Funding Source	Funding Amount
GHP-State	1,516,997

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17947		
Mechanism Name: Implementation of Sustainable Laboratory Quality Systems		
Prime Partner Name: African Medical and Research Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,208,843
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	72,358
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	145,796
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	90,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17948	Mechanism Name: Laboratory Networking
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 60,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 60,000	
Funding Source	Funding Amount
GHP-State	60,000

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17948		
Mechanism Name: Laboratory Networking		
Prime Partner Name: African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	60,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17950	Mechanism Name: Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,021,492	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,021,492	
Funding Source	Funding Amount
GHP-State	4,021,492

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	67,184
---------------------------	--------

Budget Code Information

Mechanism ID:	17950	
Mechanism Name:	Implementation of Sustainable Laboratory Quality Systems	
Prime Partner Name:	University of Maryland	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	2,915,829
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	172,039
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	247,781
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	361,250
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	324,593
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17951	Mechanism Name: Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,285,257	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,285,257	
Funding Source	Funding Amount
GHP-State	1,285,257



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17951		
Mechanism Name: Implementation of Sustainable Laboratory Quality Systems		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,053,280
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	88,003
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	143,974
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17954	Mechanism Name: Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Implementation Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 2,695,640	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,695,640	
Funding Source	Funding Amount
GHP-State	2,695,640

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17954	
Mechanism Name:	Implementation of Sustainable Laboratory Quality Systems	
Prime Partner Name:	Global Implementation Solutions	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	2,043,790
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	125,160
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	526,690
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17956	Mechanism Name: VMCM QA Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 349,729	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 349,729	
Funding Source	Funding Amount
GHP-State	349,729

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 17956 Mechanism Name: VMMC QA Support Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	349,729
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17958	Mechanism Name: Afyainfo National Mechanism Follow on (HIGDA)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,053,546	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 846,454	
Total All Funding Sources and Applied Pipeline Amount: 1,900,000	
Funding Source	Funding Amount
GHP-State	1,053,546

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17958	
Mechanism Name:	Afyainfo National Mechanism Follow on (HIGDA)	
Prime Partner Name:	Palladium Group	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	1,053,546
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17959	Mechanism Name: Sustaining National HMIS Kenya
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,155,255	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,400,000	
Total All Funding Sources and Applied Pipeline Amount: 2,555,255	
Funding Source	Funding Amount
GHP-State	1,155,255



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17959		
Mechanism Name: Sustaining National HMIS Kenya		
Prime Partner Name: University of Nairobi		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	300,179
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	855,076
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17960	Mechanism Name: Avenir Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17960 Mechanism Name: Avenir Health Prime Partner Name: Population Council		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17964	Mechanism Name: Measure Evaluation IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17964 Mechanism Name: Measure Evaluation IV Prime Partner Name: University of North Carolina		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18203	Mechanism Name: EGPAF Timiza
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 15,822,446	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 15,822,446	
Funding Source	Funding Amount
GHP-State	15,822,446

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	26,400
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	105,600
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	350,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	350,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation



Sub Area:	Capacity building
Human Resources for Health	3,188,759
Renovation	500,000

Budget Code Information

Mechanism ID: 18203		
Mechanism Name: EGPAF Timiza		
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	913,036
Strategic Area	Budget Code	Planned Amount
Care	HVTB	669,200
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	82,932
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	2,243,847
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	7,823
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	7,290
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	13,396
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	3,248,639
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	401,865
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	840,976
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	6,708,118
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	685,324

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,149
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,290
PMTCT_ART_DSD	New on ART	1,134
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,015
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,290
PMTCT_STAT_DSD	Number of new ANC and L&D clients	43,895
PMTCT_STAT_DSD	By Age (Denominator): 10-14	131
PMTCT_STAT_DSD	By Age (Denominator): <15-19	9,769
PMTCT_STAT_DSD	By Age (Denominator): 20-24	16,512
PMTCT_STAT_DSD	By Age (Denominator): 50+	31
PMTCT_STAT_DSD	By Number of known positives: 10-14	3
PMTCT_STAT_DSD	By Number of known positives: 15-19	669
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,391
PMTCT_STAT_DSD	By Number of new positives: 10-14	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	296
PMTCT_STAT_DSD	By Number of new positives: 20-24	452
PMTCT_STAT_DSD	By Number of new positives: 50+	3
PMTCT_STAT_DSD	By Number of new negative: 10-14	100
PMTCT_STAT_DSD	By Number of new negative: 15-19	7,203
PMTCT_STAT_DSD	By Number of new negative: 20-24	13,206
PMTCT_STAT_DSD	By Number of new negative: 50+	167
PMTCT_STAT_DSD	By Age (Numerator): 10-14	108
PMTCT_STAT_DSD	By Age (Numerator): 15-19	8,157
PMTCT_STAT_DSD	By Age (Numerator): 20-24	15,044
PMTCT_STAT_DSD	By Age (Numerator): 50+	170



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,363
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	4,363
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	4,363
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	4,363
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	143
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	4,338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	143
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	4,338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	143
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	4,171
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	142
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	4,986
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	4,986
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	4,986
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,822
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention	49,052



	program within the reporting period	
VMMC_CIRC_DSD	By Age: 0-60 days	609
VMMC_CIRC_DSD	By Age: 2 months - 9 years	206
VMMC_CIRC_DSD	By Age: 10-14	27,420
VMMC_CIRC_DSD	By Age: 15-19	11,959
VMMC_CIRC_DSD	By Age: 20-24	5,043
VMMC_CIRC_DSD	By Age: 25-29	1,794
VMMC_CIRC_DSD	By Age: 50+	38
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	44,460
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	46,254
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	40,331
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	318
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	507
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	507
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	507
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,584
PrEP_NEW_DSD	Male 15-19	16
PrEP_NEW_DSD	Male 20-24	95
PrEP_NEW_DSD	Male 50+	31
PrEP_NEW_DSD	Female 15-19	190
PrEP_NEW_DSD	Female 20-24	650
PrEP_NEW_DSD	Female 50+	31
PrEP_NEW_DSD	FSW	222
PrEP_NEW_DSD	MSM	111
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	111
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	48
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	79
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	63
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	79
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	63



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	79
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	48
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,310
PP_PREV_DSD	Age/sex: 10-14 Male	305
PP_PREV_DSD	Age/sex: 15-19 Male	1,402
PP_PREV_DSD	Age/sex: 20-24 Male	1,290
PP_PREV_DSD	Age/sex: 50+ Male	437
PP_PREV_DSD	Age/sex: 10-14 Female	1,417
PP_PREV_DSD	Age/sex: 15-19 Female	3,269
PP_PREV_DSD	Age/sex: 20-24 Female	2,857
PP_PREV_DSD	Age/sex: 50+ Female	494
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,471
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	573
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	886
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	573
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	886
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	573
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	886
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	573
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	886
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,276
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	197
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key	160



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,919
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	644,738
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	900
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,074
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	815
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	975
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,817
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	3,121
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	73



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	115
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	2,814
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	5,924
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6,655
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	7,159
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	22,119
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	414
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	47,034
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	890
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	112,814
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,152
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	116,475
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	2,187



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,049
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	4,474
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	16,766
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	40,055
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	37



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	7,353
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	11,022
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	11,025
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	815
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	675
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	14



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	157
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	525
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	203
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,631
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	562
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,573
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	610
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	1,191
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	4,097
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	77
HTC_TST_DSD	By Key Population: FSW, Negative	1,927
HTC_TST_DSD	By Key Population: FSW, Positive	42
HTC_TST_DSD	By Key Population: MSM, Negative	138
HTC_TST_DSD	By Key Population: MSM, Positive	2
HTC_TST_DSD	By Key Population: PWID, Negative	47
HTC_TST_DSD	By Key Population: PWID, Positive	3
HTC_TST_DSD	By Key Population: TG, Negative	1



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	128
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	69
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	556
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	1,248
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	7,746
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	201
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	13,625
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	461
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	167
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	112
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,429
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,829
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	38



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	8,368
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,050
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	167
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	355
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	652
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	384



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	384
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	625
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	578
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	750
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	7



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	750
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	5,210
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	24,553
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	446
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	5,720
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	29,575
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	546
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,100



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	26,843
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	508
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,100
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	8,949
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	164
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	3,746
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	250
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,746
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	155
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,746
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3,746
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	562
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	626



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,946
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,996
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	381
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	37



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	59
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,166
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,781
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,331
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	26



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,140
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	333
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,140
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	333
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	714
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	7,351
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	23
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,171
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,171
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	146
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	948



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	224
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	856
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	146
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	948
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	224
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	856
GEND_GBV_DSD	Number of people receiving post-GBV care	9,916
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,957
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4,956
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,691
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	99
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	99
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	298
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	297
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	99
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	991
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	993



GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	99
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,388
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,388
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	99
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	99
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	99
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	297
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	297
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	297
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	297
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	297
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	297
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	98



	35-39, Male, Sexual Violence (Post-Rape Care)	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	297
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	297
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	98
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	98
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,832
OVC_SERVDSD	Age/Sex: 10-14 Male	2,172
OVC_SERVDSD	Age/Sex: 15-17 Male	1,352
OVC_SERVDSD	By: Age/sex: Male 18-24	846
OVC_SERVDSD	By: Age/sex: Male 25+	2
OVC_SERVDSD	Age/Sex: 10-14 Female	3,627
OVC_SERVDSD	Age/Sex: 15-17 Female	4,273
OVC_SERVDSD	By: Age/sex: 18-24 Female	2,850
OVC_SERVDSD	By: Age/sex: 25+ Female	1
OVC_SERVDSD	Sum of Age/Sex disaggregates	11,424
OVC_SERVDSD	Age/Sex: <1	33
OVC_SERVDSD	Age/Sex: 1-9	3,679
OVC_SERVDSD	Program Completion: Active	18,778
OVC_SERVDSD	Program Completion: Graduation	54
OVC_HIVSTATDSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	15,136
OVC_HIVSTATDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,832
TB_ARTDSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	907

	during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	480
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	418
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	916
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	916
PMTCT_EID_DSD	Sum of Infant Age disaggregates	916
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	81,776
TX_CURR_DSD	Age/Sex: 15-19 Male	1,400
TX_CURR_DSD	Age/Sex: 15-19 Female	2,724
TX_CURR_DSD	Sum of age/sex disaggregates	4,124
TX_CURR_DSD	Age/Sex: <1	311
TX_CURR_DSD	Age/Sex: <1-9	3,960
TX_CURR_DSD	Age/Sex: 10-14 Male	1,181
TX_CURR_DSD	Age/Sex: 10-14 Female	1,331
TX_CURR_DSD	Age/Sex: 20-24 Male	1,844
TX_CURR_DSD	Age/Sex: 50+ Male	2,138
TX_CURR_DSD	Age/Sex: 20-24 Female	7,600
TX_CURR_DSD	Age/Sex: 50+ Female	4,525
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	10,923
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,807
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	8,289



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,953
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8,289
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5,953
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,657
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,953
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,367
TX_NEW_DSD	By Age/Sex: <1	208
TX_NEW_DSD	By Age/Sex: 1-9	253
TX_NEW_DSD	By Age/Sex: 10-14 Male	29
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,024
TX_NEW_DSD	By Age/Sex: 20-24 Male	3,335
TX_NEW_DSD	By Age/Sex: 50+ Male	115
TX_NEW_DSD	By Age/Sex: 10-14 Female	36
TX_NEW_DSD	By Age/Sex: 15-19 Female	959
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,323
TX_NEW_DSD	By Age/Sex: 50+ Female	29
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,850
TX_NEW_DSD	Pregnancy status	1,092
TX_NEW_DSD	Breastfeeding status	146
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	206
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	667
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	240
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	802



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	57
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	802
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	57
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	258
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	80,407
TX_PVLS_DSD	Denominator: Indication: Routine	75,165
TX_PVLS_DSD	Denominator: Indication: Targeted	5,242
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	82
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,114
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	202
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,844
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,750
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	24,948
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,107
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	44,360
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	26,013
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	29,244



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Breastfeeding	210
TX_RET_DSD	Denominator by Status: Pregnant	715
TX_RET_DSD	Denominator by Status: Breastfeeding	216
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,364
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,649
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,745
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,178
HTS_SELF_DSD	HTS_SELF_N_DSD	4,895
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	262



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	87



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	87
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	2,452
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,443
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	245
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	1,222
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	977
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	3,274
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	733
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	293
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	11,941
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the	14,115



	minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	835
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,046
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	8,146
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,118
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	667
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	915
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	6,853
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,463
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	14,115
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	81,884
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,893
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	4,057
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	49,459
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	23,474
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	6,457
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	708
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	5,632

Implementing Mechanism Details

Mechanism ID: 18204	Mechanism Name: UON CRISSP Plus
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 3,792,880	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,792,880	
Funding Source	Funding Amount
GHP-State	3,792,880

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	87,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	130,500
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	150,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Renovation	174,000



Human Resources for Health	1,172,664
----------------------------	-----------

Budget Code Information

Mechanism ID: 18204		
Mechanism Name: UON CRISSP Plus		
Prime Partner Name: University of Nairobi		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	241,916
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	517,298
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	455,456
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,413,414
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	164,796

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received	1,335



	ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,776
PMTCT_ART_DSD	New on ART	553
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	782
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,776
PMTCT_STAT_DSD	Number of new ANC and L&D clients	41,490
PMTCT_STAT_DSD	By Age (Denominator): 10-14	12
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,288
PMTCT_STAT_DSD	By Age (Denominator): 20-24	13,791
PMTCT_STAT_DSD	By Age (Denominator): 50+	327
PMTCT_STAT_DSD	By Number of known positives: 15-19	15
PMTCT_STAT_DSD	By Number of known positives: 20-24	140
PMTCT_STAT_DSD	By Number of new positives: 15-19	40
PMTCT_STAT_DSD	By Number of new positives: 20-24	198
PMTCT_STAT_DSD	By Number of new negative: 10-14	12
PMTCT_STAT_DSD	By Number of new negative: 15-19	3,265
PMTCT_STAT_DSD	By Number of new negative: 20-24	13,337
PMTCT_STAT_DSD	By Number of new negative: 50+	36
PMTCT_STAT_DSD	By Age (Numerator): 10-14	12
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,282
PMTCT_STAT_DSD	By Age (Numerator): 20-24	13,475
PMTCT_STAT_DSD	By Age (Numerator): 50+	36
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	6,018
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	6,018
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	6,018
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	6,018
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	166



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,828
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	166
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	5,828
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	166
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,828
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	166
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	5,828
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	6,000
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	6,000
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	6,000
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	6,000
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,191
PrEP_NEW_DSD	Male 15-19	12
PrEP_NEW_DSD	Male 20-24	70
PrEP_NEW_DSD	Male 50+	23
PrEP_NEW_DSD	Female 15-19	141
PrEP_NEW_DSD	Female 20-24	493



PrEP_NEW_DSD	Female 50+	23
PrEP_NEW_DSD	FSW	167
PrEP_NEW_DSD	MSM	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	83
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	36
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	36
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	264,592
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,211
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	4,172
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	612
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	10



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	429
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	9,460
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	244
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	6,474
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	48,453
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,267
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,976



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	3,754
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	405
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	331
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,390
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	25



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	232
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	724
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	12



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,493
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	411
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,413
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	203
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	257
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	604
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	66
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	228
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,112
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	12,476
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	134
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,067
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	705
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	10,565
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	340
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,256
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	628



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,420
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	247
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,622
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	405
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49,	405



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,126
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,430
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	607
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	607
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	17



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	169
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	4

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	20,134
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	571
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	8,169
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	219
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	22,353
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	636
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	10,109
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	271
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	7,507
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	211
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,432
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	7,507
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	211
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	811
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29,	5,497



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	122
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,497
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	122
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	5,497
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	5,497
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	380
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	44
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,310
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	740
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34,	847



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	211
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	211
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34,	17



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4,396
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	164
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	401
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	5,024
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	187
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	481



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,256
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	481
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,256
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	161
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	6
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,559
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,598
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	136
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,533
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	757



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	131
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,575
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	115
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	778
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	599
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	342
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	257
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	124
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	124
PMTCT_EID_DSD	Sum of Infant Age disaggregates	124
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	34,085
TX_CURR_DSD	Age/Sex: 15-19 Male	294
TX_CURR_DSD	Age/Sex: 15-19 Female	567
TX_CURR_DSD	Sum of age/sex disaggregates	861



TX_CURR_DSD	Age/Sex: <1	25
TX_CURR_DSD	Age/Sex: <1-9	797
TX_CURR_DSD	Age/Sex: 10-14 Male	465
TX_CURR_DSD	Age/Sex: 10-14 Female	430
TX_CURR_DSD	Age/Sex: 20-24 Male	400
TX_CURR_DSD	Age/Sex: 50+ Male	567
TX_CURR_DSD	Age/Sex: 20-24 Female	1,530
TX_CURR_DSD	Age/Sex: 50+ Female	2,666
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	6,453
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,034
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	5,702
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,633
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,888
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,634
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,366
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,634
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,555
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	229
TX_NEW_DSD	By Age/Sex: 10-14 Male	128
TX_NEW_DSD	By Age/Sex: 15-19 Male	84
TX_NEW_DSD	By Age/Sex: 20-24 Male	114
TX_NEW_DSD	By Age/Sex: 50+ Male	163
TX_NEW_DSD	By Age/Sex: 10-14 Female	123



TX_NEW_DSD	By Age/Sex: 15-19 Female	163
TX_NEW_DSD	By Age/Sex: 20-24 Female	439
TX_NEW_DSD	By Age/Sex: 50+ Female	764
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,978
TX_NEW_DSD	Pregnancy status	770
TX_NEW_DSD	Breastfeeding status	107
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,853
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	298
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,443
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	462
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,401
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	462
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	963
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	462
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,279
TX_PVLS_DSD	Denominator: Indication: Routine	29,286
TX_PVLS_DSD	Denominator: Indication: Targeted	3,993
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	328
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,667
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	328
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	1,667



	Female Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,993
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,657
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,993
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	13,646
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,479
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,050
TX_RET_DSD	Numerator by Status: Breastfeeding	63
TX_RET_DSD	Denominator by Status: Pregnant	304
TX_RET_DSD	Denominator by Status: Breastfeeding	66
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	113
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,290
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	106
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,970
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	131



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,904
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	121
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,899
HTS_SELF_DSD	HTS_SELF_N_DSD	1,166
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	62



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	62



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	583
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	583
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	59
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	292
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	234
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	783
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	70
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,178
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	9,453
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,034
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,034
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,156
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,208
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	900



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	900
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,601
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,779
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	3,116
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2,081
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,169
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,081
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	2,927
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,959
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,042
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,959
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	34,079
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	991
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,399
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	21,810
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	9,877
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	679
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	97
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	558



Implementing Mechanism Details

Mechanism ID: 18205	Mechanism Name: UMB PACT Kamili
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,364,493	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,364,493	
Funding Source	Funding Amount
GHP-State	6,364,493

Cross-Cutting Budget Attribution(s)

Gender: GBV	17,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	127,400
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Renovation	12,871
Human Resources for Health	1,657,197
Motor Vehicles: Purchased	67,184



Budget Code Information

Mechanism ID: 18205		
Mechanism Name: UMB PACT Kamili		
Prime Partner Name: University of Maryland Baltimore		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	264,456
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	167,067
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	566,621
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,872,136
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	417,669
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	328,961
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,672,884
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	74,699

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	1,683



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	32,180
PMTCT_ART_DSD	New on ART	665
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,018
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	32,180
PMTCT_STAT_DSD	Number of new ANC and L&D clients	32,691
PMTCT_STAT_DSD	By Age (Denominator): 10-14	18
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,741
PMTCT_STAT_DSD	By Age (Denominator): 20-24	11,020
PMTCT_STAT_DSD	By Number of known positives: 15-19	30
PMTCT_STAT_DSD	By Number of known positives: 20-24	193
PMTCT_STAT_DSD	By Number of new positives: 15-19	51
PMTCT_STAT_DSD	By Number of new positives: 20-24	240
PMTCT_STAT_DSD	By Number of new negative: 10-14	20
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,380
PMTCT_STAT_DSD	By Number of new negative: 20-24	10,580
PMTCT_STAT_DSD	By Number of new negative: 50+	2
PMTCT_STAT_DSD	By Age (Numerator): 10-14	23
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,464
PMTCT_STAT_DSD	By Age (Numerator): 20-24	11,036
PMTCT_STAT_DSD	By Age (Numerator): 50+	2
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,728
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	4,728
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	4,728
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	4,728
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	209
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,365



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	97
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	209
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	4,365
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	97
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	209
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	4,365
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	97
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	209
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	4,365
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	97
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	4,675
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	4,630
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	4,675
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,675
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	2,400
KP_MAT_DSD	Sex: Male	1,400
KP_MAT_DSD	Sex: Female	1,000
KP_MAT_DSD	Sum of Sex disaggregates	2,400
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	624
PrEP_NEW_DSD	Male 15-19	6



PrEP_NEW_DSD	Male 20-24	37
PrEP_NEW_DSD	Male 50+	12
PrEP_NEW_DSD	Female 15-19	75
PrEP_NEW_DSD	Female 20-24	256
PrEP_NEW_DSD	Female 50+	12
PrEP_NEW_DSD	FSW	87
PrEP_NEW_DSD	MSM	44
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	44
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	19
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	25
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	25
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	19
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	54,122
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,727
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	432
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	42,164



KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,117
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	682
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	264,475
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	349
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,202
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	532
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	301



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	15,863
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	210
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	15,920
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	216
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	74,160
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,002
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	32,809
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	446
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	636
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,869
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	460
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	4



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,001
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	8



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	561
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	841
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	841
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	118
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	402
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	113



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	393
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	277
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_DSD	By Key Population: FSW, Negative	10,510
HTC_TST_DSD	By Key Population: FSW, Positive	565
HTC_TST_DSD	By Key Population: MSM, Negative	1,319
HTC_TST_DSD	By Key Population: MSM, Positive	224
HTC_TST_DSD	By Key Population: PWID, Negative	3,254
HTC_TST_DSD	By Key Population: PWID, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,394
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	10,652
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	213
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female,	3,231



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,539
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	11,134
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	205
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	4,924
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	279
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	12



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	182



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	182
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,461
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	9,352
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	5,098
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	11,218
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,278
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	11,218



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,278
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,735
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,389
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	452
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,389
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,389
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,389
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	317
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	17



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	43



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	670
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,402
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	766
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,685
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,685
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	31



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	560
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	561
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	15
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,880
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,877
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	69
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,049
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	57
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	705
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	69
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,048



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	694
GEND_GBV_DSD	Number of people receiving post-GBV care	14,687
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,341
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	7,344
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,814
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	147
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	147
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	147
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	147
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	442
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	443
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	146
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	152
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,464
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,469
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	149
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	152
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	2,057
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,056
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	150
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	149
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	151
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	149
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	146
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	442



	25-29, Female, Physical and/or Emotional Violence	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	440
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	149
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	392
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	440
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	149
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	442
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	440
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	149
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	442
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	440
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	149
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	568



TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	321
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	247
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	32
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	32
PMTCT_EID_DSD	Sum of Infant Age disaggregates	32
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,270
TX_CURR_DSD	Age/Sex: 15-19 Male	365
TX_CURR_DSD	Age/Sex: 15-19 Female	673
TX_CURR_DSD	Sum of age/sex disaggregates	1,038
TX_CURR_DSD	Age/Sex: <1	15
TX_CURR_DSD	Age/Sex: <1-9	476
TX_CURR_DSD	Age/Sex: 10-14 Male	243
TX_CURR_DSD	Age/Sex: 10-14 Female	250
TX_CURR_DSD	Age/Sex: 20-24 Male	484
TX_CURR_DSD	Age/Sex: 50+ Male	745
TX_CURR_DSD	Age/Sex: 20-24 Female	1,880
TX_CURR_DSD	Age/Sex: 50+ Female	1,755
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,240
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,322
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,217
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,065



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,217
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,065
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,193
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,065
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,561
TX_NEW_DSD	By Age/Sex: <1	51
TX_NEW_DSD	By Age/Sex: 1-9	24
TX_NEW_DSD	By Age/Sex: 10-14 Male	7
TX_NEW_DSD	By Age/Sex: 15-19 Male	191
TX_NEW_DSD	By Age/Sex: 20-24 Male	585
TX_NEW_DSD	By Age/Sex: 50+ Male	54
TX_NEW_DSD	By Age/Sex: 10-14 Female	5
TX_NEW_DSD	By Age/Sex: 15-19 Female	509
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,746
TX_NEW_DSD	By Age/Sex: 50+ Female	13
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,110
TX_NEW_DSD	Pregnancy status	550
TX_NEW_DSD	Breastfeeding status	36
TX_NEW_DSD	FSW	106
TX_NEW_DSD	MSM	48
TX_NEW_DSD	TG	10
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	143
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	259
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	159
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	310



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	42
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	310
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	42
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	103
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	26,472
TX_PVLS_DSD	Denominator: Indication: Routine	25,149
TX_PVLS_DSD	Denominator: Indication: Targeted	1,323
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	23
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	442
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	24
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	835
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	445
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,402
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	463
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	15,838
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,610
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	8,196



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	692
TX_RET_DSD	Numerator by Status: Breastfeeding	144
TX_RET_DSD	Denominator by Status: Pregnant	692
TX_RET_DSD	Denominator by Status: Breastfeeding	144
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	57
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,319
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	126
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,109
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,500
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	122
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	5,519



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	82,554
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	1,474



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	4,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	41,277
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	41,277
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	4,128
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	20,638
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	16,511



HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	55,311
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	12,383
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	4,953
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,663
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,131
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	108
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	118
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,858
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,047
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	85
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	98
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,585
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	895
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,131
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	27,270
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	550
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	434
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	17,174
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	9,116
TX_TB_DSD	Denominator: Number of ART patients who had a	891



	specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	270
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	593

Implementing Mechanism Details

Mechanism ID: 18206	Mechanism Name: KCCB KARP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Conference of Catholic Bishops	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,722,497	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,722,497	
Funding Source	Funding Amount
GHP-State	9,722,497

Cross-Cutting Budget Attribution(s)

Gender: GBV	240,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	240,000
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	1,425,007
Motor Vehicles: Purchased	152,028
Adolescent Girls and Young Women (AGYW)	343,239

Budget Code Information

Mechanism ID: 18206 Mechanism Name: KCCB KARP Prime Partner Name: Kenya Conference of Catholic Bishops		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	138,303
Strategic Area	Budget Code	Planned Amount
Care	HVTB	684,072
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	90,136
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	874,199
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	114,800
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	312,521
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	6,913,339
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	595,127

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,895
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,760
PMTCT_ART_DSD	New on ART	754
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,141
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,760
PMTCT_STAT_DSD	Number of new ANC and L&D clients	24,042
PMTCT_STAT_DSD	By Age (Denominator): 10-14	113
PMTCT_STAT_DSD	By Age (Denominator): <15-19	4,239
PMTCT_STAT_DSD	By Age (Denominator): 20-24	8,892
PMTCT_STAT_DSD	By Age (Denominator): 50+	30
PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	248
PMTCT_STAT_DSD	By Number of known positives: 20-24	903
PMTCT_STAT_DSD	By Number of new positives: 10-14	3
PMTCT_STAT_DSD	By Number of new positives: 15-19	144
PMTCT_STAT_DSD	By Number of new positives: 20-24	291
PMTCT_STAT_DSD	By Number of new negative: 10-14	89
PMTCT_STAT_DSD	By Number of new negative: 15-19	3,531
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,435
PMTCT_STAT_DSD	By Number of new negative: 50+	25
PMTCT_STAT_DSD	By Age (Numerator): 10-14	94
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,923



PMTCT_STAT_DSD	By Age (Numerator): 20-24	8,629
PMTCT_STAT_DSD	By Age (Numerator): 50+	25
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,692
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,692
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,692
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2,692
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	497
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	2,101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	497
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,482
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	497
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	497
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,677
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,058
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,677



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,677
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,175
PrEP_NEW_DSD	Male 15-19	12
PrEP_NEW_DSD	Male 20-24	72
PrEP_NEW_DSD	Male 50+	25
PrEP_NEW_DSD	Female 15-19	141
PrEP_NEW_DSD	Female 20-24	482
PrEP_NEW_DSD	Female 50+	25
PrEP_NEW_DSD	FSW	165
PrEP_NEW_DSD	MSM	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	34
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	59
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	58
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	58
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	34
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,316
PP_PREV_DSD	Age/sex: 10-14 Male	1,540
PP_PREV_DSD	Age/sex: 10-14 Female	1,776
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,316
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	296,189
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	185
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,998
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,497
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	10,326
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	197
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	7,988
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	133
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	209
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	644
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	711
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	49



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	156
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	639
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	406
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	7,684
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	10,744
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	273
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	36,392
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	904
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	25,171
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	660
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	563
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	8



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,083
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	546
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,458
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,613
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	22



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	955
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	615
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,484
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	215
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	916
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	149
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	5,113
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	724
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	4,963



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	502
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	211
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	876
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	3,736
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	55
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	31
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	106
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	5



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,656
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	7,629
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	290
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	359
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5,596
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	170
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,874
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	19,273
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	581
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,205
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	335



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	112
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	710
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	272
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,480
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,049
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,260
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,260



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	420
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,465
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	3,213
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,673
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	3,855
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	417
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	3,855
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	63



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	417
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,286
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	101
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,766
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	11,588
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	279
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,047
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	13,953
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	336
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	15



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	12,495
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	316
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,165
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,181
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,181
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,181
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,181
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	363
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	184



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,252
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	586
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	45



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	782
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	23



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	3,548
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	893
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,260
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	223
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	4,260
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	223
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,420
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	45
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,153
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,153
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	78



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	960
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	100
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,015
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	81
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	973
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	112
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	987
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	96
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	156
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	132
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	22
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	15
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	8



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	980
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	206
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	99
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	292
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	182
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	126
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	716
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,343
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	949
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	83
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	53
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	34
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,419
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	672
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	747



	TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	428
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	305
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	123
PMTCT_EID_DSD	Sum of Infant Age disaggregates	428
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	90,010
TX_CURR_DSD	Age/Sex: 15-19 Male	1,389
TX_CURR_DSD	Age/Sex: 15-19 Female	2,919
TX_CURR_DSD	Sum of age/sex disaggregates	4,308
TX_CURR_DSD	Age/Sex: <1	89
TX_CURR_DSD	Age/Sex: <1-9	3,988
TX_CURR_DSD	Age/Sex: 10-14 Male	1,199
TX_CURR_DSD	Age/Sex: 10-14 Female	1,384
TX_CURR_DSD	Age/Sex: 20-24 Male	1,855
TX_CURR_DSD	Age/Sex: 50+ Male	2,351
TX_CURR_DSD	Age/Sex: 20-24 Female	8,140
TX_CURR_DSD	Age/Sex: 50+ Female	5,151
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	12,452
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	4,177
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	9,448
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6,526
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	9,446
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	6,526



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	6,444
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,526
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,176
TX_NEW_DSD	By Age/Sex: <1	137
TX_NEW_DSD	By Age/Sex: 1-9	116
TX_NEW_DSD	By Age/Sex: 10-14 Male	18
TX_NEW_DSD	By Age/Sex: 15-19 Male	569
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,814
TX_NEW_DSD	By Age/Sex: 50+ Male	130
TX_NEW_DSD	By Age/Sex: 10-14 Female	29
TX_NEW_DSD	By Age/Sex: 15-19 Female	751
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,591
TX_NEW_DSD	By Age/Sex: 50+ Female	22
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,924
TX_NEW_DSD	Pregnancy status	819
TX_NEW_DSD	Breastfeeding status	213
TX_NEW_DSD	FSW	64
TX_NEW_DSD	MSM	10
TX_NEW_DSD	People in prisons and other enclosed settings	49
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	152
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	674
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	172
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	827
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	43



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	816
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	43
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	272
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	89,402
TX_PVLS_DSD	Denominator: Indication: Routine	76,862
TX_PVLS_DSD	Denominator: Indication: Targeted	12,540
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	262
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3,777
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	304
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	8,200
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,605
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	23,163
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,858
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	50,240
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	18,341
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,983
TX_RET_DSD	Numerator by Status: Breastfeeding	562



TX_RET_DSD	Denominator by Status: Pregnant	1,359
TX_RET_DSD	Denominator by Status: Breastfeeding	571
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	258
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,406
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	578
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,099
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	321
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,314
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	549
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,799
TB_PREV_DSD	The number of ART patients who completed a course	8,629



	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	9,268
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	453
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	568
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,419
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,828
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	415
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	480
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,053
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,681
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	9,268
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,246
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	90,006
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,237
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	4,671
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	55,382
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	25,716
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	6,909
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	641
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	6,024



	Specimen Sent]: Gene Xpert MTB / R if Assay	
--	---	--

Implementing Mechanism Details

Mechanism ID: 18207	Mechanism Name: Columbia STARS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,078,035	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,078,035	
Funding Source	Funding Amount
GHP-State	3,078,035

Cross-Cutting Budget Attribution(s)

Gender: GBV	5,674
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	2,917,402
Renovation	103,622

Budget Code Information



Mechanism ID: 18207 Mechanism Name: Columbia STARS Prime Partner Name: Columbia University		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	197,922
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	166,794
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	228,911
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	100,696
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	59,139
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	48,465
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,929,743
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	346,365

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	420
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,065
PMTCT_ART_DSD	New on ART	122



PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	298
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,065
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,098
PMTCT_STAT_DSD	By Age (Denominator): 10-14	16
PMTCT_STAT_DSD	By Age (Denominator): <15-19	545
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,126
PMTCT_STAT_DSD	By Age (Denominator): 50+	7
PMTCT_STAT_DSD	By Number of known positives: 15-19	13
PMTCT_STAT_DSD	By Number of known positives: 20-24	81
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	23
PMTCT_STAT_DSD	By Number of new positives: 20-24	46
PMTCT_STAT_DSD	By Number of new negative: 10-14	9
PMTCT_STAT_DSD	By Number of new negative: 15-19	504
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,004
PMTCT_STAT_DSD	By Age (Numerator): 10-14	10
PMTCT_STAT_DSD	By Age (Numerator): 15-19	540
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,131
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	351
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	351
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	351
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	351
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	51
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	282
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	51
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	282

	30-34, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	51
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	282
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	51
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	282
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	346
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	346
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	346
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	346
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	300
KP_MAT_DSD	Sex: Male	250
KP_MAT_DSD	Sex: Female	50
KP_MAT_DSD	Sum of Sex disaggregates	300
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,564
VMMC_CIRC_DSD	By Age: 0-60 days	72
VMMC_CIRC_DSD	By Age: 10-14	1,551
VMMC_CIRC_DSD	By Age: 15-19	517
VMMC_CIRC_DSD	By Age: 20-24	272
VMMC_CIRC_DSD	By Age: 25-29	152



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	2,340
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,492
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	20
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	61
PrEP_NEW_DSD	Male 15-19	1
PrEP_NEW_DSD	Male 20-24	4
PrEP_NEW_DSD	Male 50+	1
PrEP_NEW_DSD	Female 15-19	7
PrEP_NEW_DSD	Female 20-24	25
PrEP_NEW_DSD	Female 50+	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	2
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	35,840
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	825
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	147



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,842
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	471
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,925
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	962
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	8,439



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	238
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	316
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	474
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	474
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	48



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	490
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	977
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	835
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	149
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,876
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	477
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	8



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	401
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	481
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	481
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,190
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,428
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,428
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	476
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	274
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	274
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	274
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	274



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	469
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	6



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	406
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	487
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	487
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	8



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	316
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	196
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	196
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	101
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	78
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	101
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	78



GEND_GBV_DSD	Number of people receiving post-GBV care	5,955
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,977
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,978
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,851
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	60
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	179
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	596
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	596
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	834
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	834
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	60
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	45
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	60



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	60
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	117
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	63
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	54



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	13
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	13
PMTCT_EID_DSD	Sum of Infant Age disaggregates	13
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,244
TX_CURR_DSD	Age/Sex: 15-19 Male	121
TX_CURR_DSD	Age/Sex: 15-19 Female	256
TX_CURR_DSD	Sum of age/sex disaggregates	377
TX_CURR_DSD	Age/Sex: <1	7
TX_CURR_DSD	Age/Sex: <1-9	226
TX_CURR_DSD	Age/Sex: 10-14 Male	80
TX_CURR_DSD	Age/Sex: 10-14 Female	88
TX_CURR_DSD	Age/Sex: 20-24 Male	162
TX_CURR_DSD	Age/Sex: 50+ Male	201
TX_CURR_DSD	Age/Sex: 20-24 Female	714
TX_CURR_DSD	Age/Sex: 50+ Female	402
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	974
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	357
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	739
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	558
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	739
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	558



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	504
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	558
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	481
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	5
TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	12
TX_NEW_DSD	By Age/Sex: 20-24 Male	37
TX_NEW_DSD	By Age/Sex: 50+ Male	6
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	66
TX_NEW_DSD	By Age/Sex: 20-24 Female	226
TX_NEW_DSD	Sum of Age/Sex disaggregates	349
TX_NEW_DSD	Pregnancy status	38
TX_NEW_DSD	Breastfeeding status	10
TX_NEW_DSD	FSW	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	32
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	38
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	38
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	13
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,197
TX_PVLS_DSD	Denominator: Indication: Routine	7,055



TX_PVLS_DSD	Denominator: Indication: Targeted	142
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	8
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	27
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	8
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	98
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	184
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,223
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	184
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,464
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,162
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,232
TX_RET_DSD	Numerator by Status: Pregnant	86
TX_RET_DSD	Numerator by Status: Breastfeeding	34
TX_RET_DSD	Denominator by Status: Pregnant	96
TX_RET_DSD	Denominator by Status: Breastfeeding	38
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	291
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number	23

	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	825
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	308
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	875
HTS_SELF_DSD	HTS_SELF_N_DSD	242
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	4



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49,	13



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	122
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	120
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	12
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	60
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	48
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	161
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	14
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,027
TB_PREV_DSD	The number of ART patients who were newly started on	1,113



	TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	48
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	69
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	612
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	384
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	44
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	45
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	565
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	373
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,113
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,027
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	7,244
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	310
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	427
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	4,229
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	2,278
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	388
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	19
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	358

Implementing Mechanism Details

Mechanism ID: 18208	Mechanism Name: IRDO Tuungane 3
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,275,144	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,275,144	
Funding Source	Funding Amount
GHP-State	7,275,144

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	156,434
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	496,400
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	320,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Economic Strengthening	4,360,870
Adolescent Girls and Young Women (AGYW)	5,193,516
Human Resources for Health	897,565

Budget Code Information

Mechanism ID: 18208		
Mechanism Name: IRDO Tuungane 3		
Prime Partner Name: Impact Research and Development Organization		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	783,065
Strategic Area	Budget Code	Planned Amount
Care	HVTB	9,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	616,492
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	24,303
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,149,054
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	4,590,161
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	12,068
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	91,001
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,405
VMMC_CIRC_DSD	By Age: 10-14	8,029
VMMC_CIRC_DSD	By Age: 15-19	3,623
VMMC_CIRC_DSD	By Age: 20-24	1,076
VMMC_CIRC_DSD	By Age: 25-29	663
VMMC_CIRC_DSD	By Age: 50+	16
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	12,744
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	13,407
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	13,332
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	75
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,211
PrEP_NEW_DSD	Male 15-19	12
PrEP_NEW_DSD	Male 20-24	73
PrEP_NEW_DSD	Male 50+	24
PrEP_NEW_DSD	Female 15-19	145
PrEP_NEW_DSD	Female 20-24	494
PrEP_NEW_DSD	Female 50+	24
PrEP_NEW_DSD	FSW	933
PrEP_NEW_DSD	MSM	278
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	85
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	36
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	48



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	48
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	36
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	84,425
PP_PREV_DSD	Age/sex: 10-14 Male	1,560
PP_PREV_DSD	Age/sex: 15-19 Male	6,283
PP_PREV_DSD	Age/sex: 20-24 Male	7,243
PP_PREV_DSD	Age/sex: 50+ Male	1,808
PP_PREV_DSD	Age/sex: 10-14 Female	14,194
PP_PREV_DSD	Age/sex: 15-19 Female	10,109
PP_PREV_DSD	Age/sex: 20-24 Female	9,836
PP_PREV_DSD	Age/sex: 50+ Female	1,936
PP_PREV_DSD	Sum of Age/Sex disaggregates	52,969
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,946
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	4,912
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	2,946
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	4,912
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	2,970
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	4,912
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	2,946
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	4,912
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,622
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	611



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,869
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	125
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	17
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	93,623
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	4,486
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	146
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	4,124
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	138
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	15,452
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	506
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	13,199
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	433
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	595



	50+, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	327
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	583
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,655
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,368
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	2,093
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,805
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	7,201
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	5,790
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	281
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	7



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,219
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	3,329
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,327
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	6
HTC_TST_DSD	By Key Population: FSW, Negative	3,521
HTC_TST_DSD	By Key Population: FSW, Positive	236
HTC_TST_DSD	By Key Population: MSM, Negative	360
HTC_TST_DSD	By Key Population: MSM, Positive	7
HTC_TST_DSD	By Key Population: PWID, Negative	100
HTC_TST_DSD	By Key Population: PWID, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	242
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	250



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	836
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	799
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2,970
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	3,565
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	116



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	3,565
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	116
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,188
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	40



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	347
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	1,403
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	1,684
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	1,684
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	14



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	561
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	10



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,218
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	1
GEND_GBV_DSD	Number of people receiving post-GBV care	19,951
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	9,975
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	9,976
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	681
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	200
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	200
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	200
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	200
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	600
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	600
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	200
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	197
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,998
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,990
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	199
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	201
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	2,793
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,791
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	199
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	201
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	198
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	200
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	203



GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	200
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	600
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	600
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	204
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	204
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	600
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	600
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	204
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	204
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	600
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	600
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	204
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	204
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	574
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	575
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	204
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	204
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR	31,205



	OVC programs for children and families affected by HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,279
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,430
OVC_SERV_DSD	By: Age/sex: Male 18-24	819
OVC_SERV_DSD	Age/Sex: 10-14 Female	7,359
OVC_SERV_DSD	Age/Sex: 15-17 Female	8,231
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,655
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,689
OVC_SERV_DSD	Sum of Age/Sex disaggregates	19,299
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	123
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,038
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	351
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	572
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	79
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	1,198
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	264
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	225



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	200
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,858
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	896
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	512
OVC_SERV_DSD	Age/Sex: <1	32
OVC_SERV_DSD	Age/Sex: 1-9	3,703
OVC_SERV_DSD	Program Completion: Active	31,199
OVC_SERV_DSD	Program Completion: Graduation	6
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	23,038
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	31,205
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral	211



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	4
TX_CURR_DSD	Age/Sex: 15-19 Female	9
TX_CURR_DSD	Sum of age/sex disaggregates	13
TX_CURR_DSD	Age/Sex: 20-24 Male	5
TX_CURR_DSD	Age/Sex: 50+ Male	4
TX_CURR_DSD	Age/Sex: 20-24 Female	21
TX_CURR_DSD	Age/Sex: 50+ Female	15
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	21
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	13
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	23
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	17
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	26
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	19
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	17
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	17
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	109
TX_NEW_DSD	By Age/Sex: 15-19 Male	2
TX_NEW_DSD	By Age/Sex: 20-24 Male	24
TX_NEW_DSD	By Age/Sex: 15-19 Female	11
TX_NEW_DSD	By Age/Sex: 20-24 Female	37
TX_NEW_DSD	Sum of Age/Sex disaggregates	74
TX_NEW_DSD	Pregnancy status	9
TX_NEW_DSD	Breastfeeding status	1



TX_NEW_DSD	FSW	50
TX_NEW_DSD	MSM	20
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	8
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	7
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	212
TX_PVLS_DSD	Denominator: Indication: Routine	168
TX_PVLS_DSD	Denominator: Indication: Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	26
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	18
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	57
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	112
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	33



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	36
TX_RET_DSD	Numerator by Status: Breastfeeding	2
TX_RET_DSD	Denominator by Status: Pregnant	5
TX_RET_DSD	Denominator by Status: Breastfeeding	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
HTS_SELF_DSD	HTS_SELF_N_DSD	8,637
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	150



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	463



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	463
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	4,322
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	4,315
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	430
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	2,163
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,725
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	5,790
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	1,298
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	515
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	213
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	11
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	9
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	129
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	63



TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	17
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	15

Implementing Mechanism Details

Mechanism ID: 18209		Mechanism Name: LVCT Daraja	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Liverpool VCT and Care			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

Total All Funding Sources: 4,382,617		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 4,382,617			
Funding Source		Funding Amount	
GHP-State		4,382,617	

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	19,500
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	19,500
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs



	and clients
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	3,097,549
Motor Vehicles: Purchased	51,020
Renovation	61,224
Human Resources for Health	265,905

Budget Code Information

Mechanism ID:	18209	
Mechanism Name:	LVCT Daraja	
Prime Partner Name:	Liverpool VCT and Care	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	795,145
Strategic Area	Budget Code	Planned Amount



Care	HVTB	9,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	226,249
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	363,348
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	2,840,593
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	57,282



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	91,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	956
PrEP_NEW_DSD	Male 15-19	9
PrEP_NEW_DSD	Male 20-24	58
PrEP_NEW_DSD	Male 50+	20
PrEP_NEW_DSD	Female 15-19	116
PrEP_NEW_DSD	Female 20-24	393
PrEP_NEW_DSD	Female 50+	20
PrEP_NEW_DSD	FSW	134
PrEP_NEW_DSD	MSM	67
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	67
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	29
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	38
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	47



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	38
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	29
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,853
PP_PREV_DSD	Age/sex: 10-14 Male	41
PP_PREV_DSD	Age/sex: 15-19 Male	545
PP_PREV_DSD	Age/sex: 20-24 Male	366
PP_PREV_DSD	Age/sex: 50+ Male	50
PP_PREV_DSD	Age/sex: 10-14 Female	612
PP_PREV_DSD	Age/sex: 15-19 Female	1,627
PP_PREV_DSD	Age/sex: 20-24 Female	1,768
PP_PREV_DSD	Age/sex: 50+ Female	167
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,176
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	248
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	121
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	248
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	121
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	248
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	121
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	248
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	121
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	19,446
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,888
KP_PREV_DSD	By key population type: Female sex workers (FSW)	11,665



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,848
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	45
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	120,886
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,068
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	510
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	3,677
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,631
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	33



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	241
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	287
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	112
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	827
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	958
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	807
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	378
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	75



HTC_TST_DSD	By Key Population: FSW, Negative	17,306
HTC_TST_DSD	By Key Population: FSW, Positive	288
HTC_TST_DSD	By Key Population: MSM, Negative	3,172
HTC_TST_DSD	By Key Population: MSM, Positive	116
HTC_TST_DSD	By Key Population: PWID, Negative	1,497
HTC_TST_DSD	By Key Population: PWID, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	282
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	129
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	969
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	422
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	60



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	10,467
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	171
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	3,608
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	36,052
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	591
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	11,548
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,248
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	728
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	73
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	11

HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	104
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	213
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	17

HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	466
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	254
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	554
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	554
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	185
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	142
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	142
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	8,724
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	196
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	3,646
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	52



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	9,968
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	221
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,374
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,492
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	4,374
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,492
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,457
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	1



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	24
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	24
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
GEND_GBV_DSD	Number of people receiving post-GBV care	12,675



GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6,341
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,342
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	3,731
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	126
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	126
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	380
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	377
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	126
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,265
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,269
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	128
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,778
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,777
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	129
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	127
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	126
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	128
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	125
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	385
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	381
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	127
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	126



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	385
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	381
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	127
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	385
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	381
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	127
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	385
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	381
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	127
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	126
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,571
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,395
OVC_SERV_DSD	Age/Sex: 15-17 Male	715
OVC_SERV_DSD	By: Age/sex: Male 18-24	409
OVC_SERV_DSD	By: Age/sex: Male 25+	6
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,630
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,904
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,255



OVC_SERV_DSD	By: Age/sex: 25+ Female	26
OVC_SERV_DSD	Sum of Age/Sex disaggregates	6,644
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,894
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	6,598
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	699
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	85
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	3,064
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	35
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	797
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	230
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	435
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	186
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	156
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	75
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	398



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	445
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	181
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	465
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	606
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,001
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	4,254
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	3,678
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	151
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	282
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	236
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	29



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	3
OVC_SERV_DSD	Age/Sex: <1	147
OVC_SERV_DSD	Age/Sex: 1-9	4,089
OVC_SERV_DSD	Program Completion: Active	12,529
OVC_SERV_DSD	Program Completion: Graduation	42
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	10,874
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,571
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	18
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,723
TX_CURR_DSD	Age/Sex: 15-19 Male	71
TX_CURR_DSD	Age/Sex: 15-19 Female	127
TX_CURR_DSD	Sum of age/sex disaggregates	198
TX_CURR_DSD	Age/Sex: <1	1
TX_CURR_DSD	Age/Sex: <1-9	30
TX_CURR_DSD	Age/Sex: 10-14 Male	15
TX_CURR_DSD	Age/Sex: 10-14 Female	16
TX_CURR_DSD	Age/Sex: 20-24 Male	92
TX_CURR_DSD	Age/Sex: 50+ Male	128



TX_CURR_DSD	Age/Sex: 20-24 Female	359
TX_CURR_DSD	Age/Sex: 50+ Female	311
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	756
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	224
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	574
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	353
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	574
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	353
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	392
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	353
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	736
TX_NEW_DSD	By Age/Sex: 15-19 Male	32
TX_NEW_DSD	By Age/Sex: 20-24 Male	102
TX_NEW_DSD	By Age/Sex: 50+ Male	6
TX_NEW_DSD	By Age/Sex: 15-19 Female	80
TX_NEW_DSD	By Age/Sex: 20-24 Female	278
TX_NEW_DSD	By Age/Sex: 50+ Female	5
TX_NEW_DSD	Sum of Age/Sex disaggregates	503
TX_NEW_DSD	Pregnancy status	85
TX_NEW_DSD	Breastfeeding status	7
TX_NEW_DSD	FSW	16
TX_NEW_DSD	MSM	7
TX_NEW_DSD	People in prisons and other enclosed settings	3
TX_NEW_DSD	TG	1



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	42
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	31
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	48
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	37
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	12
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	37
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	12
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	12
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,947
TX_PVLS_DSD	Denominator: Indication: Routine	4,615
TX_PVLS_DSD	Denominator: Indication: Targeted	332
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	9
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	136
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	5
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	182
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	39
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,659
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	31



	Female Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,886
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	826
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	845
TX_RET_DSD	Numerator by Status: Breastfeeding	15
TX_RET_DSD	Denominator by Status: Pregnant	70
TX_RET_DSD	Denominator by Status: Breastfeeding	13
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	264
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	573
HTS_SELF_DSD	HTS_SELF_N_DSD	19,078
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	340



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	340



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	1,022
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	340
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	9,539
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	9,539
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	953
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	4,770
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	3,816
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	12,782
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	2,862
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	1,145
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	170



	period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	198
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	7
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	8
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	117
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	66
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	6
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	7
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	99
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	57
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	198
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	4,723
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	117
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	118
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	3,041
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,448
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	151
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	45
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	100

Implementing Mechanism Details

Mechanism ID: 18213	Mechanism Name: Partnership with MOH on
----------------------------	--



	HIV/AIDS and TB Programs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,427,832	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,427,832	
Funding Source	Funding Amount
GHP-State	2,427,832

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	54,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	64,800
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building



Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	50,000

Budget Code Information

Mechanism ID: 18213		
Mechanism Name: Partnership with MOH on HIV/AIDS and TB Programs		
Prime Partner Name: Ministry of Health (MOH)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	379,775
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	33,086
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	199,914
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	49,875
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	31,835
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	187,053
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	99,751
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	879,715
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	340,097
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	226,731



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18214	Mechanism Name: Health Information Systems Innovations
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,726,177	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,726,177	
Funding Source	Funding Amount
GHP-State	3,726,177

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18214		
Mechanism Name: Health Information Systems Innovations		
Prime Partner Name: Palladium Group		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	3,249,226
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	476,951
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18215	Mechanism Name: Coptic Hospitals
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Coptic Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,977,262	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,977,262	
Funding Source	Funding Amount



GHP-State	1,977,262
-----------	-----------

Cross-Cutting Budget Attribution(s)

Gender: GBV	47,800
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	629,384

Budget Code Information

Mechanism ID: 18215		
Mechanism Name: Coptic Hospitals		
Prime Partner Name: Coptic Hospital		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	163,742
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	124,223
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	33,681
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,510,067
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	145,549

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	346
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,284
PMTCT_ART_DSD	New on ART	7
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	339
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,284
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,304
PMTCT_STAT_DSD	By Age (Denominator): <15-19	37
PMTCT_STAT_DSD	By Age (Denominator): 20-24	105
PMTCT_STAT_DSD	By Number of known positives: 15-19	11
PMTCT_STAT_DSD	By Number of known positives: 20-24	37
PMTCT_STAT_DSD	By Number of new positives: 15-19	1
PMTCT_STAT_DSD	By Number of new positives: 20-24	1
PMTCT_STAT_DSD	By Number of new negative: 15-19	25
PMTCT_STAT_DSD	By Number of new negative: 20-24	63
PMTCT_STAT_DSD	By Age (Numerator): 15-19	37
PMTCT_STAT_DSD	By Age (Numerator): 20-24	100



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	550
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	402
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	171
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	106
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	435
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	87
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	313
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	94
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	74
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	21
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	542
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	401
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	169
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	35
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	165
PrEP_NEW_DSD	Male 15-19	2



PrEP_NEW_DSD	Male 20-24	10
PrEP_NEW_DSD	Male 50+	3
PrEP_NEW_DSD	Female 15-19	19
PrEP_NEW_DSD	Female 20-24	67
PrEP_NEW_DSD	Female 50+	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	5
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,381
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	375
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	206
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,289
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male,	660



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,053
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,243
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,890
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,803
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	222
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+,	4



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	202
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	559
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	447
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,925
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,431
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	6



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	3



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	256
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	221
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	292
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	265
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	265
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49,	89

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,303
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,284
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,463
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,553
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,237
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	412
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	6

	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	8



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	2



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,261
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	618
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,441
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	743
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	361
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	743
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	361
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	247



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	7
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	271
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	272
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	127
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	126
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	129
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	122
GEND_GBV_DSD	Number of people receiving post-GBV care	81
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	41



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	11
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	8
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	11
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	2



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	166
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	12



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	70
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	31
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	31
PMTCT_EID_DSD	Sum of Infant Age disaggregates	31
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,000
TX_CURR_DSD	Age/Sex: 15-19 Male	212
TX_CURR_DSD	Age/Sex: 15-19 Female	391
TX_CURR_DSD	Sum of age/sex disaggregates	603
TX_CURR_DSD	Age/Sex: <1	7
TX_CURR_DSD	Age/Sex: <1-9	301
TX_CURR_DSD	Age/Sex: 10-14 Male	110
TX_CURR_DSD	Age/Sex: 10-14 Female	121
TX_CURR_DSD	Age/Sex: 20-24 Male	283
TX_CURR_DSD	Age/Sex: 50+ Male	422
TX_CURR_DSD	Age/Sex: 20-24 Female	1,072
TX_CURR_DSD	Age/Sex: 50+ Female	1,056
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,631
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	749
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,893
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,170



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,922
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,170
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,320
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,170
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,245
TX_NEW_DSD	By Age/Sex: <1	9
TX_NEW_DSD	By Age/Sex: 1-9	5
TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	57
TX_NEW_DSD	By Age/Sex: 20-24 Male	185
TX_NEW_DSD	By Age/Sex: 50+ Male	14
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	93
TX_NEW_DSD	By Age/Sex: 20-24 Female	326
TX_NEW_DSD	By Age/Sex: 50+ Female	14
TX_NEW_DSD	Sum of Age/Sex disaggregates	691
TX_NEW_DSD	Pregnancy status	7
TX_NEW_DSD	Breastfeeding status	8
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	102
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	70
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	119
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	82
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	29



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	82
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	29
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	27
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	16,526
TX_PVLS_DSD	Denominator: Indication: Routine	13,224
TX_PVLS_DSD	Denominator: Indication: Targeted	3,302
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	52
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,076
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	54
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,120
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	214
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,304
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	222
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,484
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,822
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,825
TX_RET_DSD	Numerator by Status: Breastfeeding	39



TX_RET_DSD	Denominator by Status: Pregnant	149
TX_RET_DSD	Denominator by Status: Breastfeeding	39
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	546
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,276
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	549
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,276
HTS_SELF_DSD	HTS_SELF_N_DSD	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34,	1



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	2
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	2
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	1
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,442
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the	2,766



	minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	111
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	115
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,631
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	910
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	94
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	99
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,448
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	801
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,766
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	16,000
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	274
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	265
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	10,285
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	5,176
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	924
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	175
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	711

Implementing Mechanism Details

Mechanism ID: 18216	Mechanism Name: UMB PACE Kamilisha
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 500,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18216		
Mechanism Name: UMB PACE Kamilisha		
Prime Partner Name: University of Maryland Baltimore		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	45,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	455,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18217	Mechanism Name: Ngima for Sure
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: County Government of Siaya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,911,377	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,911,377	
Funding Source	Funding Amount
GHP-State	1,911,377

Cross-Cutting Budget Attribution(s)

Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building



Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	669,829

Budget Code Information

Mechanism ID: 18217		
Mechanism Name: Ngima for Sure		
Prime Partner Name: County Government of Siaya		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	123,378
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	412,364
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	62,167
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,247,487
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	65,981

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	210
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,329
PMTCT_ART_DSD	New on ART	57
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	153
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,329
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,359
PMTCT_STAT_DSD	By Age (Denominator): 10-14	3
PMTCT_STAT_DSD	By Age (Denominator): <15-19	253
PMTCT_STAT_DSD	By Age (Denominator): 20-24	478
PMTCT_STAT_DSD	By Age (Denominator): 50+	5
PMTCT_STAT_DSD	By Number of known positives: 15-19	8
PMTCT_STAT_DSD	By Number of known positives: 20-24	46
PMTCT_STAT_DSD	By Number of new positives: 15-19	10
PMTCT_STAT_DSD	By Number of new positives: 20-24	23
PMTCT_STAT_DSD	By Number of new negative: 10-14	4
PMTCT_STAT_DSD	By Number of new negative: 15-19	205
PMTCT_STAT_DSD	By Number of new negative: 20-24	394
PMTCT_STAT_DSD	By Number of new negative: 50+	4
PMTCT_STAT_DSD	By Age (Numerator): 10-14	4
PMTCT_STAT_DSD	By Age (Numerator): 15-19	223
PMTCT_STAT_DSD	By Age (Numerator): 20-24	463
PMTCT_STAT_DSD	By Age (Numerator): 50+	4



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	155
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	155
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	155
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	155
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	121
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	136
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	121
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	121
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	155
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	170
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	155
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	155
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in	69



	the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	1
PrEP_NEW_DSD	Male 20-24	4
PrEP_NEW_DSD	Male 50+	1
PrEP_NEW_DSD	Female 15-19	8
PrEP_NEW_DSD	Female 20-24	28
PrEP_NEW_DSD	Female 50+	1
PrEP_NEW_DSD	FSW	10
PrEP_NEW_DSD	MSM	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	4
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	2
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	2
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,852
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	28



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	603
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,058
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,071
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,463
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	118
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	199
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male,	1



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	4



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	360
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	598
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34,	2



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	718
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	718
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male,	11



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	10
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	10
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5
GEND_GBV_DSD	Number of people receiving post-GBV care	146
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	73
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	74
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	74
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	5



GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	14
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	21
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	21
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases	7



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	41
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	41
PMTCT_EID_DSD	Sum of Infant Age disaggregates	41
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,896
TX_CURR_DSD	Age/Sex: 15-19 Male	72
TX_CURR_DSD	Age/Sex: 15-19 Female	143
TX_CURR_DSD	Sum of age/sex disaggregates	215
TX_CURR_DSD	Age/Sex: <1	5
TX_CURR_DSD	Age/Sex: <1-9	189
TX_CURR_DSD	Age/Sex: 10-14 Male	57
TX_CURR_DSD	Age/Sex: 10-14 Female	64
TX_CURR_DSD	Age/Sex: 20-24 Male	98
TX_CURR_DSD	Age/Sex: 50+ Male	106
TX_CURR_DSD	Age/Sex: 20-24 Female	397
TX_CURR_DSD	Age/Sex: 50+ Female	205
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	495
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	187
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	375



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	291
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	375
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	291
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	255
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	291
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	537
TX_NEW_DSD	By Age/Sex: <1	8
TX_NEW_DSD	By Age/Sex: 1-9	6
TX_NEW_DSD	By Age/Sex: 15-19 Male	42
TX_NEW_DSD	By Age/Sex: 20-24 Male	147
TX_NEW_DSD	By Age/Sex: 50+ Male	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	48
TX_NEW_DSD	By Age/Sex: 20-24 Female	167
TX_NEW_DSD	Sum of Age/Sex disaggregates	408
TX_NEW_DSD	Pregnancy status	43
TX_NEW_DSD	Breastfeeding status	4
TX_NEW_DSD	FSW	2
TX_NEW_DSD	People in prisons and other enclosed settings	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	47
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	32
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	27
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	9
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	676



	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Denominator: Indication: Routine	676
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	26
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	252
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	26
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	372
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,466
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,557
TX_RET_DSD	Numerator by Status: Breastfeeding	99
TX_RET_DSD	Denominator by Status: Pregnant	194
TX_RET_DSD	Denominator by Status: Breastfeeding	99
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	554
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	912
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	543
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1,014



	including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	120
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	60
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	60
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	6
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	30
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	24
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW,	80

	Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	7
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	187
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	207
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	9
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	8
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	124
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	66
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	8
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	7
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	112
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	60
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	207
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,897
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	188
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	162
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	2,355
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,192
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB	331



	disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	23
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	303

Implementing Mechanism Details

Mechanism ID: 18223	Mechanism Name: Kemri Non-Research	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Maryland		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,823,335	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,823,335	
Funding Source	Funding Amount
GHP-State	2,823,335

Cross-Cutting Budget Attribution(s)

Gender: GBV	92,120
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	92,120
Focus Area:	Equity in HIV prevention, care, treatment and support



Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	750,000

Budget Code Information

Mechanism ID: 18223		
Mechanism Name: Kemri Non-Research		
Prime Partner Name: University of Maryland		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	750,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	1,593,335
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	480,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18260		Mechanism Name: International AIDS Education and Training Center (I-TECH)	
Funding Agency: HHS/HRSA		Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	
Total All Funding Sources: 450,000		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 450,000			
Funding Source		Funding Amount	
GHP-State		450,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18260		
Mechanism Name: International AIDS Education and Training Center (I-TECH)		
Prime Partner Name: University of Washington		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	450,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18262	Mechanism Name: Strengthening Public Health Capacity and SI Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	Funding Amount



GHP-State	100,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18262		
Mechanism Name: Strengthening Public Health Capacity and SI Systems		
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	100,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18281	Mechanism Name: Kenya Supply Chain System Strengthening
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics. Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 951,693	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 951,693	
Funding Source	Funding Amount
GHP-State	951,693

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18281		
Mechanism Name: Kenya Supply Chain System Strengthening		
Prime Partner Name: Chemonics. Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	726,293
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	225,400
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18283	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18284	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18285	Mechanism Name: Coordinating Comprehensive Care for Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18285		
Mechanism Name: Coordinating Comprehensive Care for Children		
Prime Partner Name: Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18318	Mechanism Name: County Measurement Learning & Accountability Project (CMLAP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,271,939	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,873,831	
Total All Funding Sources and Applied Pipeline Amount: 3,145,770	
Funding Source	Funding Amount
GHP-State	1,271,939

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18318	
Mechanism Name:	County Measurement Learning & Accountability Project	
Prime Partner Name:	(CMLAP) Palladium Group	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	250,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	1,021,939
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18493	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 18494	Mechanism Name: HIV AIDS Clinical Services Cluster 1
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 19,711,347	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 19,711,347	
Funding Source	Funding Amount
GHP-State	19,711,347

Cross-Cutting Budget Attribution(s)

Gender: GBV	830,234
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	8,583,434
Water	150,000

Budget Code Information

Mechanism ID:	18494
----------------------	--------------



Mechanism Name: HIV AIDS Clinical Services Cluster 1		
Prime Partner Name: Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,634,200
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	967,373



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	4,165,994
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	6,499,492
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	646,845
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,451,494
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	345,949

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,681
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	38,864
PMTCT_ART_DSD	New on ART	1,187
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,494



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	38,864
PMTCT_STAT_DSD	Number of new ANC and L&D clients	40,541
PMTCT_STAT_DSD	By Age (Denominator): 10-14	169
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,030
PMTCT_STAT_DSD	By Age (Denominator): 20-24	14,880
PMTCT_STAT_DSD	By Age (Denominator): 50+	38
PMTCT_STAT_DSD	By Number of known positives: 10-14	4
PMTCT_STAT_DSD	By Number of known positives: 15-19	179
PMTCT_STAT_DSD	By Number of known positives: 20-24	699
PMTCT_STAT_DSD	By Number of known positives: 50+	1
PMTCT_STAT_DSD	By Number of new positives: 10-14	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	232
PMTCT_STAT_DSD	By Number of new positives: 20-24	473
PMTCT_STAT_DSD	By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Number of new negative: 10-14	144
PMTCT_STAT_DSD	By Number of new negative: 15-19	6,433
PMTCT_STAT_DSD	By Number of new negative: 20-24	13,655
PMTCT_STAT_DSD	By Number of new negative: 50+	26
PMTCT_STAT_DSD	By Age (Numerator): 10-14	151
PMTCT_STAT_DSD	By Age (Numerator): 15-19	6,843
PMTCT_STAT_DSD	By Age (Numerator): 20-24	14,849
PMTCT_STAT_DSD	By Age (Numerator): 50+	29
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,606
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	4,606
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	4,606
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	4,606
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	416
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	3,797



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	135
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	416
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,797
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	135
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	416
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	3,797
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	135
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	416
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	3,797
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	135
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	4,344
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	4,344
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	4,344
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,344
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	38,484
VMMC_CIRC_DSD	By Age: 0-60 days	1,098
VMMC_CIRC_DSD	By Age: 2 months - 9 years	3
VMMC_CIRC_DSD	By Age: 10-14	23,395
VMMC_CIRC_DSD	By Age: 15-19	9,408
VMMC_CIRC_DSD	By Age: 20-24	4,015
VMMC_CIRC_DSD	By Age: 25-29	1,626



VMMC_CIRC_DSD	By Age: 50+	39
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	36,857
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	38,483
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	38,202
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	280
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	3,531
PrEP_NEW_DSD	Male 15-19	36
PrEP_NEW_DSD	Male 20-24	211
PrEP_NEW_DSD	Male 50+	71
PrEP_NEW_DSD	Female 15-19	424
PrEP_NEW_DSD	Female 20-24	1,448
PrEP_NEW_DSD	Female 50+	71
PrEP_NEW_DSD	FSW	494
PrEP_NEW_DSD	MSM	247
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	247
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	106
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	176
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	140
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	176
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	140
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	176
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	106
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	28,659
PP_PREV_DSD	Age/sex: 10-14 Male	365
PP_PREV_DSD	Age/sex: 15-19 Male	1,261
PP_PREV_DSD	Age/sex: 20-24 Male	1,653
PP_PREV_DSD	Age/sex: 50+ Male	444
PP_PREV_DSD	Age/sex: 10-14 Female	3,542



PP_PREV_DSD	Age/sex: 15-19 Female	7,220
PP_PREV_DSD	Age/sex: 20-24 Female	5,929
PP_PREV_DSD	Age/sex: 50+ Female	440
PP_PREV_DSD	Sum of Age/Sex disaggregates	20,854
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	947
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	994
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	947
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	994
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	947
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	994
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	947
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	994
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	459,063
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	881
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	913
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3,051
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,927



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	466
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	843
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,606
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,698
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	350
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	840
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	548
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11,023
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	218



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	19,120
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	387
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	55,437
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,127
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	44,961
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	902
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	704
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,716
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	606
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,219
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,178
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	4



HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,825
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,976



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	5,954
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	189
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	654
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	648
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,260
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	505
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,160
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	437
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	193
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	140



HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	941
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	142
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	193
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	134
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	6,298
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	13,419
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	445
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male,	46



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	9,374
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	126
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	7,325
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	32,362
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	450
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	23,442
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	326
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	283
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,133
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	964
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	194



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	193
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,151
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	233
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,151
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	233
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	384
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	421
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,090
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34,	480



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,307
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	120
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,307
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	120
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	434
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,752
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,103
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	2,103



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	701
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	2,226
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	36



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,708
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	20,774
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	415
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,415
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	24,487
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	485
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,408
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	22,258
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	440
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,408
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	7,416
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	135



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	3,736
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	614
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,736
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,736
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3,736
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	503
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,745
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	905
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male,	430



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	518
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	518
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34,	54



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	98
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	138
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,988
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	10,630
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	134
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,274
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	26



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	12,760
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	169
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	12,760
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	169
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	4,253
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	3,985
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,618
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,624
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	616
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	77



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	853
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	625
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	81
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	833
GEND_GBV_DSD	Number of people receiving post-GBV care	41,267
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20,630
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	20,630
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	12,640
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	413
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1,238
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1,238
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	4,127
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	4,127
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	413



GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	5,778
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	5,778
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	413
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	413
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	413



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1,238
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	413
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	413
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	6,071
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	14,629
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	11,979
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	683
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	454
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	273
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	7,415
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,801
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	478
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	88
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,360
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,324
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	511



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	50
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	864
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,995
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	2,090
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	937
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	357
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	220
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	519
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	2,632
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	5,124
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	452
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	281
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	192
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	15,591
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	34,844
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	24,955
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	843



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	547
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	342
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	642
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	250
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	389
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	314
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	314
PMTCT_EID_DSD	Sum of Infant Age disaggregates	314
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	58,482
TX_CURR_DSD	Age/Sex: 15-19 Male	962
TX_CURR_DSD	Age/Sex: 15-19 Female	1,999
TX_CURR_DSD	Sum of age/sex disaggregates	2,961
TX_CURR_DSD	Age/Sex: <1	58
TX_CURR_DSD	Age/Sex: <1-9	2,923
TX_CURR_DSD	Age/Sex: 10-14 Male	740
TX_CURR_DSD	Age/Sex: 10-14 Female	895
TX_CURR_DSD	Age/Sex: 20-24 Male	1,273
TX_CURR_DSD	Age/Sex: 50+ Male	1,578
TX_CURR_DSD	Age/Sex: 20-24 Female	5,578



TX_CURR_DSD	Age/Sex: 50+ Female	3,157
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	7,678
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,823
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	5,824
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4,422
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	5,824
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4,422
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,971
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,422
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,678
TX_NEW_DSD	By Age/Sex: <1	168
TX_NEW_DSD	By Age/Sex: 1-9	107
TX_NEW_DSD	By Age/Sex: 10-14 Male	12
TX_NEW_DSD	By Age/Sex: 15-19 Male	547
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,839
TX_NEW_DSD	By Age/Sex: 50+ Male	174
TX_NEW_DSD	By Age/Sex: 10-14 Female	18
TX_NEW_DSD	By Age/Sex: 15-19 Female	719
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,578
TX_NEW_DSD	By Age/Sex: 50+ Female	13
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,900
TX_NEW_DSD	Pregnancy status	880
TX_NEW_DSD	Breastfeeding status	401
TX_NEW_DSD	FSW	67



TX_NEW_DSD	MSM	8
TX_NEW_DSD	People in prisons and other enclosed settings	24
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	160
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	824
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	976
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	40
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	954
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	29
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	305
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	58,088
TX_PVLS_DSD	Denominator: Indication: Routine	52,262
TX_PVLS_DSD	Denominator: Indication: Targeted	5,826
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	41
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,146
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	94
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,737
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	874



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,105
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,456
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	36,635
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	18,185
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,490
TX_RET_DSD	Numerator by Status: Breastfeeding	432
TX_RET_DSD	Denominator by Status: Pregnant	1,205
TX_RET_DSD	Denominator by Status: Breastfeeding	455
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	175
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	418
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,905
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,930
HTS_SELF_DSD	HTS_SELF_N_DSD	2,506
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	5



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	135



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,256
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,250
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	125
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	625
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	500
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	1,676
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	375

HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	150
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,746
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	6,969
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	290
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	294
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,461
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,915
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	234
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	235
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,682
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,578
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	6,969
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	409
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	58,483
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,741
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,701
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	36,852
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	16,168
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,613



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	565
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,849

Implementing Mechanism Details

Mechanism ID: 18495	Mechanism Name: HIV/AIDS Clinical Services Cluster 2	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 10,278,236	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,278,236	
Funding Source	Funding Amount
GHP-State	10,278,236

Cross-Cutting Budget Attribution(s)

Gender: GBV	340,013
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	935,035



Budget Code Information

Mechanism ID: 18495		
Mechanism Name: HIV/AIDS Clinical Services Cluster 2		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	953,943
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	29,479
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,054,325
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	122,431
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,444,242
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	6,150,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	523,816

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	4,593



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	125,520
PMTCT_ART_DSD	New on ART	2,010
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,583
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	125,520
PMTCT_STAT_DSD	Number of new ANC and L&D clients	128,456
PMTCT_STAT_DSD	By Age (Denominator): 10-14	33
PMTCT_STAT_DSD	By Age (Denominator): <15-19	13,137
PMTCT_STAT_DSD	By Age (Denominator): 20-24	48,002
PMTCT_STAT_DSD	By Number of known positives: 15-19	164
PMTCT_STAT_DSD	By Number of known positives: 20-24	957
PMTCT_STAT_DSD	By Number of known positives: 50+	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	215
PMTCT_STAT_DSD	By Number of new positives: 20-24	741
PMTCT_STAT_DSD	By Number of new positives: 50+	2
PMTCT_STAT_DSD	By Number of new negative: 10-14	38
PMTCT_STAT_DSD	By Number of new negative: 15-19	12,103
PMTCT_STAT_DSD	By Number of new negative: 20-24	43,652
PMTCT_STAT_DSD	By Number of new negative: 50+	56
PMTCT_STAT_DSD	By Age (Numerator): 10-14	38
PMTCT_STAT_DSD	By Age (Numerator): 15-19	12,497
PMTCT_STAT_DSD	By Age (Numerator): 20-24	45,352
PMTCT_STAT_DSD	By Age (Numerator): 50+	69
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	16,821
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	16,821
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	16,821
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	16,821
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	380



	25-29, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	16,286
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	380
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	16,286
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	380
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	16,286
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	380
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	16,224
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	16,973
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	16,973
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	16,973
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	16,908
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22,033
VMMC_CIRC_DSD	By Age: 0-60 days	37
VMMC_CIRC_DSD	By Age: 2 months - 9 years	249
VMMC_CIRC_DSD	By Age: 10-14	12,954
VMMC_CIRC_DSD	By Age: 15-19	5,872



VMMC_CIRC_DSD	By Age: 20-24	2,156
VMMC_CIRC_DSD	By Age: 25-29	786
VMMC_CIRC_DSD	By Age: 50+	16
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	20,998
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	21,784
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	7,536
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	51
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,332
PrEP_NEW_DSD	Male 15-19	14
PrEP_NEW_DSD	Male 20-24	81
PrEP_NEW_DSD	Male 50+	27
PrEP_NEW_DSD	Female 15-19	160
PrEP_NEW_DSD	Female 20-24	547
PrEP_NEW_DSD	Female 50+	27
PrEP_NEW_DSD	FSW	186
PrEP_NEW_DSD	MSM	93
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	93
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	68
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	52
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	68
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	52
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	68
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	41
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,929
PP_PREV_DSD	Age/sex: 15-19 Male	1,070
PP_PREV_DSD	Age/sex: 20-24 Male	1,751
PP_PREV_DSD	Age/sex: 15-19 Female	1,000



PP_PREV_DSD	Age/sex: 20-24 Female	1,108
PP_PREV_DSD	Sum of Age/Sex disaggregates	4,929
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	433,509
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	160
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,161
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,847
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	7,446
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	5,913
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	139
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	284
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male,	110



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	666
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,123
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,390
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	10,169
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	205
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	17,834
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	363
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	51,490
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,008
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	41,805
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	861
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,917
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+,	40



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	950
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	7,618
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	17,177
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,012
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	115
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	208
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	30



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	208
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	243
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,449
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	3,674
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,674
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	257
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	436
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	128



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	389
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,505
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	433
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,453
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	373
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	874
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	60
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	46
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24,	206



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	147
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	516
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	12,886
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	44,816
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	635
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	504
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	416
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,221
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,709
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	81



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	11,094
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	329
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	8,667
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	257
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	452
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,682
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	401
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	457
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	181



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	181
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,989
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	552
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,271
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	666
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	18



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	665
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	223
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	9

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,548
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	170
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	10,577
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	229
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	8,965
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	198
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	12,016
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	251
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3,829
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,678
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3,827



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,895
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	16,020
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,039
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	15,703
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	137
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	15,258
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	15,124
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	533
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	6



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	476
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	181
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	217



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	325
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	298
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,807
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	760
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	27



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3,207
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	912
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	803
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	912
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	803
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	304
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,449
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,640
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male,	1



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	60
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	32
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	371
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	635
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,882
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,435
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24,	11



	Male, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	28
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	347
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	157
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	347
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	2



	Male, Positive	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	206
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	380
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	95
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	195
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	97
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	62
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,503
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,538
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	264
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,122
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	294



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,858
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	209
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,143
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	306
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,867
GEND_GBV_DSD	Number of people receiving post-GBV care	11,964
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5,983
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5,986
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	5,606
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	119
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	359
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	359
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,197
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,197
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	119



GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,677
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,677
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	119
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	359
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	359
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	359
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	359
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	359
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	359
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	119



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	359
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	359
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	119
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	119
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,505
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	822
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	702
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	665
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	665
PMTCT_EID_DSD	Sum of Infant Age disaggregates	665
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	74,757
TX_CURR_DSD	Age/Sex: 15-19 Male	1,081
TX_CURR_DSD	Age/Sex: 15-19 Female	1,840
TX_CURR_DSD	Sum of age/sex disaggregates	2,921
TX_CURR_DSD	Age/Sex: <1	332
TX_CURR_DSD	Age/Sex: <1-9	2,900
TX_CURR_DSD	Age/Sex: 10-14 Male	1,761
TX_CURR_DSD	Age/Sex: 10-14 Female	1,708
TX_CURR_DSD	Age/Sex: 20-24 Male	1,443



TX_CURR_DSD	Age/Sex: 50+ Male	1,614
TX_CURR_DSD	Age/Sex: 20-24 Female	5,155
TX_CURR_DSD	Age/Sex: 50+ Female	4,872
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	11,767
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,876
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	8,926
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4,490
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8,926
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4,490
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	6,085
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,490
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,550
TX_NEW_DSD	By Age/Sex: <1	182
TX_NEW_DSD	By Age/Sex: 1-9	206
TX_NEW_DSD	By Age/Sex: 10-14 Male	44
TX_NEW_DSD	By Age/Sex: 15-19 Male	729
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,336
TX_NEW_DSD	By Age/Sex: 50+ Male	63
TX_NEW_DSD	By Age/Sex: 10-14 Female	48
TX_NEW_DSD	By Age/Sex: 15-19 Female	809
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,782
TX_NEW_DSD	By Age/Sex: 50+ Female	109
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,920
TX_NEW_DSD	Pregnancy status	1,019



TX_NEW_DSD	Breastfeeding status	80
TX_NEW_DSD	FSW	41
TX_NEW_DSD	People in prisons and other enclosed settings	129
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	756
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	313
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	865
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	376
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	216
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	376
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	216
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	125
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	73,926
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	12
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	2
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	181
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	52
TX_PVLS_DSD	Undocumented Test Indication	247
TX_PVLS_DSD	Denominator: Indication: Routine	69,090
TX_PVLS_DSD	Denominator: Indication: Targeted	4,589
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	387
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	998



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	313
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,891
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,783
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	17,657
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,998
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	45,652
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,960
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,376
TX_RET_DSD	Numerator by Status: Breastfeeding	64
TX_RET_DSD	Denominator by Status: Pregnant	2,147
TX_RET_DSD	Denominator by Status: Breastfeeding	166
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	458
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	919
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,195
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	8,629



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	4,196
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	76



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	2,098
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,098
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	209
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	1,049
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	838



HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	629
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	251
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,987
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10,203
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	455
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	505
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	6,145
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,095
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	426
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	462
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,368
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,731
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,203
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	74,765
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,097
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,412
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	47,717
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	19,526
TX_TB_DSD	Denominator: Number of ART patients who had a	1,957



	specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	426
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,496

Implementing Mechanism Details

Mechanism ID: 18496	Mechanism Name: HIV/AIDS Clinical Services Cluster 3	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 7,551,081	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,551,081	
Funding Source	Funding Amount
GHP-State	7,551,081

Cross-Cutting Budget Attribution(s)

Gender: GBV	69,187
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Adolescent Girls and Young Women (AGYW)	904,086



Budget Code Information

Mechanism ID: 18496 Mechanism Name: HIV/AIDS Clinical Services Cluster 3 Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	433,065
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,109,177
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	461,225
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	749,504
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,450,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	348,110

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	2,117



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	68,100
PMTCT_ART_DSD	New on ART	817
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,300
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	68,100
PMTCT_STAT_DSD	Number of new ANC and L&D clients	69,748
PMTCT_STAT_DSD	By Age (Denominator): 10-14	39
PMTCT_STAT_DSD	By Age (Denominator): <15-19	8,502
PMTCT_STAT_DSD	By Age (Denominator): 20-24	22,003
PMTCT_STAT_DSD	By Age (Denominator): 50+	384
PMTCT_STAT_DSD	By Number of known positives: 15-19	42
PMTCT_STAT_DSD	By Number of known positives: 20-24	211
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	94
PMTCT_STAT_DSD	By Number of new positives: 20-24	279
PMTCT_STAT_DSD	By Number of new positives: 50+	6
PMTCT_STAT_DSD	By Number of new negative: 10-14	103
PMTCT_STAT_DSD	By Number of new negative: 15-19	7,389
PMTCT_STAT_DSD	By Number of new negative: 20-24	21,131
PMTCT_STAT_DSD	By Number of new negative: 50+	490
PMTCT_STAT_DSD	By Age (Numerator): 10-14	94
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,527
PMTCT_STAT_DSD	By Age (Numerator): 20-24	21,622
PMTCT_STAT_DSD	By Age (Numerator): 50+	496
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	9,705
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	9,705
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	9,705
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	9,705



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	280
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	9,212
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	280
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	9,212
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	280
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	9,212
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	280
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	9,212
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	9,954
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	9,593
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	9,593
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	9,593
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,009
PrEP_NEW_DSD	Male 15-19	20
PrEP_NEW_DSD	Male 20-24	120
PrEP_NEW_DSD	Male 50+	40



PrEP_NEW_DSD	Female 15-19	242
PrEP_NEW_DSD	Female 20-24	824
PrEP_NEW_DSD	Female 50+	40
PrEP_NEW_DSD	FSW	279
PrEP_NEW_DSD	MSM	144
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	142
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	59
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	101
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	80
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	101
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	80
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	102
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	58
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,134
PP_PREV_DSD	Age/sex: 10-14 Male	6
PP_PREV_DSD	Age/sex: 15-19 Male	22
PP_PREV_DSD	Age/sex: 20-24 Male	264
PP_PREV_DSD	Age/sex: 50+ Male	37
PP_PREV_DSD	Age/sex: 10-14 Female	20
PP_PREV_DSD	Age/sex: 15-19 Female	148
PP_PREV_DSD	Age/sex: 20-24 Female	479
PP_PREV_DSD	Age/sex: 50+ Female	120
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,096
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	147
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	107
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	147
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	107
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	147
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	107
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	147



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	107
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	473,494
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,635
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,506
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	9,033
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	4,830
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	430
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	229
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	967
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	487
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	16,446
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	470
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	21,928
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	613
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	85,351
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,415
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	43,509
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,313
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	30



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	657
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,527
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,257
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	224
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	274
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	222
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	275
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	33



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	322
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	129
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	241
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	667
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	218
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	414
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,321
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	729
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,234
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	424



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	167
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	514
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	6,900
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	19,482
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	204
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	336
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	97
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female,	1



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5,943
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,908
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	20,091
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	319
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,094
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	110
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,219
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	216
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	735
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	259



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	849
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	291
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	195
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	198
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	210
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,964
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	645



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	3,503
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	782
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	875
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	780
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	875
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	266
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	20

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	20,597
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	598
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	15,666
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	438
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	23,244
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	674
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	18,548
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	516
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	8,627
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	239



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	7,274
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	203
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	8,627
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	239
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,425
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	8,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	399
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	8,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	8,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	8,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	319
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	160



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,134
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	507
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	441
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	503
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	13



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	293
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	193
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	310
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	424
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	8,461



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,297
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	9,629
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	173
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,566
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,478
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,585
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,446
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	521
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,963
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14,	6



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	335
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	193
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,195
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	617
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	62
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	28
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male,	1



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	61
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	192
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	51
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	100
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	645
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	175
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	645



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	110
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	28
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	213
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	595
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	1,789
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	61
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	842
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	397
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,271
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	35



HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,489
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	177
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	17
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	234
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	64
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	37
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	261
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	70
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	47
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	71
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	44
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	10



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	68
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	16
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	496
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	77
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	453
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	90
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	112
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	92
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	112
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	777
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	23



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	777
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	777
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	777
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	76
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	33
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	280
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	123
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	99
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	113
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	20
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	25
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	24



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	24
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	27
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	21
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	44
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	38



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	1,366
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	214
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	1,603
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	253
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	329
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	234
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	361
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	82
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,353
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,357
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	276



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,319
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	260
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,482
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	282
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,341
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	261
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,474
GEND_GBV_DSD	Number of people receiving post-GBV care	15,030
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,519
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	7,517
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	6,352
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	150
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	150
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	150
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	450
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	450



GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	1,503
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,503
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	2,104
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,104
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	150
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	150
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	450
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	450
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	450
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	450
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	450
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3	450

	35-39, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	150
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	150
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	450
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	456
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	150
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	150
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	940
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	525
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	402
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	438
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	438
PMTCT_EID_DSD	Sum of Infant Age disaggregates	438
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	53,781
TX_CURR_DSD	Age/Sex: 15-19 Male	720
TX_CURR_DSD	Age/Sex: 15-19 Female	1,308
TX_CURR_DSD	Sum of age/sex disaggregates	2,028



TX_CURR_DSD	Age/Sex: <1	35
TX_CURR_DSD	Age/Sex: <1-9	1,610
TX_CURR_DSD	Age/Sex: 10-14 Male	975
TX_CURR_DSD	Age/Sex: 10-14 Female	972
TX_CURR_DSD	Age/Sex: 20-24 Male	944
TX_CURR_DSD	Age/Sex: 50+ Male	1,004
TX_CURR_DSD	Age/Sex: 20-24 Female	3,642
TX_CURR_DSD	Age/Sex: 50+ Female	3,900
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	9,415
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,775
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,143
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,780
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	7,143
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,780
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4,871
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,781
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,946
TX_NEW_DSD	By Age/Sex: <1	53
TX_NEW_DSD	By Age/Sex: 1-9	78
TX_NEW_DSD	By Age/Sex: 10-14 Male	8
TX_NEW_DSD	By Age/Sex: 15-19 Male	660
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,145
TX_NEW_DSD	By Age/Sex: 50+ Male	52
TX_NEW_DSD	By Age/Sex: 10-14 Female	27



TX_NEW_DSD	By Age/Sex: 15-19 Female	1,253
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,348
TX_NEW_DSD	By Age/Sex: 50+ Female	214
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,707
TX_NEW_DSD	Pregnancy status	728
TX_NEW_DSD	Breastfeeding status	187
TX_NEW_DSD	FSW	106
TX_NEW_DSD	MSM	35
TX_NEW_DSD	People in prisons and other enclosed settings	207
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,429
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	265
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,654
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	315
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	428
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	342
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	427
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	106
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	44,837
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	105
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	73
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	1,121
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	346



TX_PVLS_DSD	Undocumented Test Indication	1,645
TX_PVLS_DSD	Denominator: Indication: Routine	40,448
TX_PVLS_DSD	Denominator: Indication: Targeted	2,744
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,199
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	51
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,450
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,671
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,442
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,718
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	26,617
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,194
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,280
TX_RET_DSD	Numerator by Status: Breastfeeding	60
TX_RET_DSD	Denominator by Status: Pregnant	897
TX_RET_DSD	Denominator by Status: Breastfeeding	64
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	144
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	311



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,385
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,389
HTS_SELF_DSD	HTS_SELF_N_DSD	1,736
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	32



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	868



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	868
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	87
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	437
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	348
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	1,166
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	261
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	104
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	6,638
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10,983
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	515
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	438
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	6,788
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,242
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	309
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	257
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,122
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,947
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,983



TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	53,779
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,965
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,120
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	34,100
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	15,583
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,351
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	155
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,136

Implementing Mechanism Details

Mechanism ID: 18497	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18499	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18504	Mechanism Name: UMB Timiza
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 9,399,645	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,399,645	
Funding Source	Funding Amount
GHP-State	9,399,645

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	67,255
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	35,415
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: Gender Equality	8,300
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Motor Vehicles: Purchased	175,359
Human Resources for Health	2,020,793



Budget Code Information

Mechanism ID: 18504 Mechanism Name: UMB Timiza Prime Partner Name: University of Maryland Baltimore		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	588,842
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	897,920
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	2,956
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,067,890
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	53,084
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	689,071
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,469,318
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	630,564

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,944
PMTCT_ART_DSD	Number of pregnant women with known HIV status	49,515



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	1,075
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,869
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,515
PMTCT_STAT_DSD	Number of new ANC and L&D clients	50,229
PMTCT_STAT_DSD	By Age (Denominator): 10-14	393
PMTCT_STAT_DSD	By Age (Denominator): <15-19	10,048
PMTCT_STAT_DSD	By Age (Denominator): 20-24	17,945
PMTCT_STAT_DSD	By Age (Denominator): 50+	127
PMTCT_STAT_DSD	By Number of known positives: 10-14	6
PMTCT_STAT_DSD	By Number of known positives: 15-19	168
PMTCT_STAT_DSD	By Number of known positives: 20-24	821
PMTCT_STAT_DSD	By Number of new positives: 10-14	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	233
PMTCT_STAT_DSD	By Number of new positives: 20-24	452
PMTCT_STAT_DSD	By Number of new negative: 10-14	322
PMTCT_STAT_DSD	By Number of new negative: 15-19	9,045
PMTCT_STAT_DSD	By Number of new negative: 20-24	18,538
PMTCT_STAT_DSD	By Number of new negative: 50+	42
PMTCT_STAT_DSD	By Age (Numerator): 10-14	337
PMTCT_STAT_DSD	By Age (Numerator): 15-19	9,443
PMTCT_STAT_DSD	By Age (Numerator): 20-24	19,907
PMTCT_STAT_DSD	By Age (Numerator): 50+	43
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	5,429
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	5,429
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	5,429
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	5,429
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	506



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	6,135
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	506
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	6,039
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	506
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,615
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	506
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,598
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	6,836
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	6,613
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,236
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,100
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	19,520
VMMC_CIRC_DSD	By Age: 0-60 days	494
VMMC_CIRC_DSD	By Age: 10-14	11,970
VMMC_CIRC_DSD	By Age: 15-19	4,682
VMMC_CIRC_DSD	By Age: 20-24	1,697
VMMC_CIRC_DSD	By Age: 25-29	670



VMMC_CIRC_DSD	By Age: 50+	7
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	18,356
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	19,026
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	19,520
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,044
PrEP_NEW_DSD	Male 15-19	11
PrEP_NEW_DSD	Male 20-24	63
PrEP_NEW_DSD	Male 50+	21
PrEP_NEW_DSD	Female 15-19	125
PrEP_NEW_DSD	Female 20-24	428
PrEP_NEW_DSD	Female 50+	21
PrEP_NEW_DSD	FSW	146
PrEP_NEW_DSD	MSM	73
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	73
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	52
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	52
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	52
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	32
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	591
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8
KP_PREV_DSD	By key population type: Female sex workers (FSW)	583



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	384,771
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	724
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	807
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,494
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,581
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	356
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	7



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	212
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,615
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,197
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	10,321
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	184
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	19,651
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	351
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	45,100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	809
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	54,008
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	962
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	246
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	7,304



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	130
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1,692
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,744
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,066
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	68



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,100
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	3,151
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,151
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	662
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	500
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	230
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	270



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	795
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	748
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	142
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	118
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	707
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,910
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	21
HTC_TST_DSD	By Key Population: FSW, Negative	411
HTC_TST_DSD	By Key Population: FSW, Positive	15
HTC_TST_DSD	By Key Population: MSM, Negative	7
HTC_TST_DSD	By Key Population: PWID, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	324
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	9,083
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	18,706
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	479



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	592
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	710
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	710
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	237
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29,	126



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,783
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	143
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,139
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,139
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	713
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,717
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	36,521
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29,	652



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,962
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	43,825
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	782
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	490
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	43,825
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	782
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	490
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	14,608
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	261
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,304
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	549
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,304
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,304
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,304



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	349
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,125
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,117
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	776
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	932
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	932
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	4



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	310
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	71
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	59
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	22



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	97
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,100
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,915
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,920
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	78
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	970
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	804
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	79
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases,	986



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	68
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	794
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	800
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	384
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	416
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	723
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	723
PMTCT_EID_DSD	Sum of Infant Age disaggregates	723
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	73,334
TX_CURR_DSD	Age/Sex: 15-19 Male	860
TX_CURR_DSD	Age/Sex: 15-19 Female	2,148
TX_CURR_DSD	Sum of age/sex disaggregates	3,008
TX_CURR_DSD	Age/Sex: <1	66
TX_CURR_DSD	Age/Sex: <1-9	3,004
TX_CURR_DSD	Age/Sex: 10-14 Male	944
TX_CURR_DSD	Age/Sex: 10-14 Female	1,133
TX_CURR_DSD	Age/Sex: 20-24 Male	1,146
TX_CURR_DSD	Age/Sex: 50+ Male	1,980



TX_CURR_DSD	Age/Sex: 20-24 Female	5,992
TX_CURR_DSD	Age/Sex: 50+ Female	4,323
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	10,452
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,520
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,926
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,503
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	7,926
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5,503
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,405
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,503
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,091
TX_NEW_DSD	By Age/Sex: <1	117
TX_NEW_DSD	By Age/Sex: 1-9	77
TX_NEW_DSD	By Age/Sex: 10-14 Male	20
TX_NEW_DSD	By Age/Sex: 15-19 Male	468
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,503
TX_NEW_DSD	By Age/Sex: 50+ Male	203
TX_NEW_DSD	By Age/Sex: 10-14 Female	26
TX_NEW_DSD	By Age/Sex: 15-19 Female	376
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,299
TX_NEW_DSD	By Age/Sex: 50+ Female	7
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,902
TX_NEW_DSD	Pregnancy status	696
TX_NEW_DSD	Breastfeeding status	227



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	19
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,018
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	61
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,223
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,227
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	417
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	70,607
TX_PVLS_DSD	Denominator: Indication: Routine	70,607
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,959
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	23,125
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,996
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	42,527
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,812
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,322



TX_RET_DSD	Numerator by Status: Breastfeeding	198
TX_RET_DSD	Denominator by Status: Pregnant	648
TX_RET_DSD	Denominator by Status: Breastfeeding	261
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,291
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,521
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,125
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,197
HTS_SELF_DSD	HTS_SELF_N_DSD	3,168
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	169



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	57



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,588
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,580
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	158
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	789
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	632
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	2,117
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	474
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	190
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	7,124
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	8,315



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	420
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	328
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,269
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,298
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	363
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	282
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,536
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,943
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	8,315
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	73,331
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,425
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,072
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	47,411
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	19,423
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,369
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	263
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,999

Implementing Mechanism Details

Mechanism ID: 18505	Mechanism Name: CHS Shinda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 13,282,082	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 13,282,082	
Funding Source	Funding Amount
GHP-State	13,282,082

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	71,306
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	1,254,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Human Resources for Health	3,443,887
Motor Vehicles: Purchased	268,218
Renovation	652,632

Budget Code Information

Mechanism ID:	18505	
Mechanism Name:	CHS Shinda	
Prime Partner Name:	Center for Health Solutions (CHS)	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	656,675
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,309,982
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	2,519,814



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	559,556
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	6,645,679
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	590,376

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,166
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,775
PMTCT_ART_DSD	New on ART	979
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,187
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,775



PMTCT_STAT_DSD	Number of new ANC and L&D clients	26,351
PMTCT_STAT_DSD	By Age (Denominator): 10-14	23
PMTCT_STAT_DSD	By Age (Denominator): <15-19	4,879
PMTCT_STAT_DSD	By Age (Denominator): 20-24	9,279
PMTCT_STAT_DSD	By Age (Denominator): 50+	106
PMTCT_STAT_DSD	By Number of known positives: 15-19	161
PMTCT_STAT_DSD	By Number of known positives: 20-24	934
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	227
PMTCT_STAT_DSD	By Number of new positives: 20-24	368
PMTCT_STAT_DSD	By Number of new positives: 50+	4
PMTCT_STAT_DSD	By Number of new negative: 10-14	96
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,090
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,898
PMTCT_STAT_DSD	By Number of new negative: 50+	80
PMTCT_STAT_DSD	By Age (Numerator): 10-14	96
PMTCT_STAT_DSD	By Age (Numerator): 15-19	4,440
PMTCT_STAT_DSD	By Age (Numerator): 20-24	9,205
PMTCT_STAT_DSD	By Age (Numerator): 50+	86
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3,016
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,016
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	3,016
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,016
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	557
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	2,413
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	557
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	2,042



	30-34, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	557
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,413
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	557
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,413
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3,087
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,687
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,087
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,087
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	50,217
VMMC_CIRC_DSD	By Age: 0-60 days	1,000
VMMC_CIRC_DSD	By Age: 2 months - 9 years	11
VMMC_CIRC_DSD	By Age: 10-14	30,495
VMMC_CIRC_DSD	By Age: 15-19	16,730
VMMC_CIRC_DSD	By Age: 20-24	1,906
VMMC_CIRC_DSD	By Age: 25-29	1,050
VMMC_CIRC_DSD	By Age: 50+	25
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	49,156
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	50,206
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	50,017
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	200



PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,305
PrEP_NEW_DSD	Male 15-19	13
PrEP_NEW_DSD	Male 20-24	79
PrEP_NEW_DSD	Male 50+	25
PrEP_NEW_DSD	Female 15-19	157
PrEP_NEW_DSD	Female 20-24	536
PrEP_NEW_DSD	Female 50+	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	93
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	42
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	62
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	62
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	62
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	39
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	395,050
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	763
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	664
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	2,633



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,109
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,489
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	942
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	18,852
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	341
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	33,021
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	632
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	95,873
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,816
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	76,914



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,449
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,741
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1,624
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	6,796
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	6



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	6,103
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	9,160
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	9,158
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	395
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	256
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	713
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	608



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,430
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	524
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,378
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	463
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	85
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	423
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,794
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,974
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	7,656
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	394
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	472
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	124



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	124
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	513
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	616
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	616
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	205
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	18,684
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	355
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	22,421
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	427



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	22,421
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	427
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	7,478
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,343
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	540
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,343
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,343
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,343
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	439
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	381
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,518
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,209
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	300
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	350



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	350
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	120
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	6,108
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,272



TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,271
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	653
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	57
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	507
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	34
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	650
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	47
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	533
GEND_GBV_DSD	Number of people receiving post-GBV care	1,068
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	527
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	536
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	13
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1



GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	16
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	97
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	129
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	146
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	142
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	198
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	2

	30-34, Male, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	2
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	811
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	462
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	338



	TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	642
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	642
PMTCT_EID_DSD	Sum of Infant Age disaggregates	642
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	82,619
TX_CURR_DSD	Age/Sex: 15-19 Male	1,559
TX_CURR_DSD	Age/Sex: 15-19 Female	3,033
TX_CURR_DSD	Sum of age/sex disaggregates	4,592
TX_CURR_DSD	Age/Sex: <1	93
TX_CURR_DSD	Age/Sex: <1-9	3,819
TX_CURR_DSD	Age/Sex: 10-14 Male	1,146
TX_CURR_DSD	Age/Sex: 10-14 Female	1,290
TX_CURR_DSD	Age/Sex: 20-24 Male	2,078
TX_CURR_DSD	Age/Sex: 50+ Male	2,232
TX_CURR_DSD	Age/Sex: 20-24 Female	8,450
TX_CURR_DSD	Age/Sex: 50+ Female	4,358
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	10,535
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,976
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,984
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6,208
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	7,991
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	6,208
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,451



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,208
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,193
TX_NEW_DSD	By Age/Sex: <1	162
TX_NEW_DSD	By Age/Sex: 1-9	132
TX_NEW_DSD	By Age/Sex: 10-14 Male	4
TX_NEW_DSD	By Age/Sex: 15-19 Male	783
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,538
TX_NEW_DSD	By Age/Sex: 50+ Male	124
TX_NEW_DSD	By Age/Sex: 10-14 Female	11
TX_NEW_DSD	By Age/Sex: 15-19 Female	921
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,160
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,541
TX_NEW_DSD	Pregnancy status	834
TX_NEW_DSD	Breastfeeding status	27
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	622
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	742
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	745
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	249
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	84,861
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	78
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	16
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	656
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	266
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	169



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	963
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	598
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,811
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,168
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	23,733
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,151
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	50,308
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27,098
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	30,139
TX_RET_DSD	Numerator by Status: Pregnant	3,381
TX_RET_DSD	Numerator by Status: Breastfeeding	1,848
TX_RET_DSD	Denominator by Status: Pregnant	3,763
TX_RET_DSD	Denominator by Status: Breastfeeding	1,888
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	254
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,049
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	483
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	17,308



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	359
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,081
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	504
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,205
HTS_SELF_DSD	HTS_SELF_N_DSD	2,072
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	118
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	118
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	104
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	104



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	16



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	112
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	112
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,036
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,036
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	106
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	518
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	411
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	9,381
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	11,056
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	496
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	431
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	6,582
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,547
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	424



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	351
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,612
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,994
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	11,056
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	82,619
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,957
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,433
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	49,968
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	25,261
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	7,037
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	476
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6,420

Implementing Mechanism Details

Mechanism ID: 18506	Mechanism Name: UCSF Clinical Kisumu
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,286,800	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,286,800	
Funding Source	Funding Amount
GHP-State	9,286,800



Cross-Cutting Budget Attribution(s)

Gender: GBV	224,425
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	224,425
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Renovation	21,301
Human Resources for Health	3,327,908

Budget Code Information

Mechanism ID: 18506		
Mechanism Name: UCSF Clinical Kisumu		
Prime Partner Name: University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	506,591



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,840,230
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,082,039
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	404,633
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,958,636
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	494,671

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,885
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,774
PMTCT_ART_DSD	New on ART	672
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,213
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,774
PMTCT_STAT_DSD	Number of new ANC and L&D clients	15,906
PMTCT_STAT_DSD	By Age (Denominator): 10-14	81
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,805
PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,787
PMTCT_STAT_DSD	By Age (Denominator): 50+	37
PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	95



PMTCT_STAT_DSD	By Number of known positives: 20-24	606
PMTCT_STAT_DSD	By Number of known positives: 50+	2
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	128
PMTCT_STAT_DSD	By Number of new positives: 20-24	255
PMTCT_STAT_DSD	By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Number of new negative: 10-14	76
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,566
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,883
PMTCT_STAT_DSD	By Number of new negative: 50+	34
PMTCT_STAT_DSD	By Age (Numerator): 10-14	81
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,789
PMTCT_STAT_DSD	By Age (Numerator): 20-24	5,744
PMTCT_STAT_DSD	By Age (Numerator): 50+	37
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	1,799
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,799
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,799
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,799
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	377
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,331
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	377
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,332
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	377
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	1,332



	35-39, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	377
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,335
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	1,780
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,780
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,780
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,783
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	40,018
VMMC_CIRC_DSD	By Age: 0-60 days	717
VMMC_CIRC_DSD	By Age: 2 months - 9 years	39
VMMC_CIRC_DSD	By Age: 10-14	23,769
VMMC_CIRC_DSD	By Age: 15-19	8,913
VMMC_CIRC_DSD	By Age: 20-24	4,170
VMMC_CIRC_DSD	By Age: 25-29	2,323
VMMC_CIRC_DSD	By Age: 50+	87
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	36,939
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	39,262
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	39,701
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	317
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	782
PrEP_NEW_DSD	Male 15-19	8
PrEP_NEW_DSD	Male 20-24	47
PrEP_NEW_DSD	Male 50+	16



PrEP_NEW_DSD	Female 15-19	94
PrEP_NEW_DSD	Female 20-24	320
PrEP_NEW_DSD	Female 50+	16
PrEP_NEW_DSD	FSW	109
PrEP_NEW_DSD	MSM	55
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	55
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	39
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	39
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	23
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	337,433
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,908
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	341
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	6,573
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male,	1,090



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	185
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	141
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	935
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	723
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	26,167
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	417
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	13,079
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	114,698
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,822
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	19,021
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	301



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,241
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	822
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	9,336
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	7



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	4,931
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	7,397
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	7,396
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	382
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	294
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	359
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	76



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,237
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	257
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,211
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	334
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,320
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,797
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,584
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	280
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	4



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,662
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	5,725
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	949
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	161
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	44



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	927
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,112
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,112
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	371
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	43



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	16,173
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	262
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	19,410
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	311
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	19,410
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	311
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	6,469
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,007
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	314
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,007
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,007
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,007
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,848



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	6,366
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,055
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	898
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	1,075
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	1,075
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	359
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	4



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	807
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	969
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	969
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	11



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	4,930
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	555
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	555
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	296
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	222
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	296
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	222
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	397
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	212
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	185
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	452
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	452
PMTCT_EID_DSD	Sum of Infant Age disaggregates	452
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	52,083
TX_CURR_DSD	Age/Sex: 15-19 Male	850
TX_CURR_DSD	Age/Sex: 15-19 Female	1,796
TX_CURR_DSD	Sum of age/sex disaggregates	2,646
TX_CURR_DSD	Age/Sex: <1	64
TX_CURR_DSD	Age/Sex: <1-9	2,206
TX_CURR_DSD	Age/Sex: 10-14 Male	786
TX_CURR_DSD	Age/Sex: 10-14 Female	863
TX_CURR_DSD	Age/Sex: 20-24 Male	1,149
TX_CURR_DSD	Age/Sex: 50+ Male	1,416
TX_CURR_DSD	Age/Sex: 20-24 Female	5,028
TX_CURR_DSD	Age/Sex: 50+ Female	2,839
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	6,841



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,513
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	5,201
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,927
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	5,203
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,927
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,547
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,927
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,112
TX_NEW_DSD	By Age/Sex: <1	79
TX_NEW_DSD	By Age/Sex: 1-9	66
TX_NEW_DSD	By Age/Sex: 10-14 Male	15
TX_NEW_DSD	By Age/Sex: 15-19 Male	149
TX_NEW_DSD	By Age/Sex: 20-24 Male	476
TX_NEW_DSD	By Age/Sex: 50+ Male	78
TX_NEW_DSD	By Age/Sex: 10-14 Female	16
TX_NEW_DSD	By Age/Sex: 15-19 Female	829
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,904
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,467
TX_NEW_DSD	Pregnancy status	477
TX_NEW_DSD	Breastfeeding status	133
TX_NEW_DSD	FSW	44
TX_NEW_DSD	MSM	5
TX_NEW_DSD	People in prisons and other enclosed settings	38
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male,	398



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	472
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	472
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	158
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	53,120
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	44
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	37
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	465
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	151
TX_PVLS_DSD	Undocumented Test Indication	697
TX_PVLS_DSD	Denominator: Indication: Routine	51,265
TX_PVLS_DSD	Denominator: Indication: Targeted	1,158
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	64
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	300
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	101
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	693
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,926
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	14,819
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,514
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	32,006
TX_RET_DSD	Number of adults and children who are still alive and on	13,574

	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15,692
TX_RET_DSD	Numerator by Status: Breastfeeding	447
TX_RET_DSD	Denominator by Status: Pregnant	1,226
TX_RET_DSD	Denominator by Status: Breastfeeding	487
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	113
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,386
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	123
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,953
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	132
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,853
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	145



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,564
HTS_SELF_DSD	HTS_SELF_N_DSD	1,338
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	70
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	70
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	70



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	73
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	71
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	70
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	70
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	73
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	671
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	667
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	67

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	334
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	267
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	894
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	200
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	80
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,556
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	6,730
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	294
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	421
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,686
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,329
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	244
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	256
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,047
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,009
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	6,730
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,556
TX_TB_DSD	Number of ART patients who were screened for TB at	52,201



	least once during the reporting period	
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,230
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,076
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	30,478
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	16,417
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,794
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	138
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,656

Implementing Mechanism Details

Mechanism ID: 18507	Mechanism Name: CHS Tegemeza Plus
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,225,453	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,225,453	
Funding Source	Funding Amount
GHP-State	3,225,453

Cross-Cutting Budget Attribution(s)

Gender: GBV	128,000
Focus Area:	GBV Prevention
Sub Area:	Implementation



Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	725,093

Budget Code Information

Mechanism ID: 18507		
Mechanism Name: CHS Tegemeza Plus		
Prime Partner Name: Center for Health Solutions (CHS)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	169,424
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,137,030
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	305,010
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,462,399
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	151,590

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	822
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,759
PMTCT_ART_DSD	New on ART	310
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	512
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,759
PMTCT_STAT_DSD	Number of new ANC and L&D clients	25,250
PMTCT_STAT_DSD	By Age (Denominator): <10	30
PMTCT_STAT_DSD	By Age (Denominator): 10-14	2,335
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,456
PMTCT_STAT_DSD	By Age (Denominator): 20-24	3,853
PMTCT_STAT_DSD	By Age (Denominator): 50+	15
PMTCT_STAT_DSD	By Number of known positives: 15-19	10
PMTCT_STAT_DSD	By Number of known positives: 20-24	79
PMTCT_STAT_DSD	By Number of new positives: 15-19	29
PMTCT_STAT_DSD	By Number of new positives: 20-24	101
PMTCT_STAT_DSD	By Number of new negative: 10-14	28
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,153
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,215
PMTCT_STAT_DSD	By Number of new negative: 50+	9
PMTCT_STAT_DSD	By Age (Numerator): 10-14	30
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,237
PMTCT_STAT_DSD	By Age (Numerator): 20-24	7,371
PMTCT_STAT_DSD	By Age (Numerator): 50+	8



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3,853
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,853
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	3,853
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	3,622
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	45
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,615
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	45
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	3,615
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	45
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	3,620
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	45
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3,783
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,783
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,783
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,783
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in	784



	the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	8
PrEP_NEW_DSD	Male 20-24	46
PrEP_NEW_DSD	Male 50+	15
PrEP_NEW_DSD	Female 15-19	94
PrEP_NEW_DSD	Female 20-24	322
PrEP_NEW_DSD	Female 50+	15
PrEP_NEW_DSD	FSW	109
PrEP_NEW_DSD	MSM	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	23
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	349,225
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	977
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	524
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	7



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3,324
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,692
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	235
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,773
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2,259
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	14,944
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	232
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	21,834



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	348
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	80,647
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,265
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	42,958
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	692
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,879
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,065
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	886
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	6,149
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,471
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	32



HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	344
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	408
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	245
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,389
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,285
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	905
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,345
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	7,245

HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	602
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	692
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	111



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	171
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,458
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,664
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	391
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	23,614
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	364
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	16,155
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	259
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	25,843
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	417
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	19,961
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	331
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	9,808

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	150
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	6,340
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	9,919
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,140
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	3,585
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	231
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,660
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,635
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3,642
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	317
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	182
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,083



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	588
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	458
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	524
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	13



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	138

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,886
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,951
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,186
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	81



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	534
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	88
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,219
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	99
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	545
GEND_GBV_DSD	Number of people receiving post-GBV care	46
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	29
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	17
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	6



GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	548
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	321
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	227



PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	71
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	71
PMTCT_EID_DSD	Sum of Infant Age disaggregates	71
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	28,407
TX_CURR_DSD	Age/Sex: 15-19 Male	285
TX_CURR_DSD	Age/Sex: 15-19 Female	405
TX_CURR_DSD	Sum of age/sex disaggregates	690
TX_CURR_DSD	Age/Sex: <1	10
TX_CURR_DSD	Age/Sex: <1-9	724
TX_CURR_DSD	Age/Sex: 10-14 Male	501
TX_CURR_DSD	Age/Sex: 10-14 Female	499
TX_CURR_DSD	Age/Sex: 20-24 Male	374
TX_CURR_DSD	Age/Sex: 50+ Male	545
TX_CURR_DSD	Age/Sex: 20-24 Female	1,135
TX_CURR_DSD	Age/Sex: 50+ Female	2,213
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,381
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	963
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,062
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,494
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,062
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,494
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,766
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	1,494



	Positive	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,233
TX_NEW_DSD	By Age/Sex: <1	17
TX_NEW_DSD	By Age/Sex: 1-9	43
TX_NEW_DSD	By Age/Sex: 10-14 Male	14
TX_NEW_DSD	By Age/Sex: 15-19 Male	292
TX_NEW_DSD	By Age/Sex: 20-24 Male	936
TX_NEW_DSD	By Age/Sex: 50+ Male	22
TX_NEW_DSD	By Age/Sex: 10-14 Female	9
TX_NEW_DSD	By Age/Sex: 15-19 Female	507
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,750
TX_NEW_DSD	By Age/Sex: 50+ Female	110
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,640
TX_NEW_DSD	Pregnancy status	305
TX_NEW_DSD	Breastfeeding status	67
TX_NEW_DSD	FSW	5
TX_NEW_DSD	MSM	3
TX_NEW_DSD	People in prisons and other enclosed settings	101
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	776
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	112
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	886
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	135
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	135
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	222



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	45
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	28,820
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	858
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	8,126
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	935
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	16,021
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	95
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	903
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	97
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,785
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,022
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,602
TX_RET_DSD	Numerator by Status: Pregnant	287
TX_RET_DSD	Numerator by Status: Breastfeeding	18
TX_RET_DSD	Denominator by Status: Pregnant	399
TX_RET_DSD	Denominator by Status: Breastfeeding	25
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,649
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	132
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,186
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,842
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,557
HTS_SELF_DSD	HTS_SELF_N_DSD	650
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	12



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	12



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	325
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	325
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	32
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	161
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	129
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	434
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	97
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	39
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	7,000



	period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	7,000
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	324
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	299
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,488
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,889
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	324
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	299
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,488
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,889
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	7,000
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	28,409
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	949
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	922
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	17,585
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	8,697
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,143
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	107
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,032

Implementing Mechanism Details

Mechanism ID: 18508	Mechanism Name: CHS Naishi
----------------------------	-----------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,107,493	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,107,493	
Funding Source	Funding Amount
GHP-State	9,107,493

Cross-Cutting Budget Attribution(s)

Gender: GBV	158,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	1,332,029
Motor Vehicles: Purchased	178,812
Renovation	243,844

Budget Code Information

Mechanism ID:	18508
Mechanism Name:	CHS Naishi
Prime Partner Name:	Center for Health Solutions (CHS)



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	506,028
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	1,796,134
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	500,035
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	625,155
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,115,579
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	564,562

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,257
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	62,979
PMTCT_ART_DSD	New on ART	941
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,316
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	62,979



	their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	65,473
PMTCT_STAT_DSD	By Age (Denominator): 10-14	118
PMTCT_STAT_DSD	By Age (Denominator): <15-19	9,129
PMTCT_STAT_DSD	By Age (Denominator): 20-24	22,073
PMTCT_STAT_DSD	By Age (Denominator): 50+	1,929
PMTCT_STAT_DSD	By Number of known positives: 15-19	59
PMTCT_STAT_DSD	By Number of known positives: 20-24	276
PMTCT_STAT_DSD	By Number of new positives: 10-14	2
PMTCT_STAT_DSD	By Number of new positives: 15-19	130
PMTCT_STAT_DSD	By Number of new positives: 20-24	343
PMTCT_STAT_DSD	By Number of new positives: 50+	12
PMTCT_STAT_DSD	By Number of new negative: 10-14	146
PMTCT_STAT_DSD	By Number of new negative: 15-19	7,937
PMTCT_STAT_DSD	By Number of new negative: 20-24	21,202
PMTCT_STAT_DSD	By Number of new negative: 50+	816
PMTCT_STAT_DSD	By Age (Numerator): 10-14	148
PMTCT_STAT_DSD	By Age (Numerator): 15-19	8,126
PMTCT_STAT_DSD	By Age (Numerator): 20-24	21,821
PMTCT_STAT_DSD	By Age (Numerator): 50+	828
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	8,056
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	8,056
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	8,056
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	8,056
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	278
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	7,639
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	109
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	278



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	7,615
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	109
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	278
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	7,615
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	109
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	278
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	7,639
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	109
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	8,026
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	8,002
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	8,002
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	8,026
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,166
PrEP_NEW_DSD	Male 15-19	13
PrEP_NEW_DSD	Male 20-24	71
PrEP_NEW_DSD	Male 50+	24
PrEP_NEW_DSD	Female 15-19	139
PrEP_NEW_DSD	Female 20-24	469
PrEP_NEW_DSD	Female 50+	24
PrEP_NEW_DSD	FSW	166
PrEP_NEW_DSD	MSM	83
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	83
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	36



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	59
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	59
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	47
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	59
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	36
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,500
PP_PREV_DSD	Age/sex: 10-14 Male	58
PP_PREV_DSD	Age/sex: 15-19 Male	863
PP_PREV_DSD	Age/sex: 20-24 Male	1,914
PP_PREV_DSD	Age/sex: 50+ Male	465
PP_PREV_DSD	Age/sex: 10-14 Female	188
PP_PREV_DSD	Age/sex: 15-19 Female	36
PP_PREV_DSD	Age/sex: 20-24 Female	14
PP_PREV_DSD	Age/sex: 50+ Female	2
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,540
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	9
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	731
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	9
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	731
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	9
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	731
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	9
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	731
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,996
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group	1,890



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,615
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	254
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	228
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	401,336
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,029
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	829



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3,550
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,653
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	691
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,178
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	16,626
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	317
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	28,577
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	553



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	86,107
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,636
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	64,648
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,243
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,976
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	599
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,721
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	8,407
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	23



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	186
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	209
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	338
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	449
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	593
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	144
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	478
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,045
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	480
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,978
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	392
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	219
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,391
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	35



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	175
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	112
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	7,516
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	20,322
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	263
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	761
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,234
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	919
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	4,252
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male,	2,938



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	488
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	121
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	557
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	163



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	851
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	973
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	288
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	242
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	288
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	4

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	242
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	97
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	10,591
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	194
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	16,211
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	294



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	11,709
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	215
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	19,266
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	367
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	5,949
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	7,157
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	5,949
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,386
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	7,342
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	654
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	7,342
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	7,342
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	7,342



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	336
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	274
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,177
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	887
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	279
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	317
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	28



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	189
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	893
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	157

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,020
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,181
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,181
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	100
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	2,766

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	116
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,199
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	104
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,769
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	116
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,192
GEND_GBV_DSD	Number of people receiving post-GBV care	6,986
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,493
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,493
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	3,492
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	70
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	70
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	70
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	70
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	209
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	209
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	70
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	70



GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	699
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	699
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	70
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	70
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	878
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	878
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	69
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	69
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	69
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	69
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	69
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	209
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	211
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	390
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	245
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	209
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	211
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	69



	35-39, Male, Physical and/or Emotional Violence	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	69
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	209
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	211
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	69
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	69
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,005
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	589
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	416
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	324
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	324
PMTCT_EID_DSD	Sum of Infant Age disaggregates	324
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	59,381
TX_CURR_DSD	Age/Sex: 15-19 Male	1,026
TX_CURR_DSD	Age/Sex: 15-19 Female	1,892
TX_CURR_DSD	Sum of age/sex disaggregates	2,918
TX_CURR_DSD	Age/Sex: <1	31
TX_CURR_DSD	Age/Sex: <1-9	2,577



TX_CURR_DSD	Age/Sex: 10-14 Male	1,362
TX_CURR_DSD	Age/Sex: 10-14 Female	1,388
TX_CURR_DSD	Age/Sex: 20-24 Male	1,370
TX_CURR_DSD	Age/Sex: 50+ Male	965
TX_CURR_DSD	Age/Sex: 20-24 Female	5,264
TX_CURR_DSD	Age/Sex: 50+ Female	4,038
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	9,813
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,717
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,438
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,703
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	7,387
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,679
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,052
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,679
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,118
TX_NEW_DSD	By Age/Sex: <1	139
TX_NEW_DSD	By Age/Sex: 1-9	81
TX_NEW_DSD	By Age/Sex: 10-14 Male	28
TX_NEW_DSD	By Age/Sex: 15-19 Male	640
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,060
TX_NEW_DSD	By Age/Sex: 50+ Male	39
TX_NEW_DSD	By Age/Sex: 10-14 Female	15
TX_NEW_DSD	By Age/Sex: 15-19 Female	792
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,818



TX_NEW_DSD	By Age/Sex: 50+ Female	97
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,489
TX_NEW_DSD	Pregnancy status	677
TX_NEW_DSD	Breastfeeding status	68
TX_NEW_DSD	FSW	169
TX_NEW_DSD	MSM	18
TX_NEW_DSD	People in prisons and other enclosed settings	33
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	658
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	177
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	725
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	211
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	182
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	211
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	182
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	63
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	57,824
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,310
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	21,393
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,310
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	31,811



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,579
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15,138
TX_RET_DSD	Numerator by Status: Breastfeeding	2
TX_RET_DSD	Denominator by Status: Pregnant	22
TX_RET_DSD	Denominator by Status: Breastfeeding	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,451
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,128
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,593
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,990
HTS_SELF_DSD	HTS_SELF_N_DSD	13,634
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	244



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	243
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	243
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	730



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	6,817
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	6,817
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	682
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	3,408
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	2,726
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	9,133
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	2,044
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	535
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	7,905
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly	9,267



	started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	666
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	633
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,840
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,128
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	582
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	556
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,946
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,821
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	9,267
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	59,409
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,981
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,912
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	38,843
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	14,673
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,229
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	60
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,177

Implementing Mechanism Details

Mechanism ID: 18509	Mechanism Name: AMREF Nairobi Kitui
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 2,363,795	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,363,795	
Funding Source	Funding Amount
GHP-State	2,363,795

Cross-Cutting Budget Attribution(s)

Gender: GBV	6,760
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	275,240

Budget Code Information

Mechanism ID: 18509		
Mechanism Name: AMREF Nairobi Kitui		
Prime Partner Name: African Medical and Research Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	162,543
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	263,827
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	313,781
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,596,851
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	26,793

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	739
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,358
PMTCT_ART_DSD	New on ART	209
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	530
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,358
PMTCT_STAT_DSD	Number of new ANC and L&D clients	7,514
PMTCT_STAT_DSD	By Age (Denominator): 10-14	4
PMTCT_STAT_DSD	By Age (Denominator): <15-19	638



PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,564
PMTCT_STAT_DSD	By Number of known positives: 15-19	20
PMTCT_STAT_DSD	By Number of known positives: 20-24	113
PMTCT_STAT_DSD	By Number of known positives: 50+	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	18
PMTCT_STAT_DSD	By Number of new positives: 20-24	78
PMTCT_STAT_DSD	By Number of new negative: 10-14	4
PMTCT_STAT_DSD	By Number of new negative: 15-19	527
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,314
PMTCT_STAT_DSD	By Age (Numerator): 10-14	4
PMTCT_STAT_DSD	By Age (Numerator): 15-19	569
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,485
PMTCT_STAT_DSD	By Age (Numerator): 50+	1
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	1,077
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,077
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,077
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,077
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	104
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	937
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	104
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	937
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	104
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	937



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	104
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	937
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	1,076
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,076
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,076
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,076
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	225
PrEP_NEW_DSD	Male 15-19	1
PrEP_NEW_DSD	Male 20-24	8
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	21
PrEP_NEW_DSD	Female 20-24	121
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	4
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	17
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	6
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	42,969
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	40



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,693
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,808
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	8,010
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	283
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,768
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	131
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	207
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	3



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	674
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	97
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	799
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	419
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,752
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,677
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	72
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	409
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	531



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,337
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	302
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,043
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	586
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29,	360



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	432
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	432
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	527
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,091
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	38



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	610
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,297
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	166
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,242
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	166
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	415
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	948
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	135
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	948
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	948



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	948
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	19



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	1



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	143
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	176
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	176
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	59
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	436
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	423
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	244
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	161
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	239
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	155
GEND_GBV_DSD	Number of people receiving post-GBV care	355
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	178
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	178
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	45
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	11
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	37
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	37
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	2



GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	51
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	53
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	3
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	3
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	5
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	10

GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	3
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	122
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	69
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	53
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	22
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	22
PMTCT_EID_DSD	Sum of Infant Age disaggregates	22
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,220
TX_CURR_DSD	Age/Sex: 15-19 Male	189
TX_CURR_DSD	Age/Sex: 15-19 Female	352
TX_CURR_DSD	Sum of age/sex disaggregates	541
TX_CURR_DSD	Age/Sex: <1	10
TX_CURR_DSD	Age/Sex: <1-9	282
TX_CURR_DSD	Age/Sex: 10-14 Male	151
TX_CURR_DSD	Age/Sex: 10-14 Female	157
TX_CURR_DSD	Age/Sex: 20-24 Male	254
TX_CURR_DSD	Age/Sex: 50+ Male	378
TX_CURR_DSD	Age/Sex: 20-24 Female	978



TX_CURR_DSD	Age/Sex: 50+ Female	915
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,217
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	672
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,682
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,050
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,682
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,051
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,146
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,051
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,664
TX_NEW_DSD	By Age/Sex: <1	21
TX_NEW_DSD	By Age/Sex: 1-9	12
TX_NEW_DSD	By Age/Sex: 10-14 Male	2
TX_NEW_DSD	By Age/Sex: 15-19 Male	90
TX_NEW_DSD	By Age/Sex: 20-24 Male	290
TX_NEW_DSD	By Age/Sex: 50+ Male	16
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	178
TX_NEW_DSD	By Age/Sex: 20-24 Female	615
TX_NEW_DSD	By Age/Sex: 50+ Female	5
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,198
TX_NEW_DSD	Pregnancy status	199
TX_NEW_DSD	Breastfeeding status	11
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	45



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	80
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	52
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	97
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	97
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	33
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,511
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	42
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	822
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	48
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,302
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	151
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,646
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	157
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,342



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,468
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,550
TX_RET_DSD	Numerator by Status: Breastfeeding	41
TX_RET_DSD	Denominator by Status: Pregnant	231
TX_RET_DSD	Denominator by Status: Breastfeeding	34
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	717
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,694
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	767
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	32



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,727
HTS_SELF_DSD	HTS_SELF_N_DSD	436
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34,	23



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	218
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	218
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	22
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted -	109

	Self	
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	87
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	291
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	65
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	26
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,740
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,121
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	75
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	79
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,286
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	680
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	58
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	65
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,059
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	560
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,121
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	14,220
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	371
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	361



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	9,192
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	4,298
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	436
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	129
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	290

Implementing Mechanism Details

Mechanism ID: 18511	Mechanism Name: CHAK CHAP Uzima
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,654,026	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,654,026	
Funding Source	Funding Amount
GHP-State	7,654,026

Cross-Cutting Budget Attribution(s)

Gender: GBV	194,651
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation



Sub Area:	Capacity building
Motor Vehicles: Purchased	300,000
Human Resources for Health	2,834,029

Budget Code Information

Mechanism ID: 18511		
Mechanism Name: CHAK CHAP Uzima		
Prime Partner Name: Christian Health Association of Kenya		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	307,779
Strategic Area	Budget Code	Planned Amount
Care	HVTB	488,099
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	656,397
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	588,613
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,003,014
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	610,124

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,179
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,350
PMTCT_ART_DSD	New on ART	487
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,692
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,350
PMTCT_STAT_DSD	Number of new ANC and L&D clients	43,885
PMTCT_STAT_DSD	By Age (Denominator): 10-14	27
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,086
PMTCT_STAT_DSD	By Age (Denominator): 20-24	14,448
PMTCT_STAT_DSD	By Number of known positives: 15-19	33
PMTCT_STAT_DSD	By Number of known positives: 20-24	320
PMTCT_STAT_DSD	By Number of new positives: 15-19	28
PMTCT_STAT_DSD	By Number of new positives: 20-24	173
PMTCT_STAT_DSD	By Number of new negative: 10-14	17
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,452
PMTCT_STAT_DSD	By Number of new negative: 20-24	13,606
PMTCT_STAT_DSD	By Age (Numerator): 10-14	17
PMTCT_STAT_DSD	By Age (Numerator): 15-19	4,513
PMTCT_STAT_DSD	By Age (Numerator): 20-24	14,099
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	6,081
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	6,081
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	6,081
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	6,081
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	338



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,617
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	63
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	6,568
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	63
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,617
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	63
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	5,315
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	63
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	6,018
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	6,969
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	6,018
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	5,716
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,064
PrEP_NEW_DSD	Male 15-19	9
PrEP_NEW_DSD	Male 20-24	61
PrEP_NEW_DSD	Male 50+	17
PrEP_NEW_DSD	Female 15-19	128
PrEP_NEW_DSD	Female 20-24	436



PrEP_NEW_DSD	Female 50+	19
PrEP_NEW_DSD	FSW	151
PrEP_NEW_DSD	MSM	72
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	72
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	33
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	59
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	45
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	43
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	34
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	385,762
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	7,203
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	3,601
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	24,804
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	250
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	11,523
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	94



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,092
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	342
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	565
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	782
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	665
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11,649
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	209
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	14,556
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	241
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	59,314
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,044
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	28,749



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	471
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,838
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	888
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	465
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,445
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,968
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	128



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,297
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,115
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,103
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	869
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	76



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,803
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	383
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,666
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	245
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	203
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	765
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	3,731
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	54
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	184
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24,	210



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	4,521
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	13,773
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	137
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	147
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,899
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	10,865
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	370



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	6,085
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	207
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	482
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,416
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,615
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	166
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	368
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	405
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	368



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	405
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	121
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	7,642
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,698
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	8,733
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,040
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	2,182
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,040
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	18



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	2,182
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	678
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	133
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	5



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	13,711
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	265
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	10,608
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	181
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	15,537
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	296
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	12,515
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	216
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	5,681
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,324
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	5,683
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,775
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29,	5,682



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	280
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,679
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	5,684
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	5,683
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	302
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	143
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,043
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	458
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	432
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34,	492



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	101
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	142
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39,	110



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	199
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	3,370
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	134
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	884
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	4,246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,137
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	963
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	33



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,061
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	963
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	354
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	12
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,014
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,047
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	139
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,802
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	126
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	947
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	138
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases,	1,826



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	126
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	957
GEND_GBV_DSD	Number of people receiving post-GBV care	898
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	441
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	457
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	57
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	9
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	27
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	89
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	89
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	126
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	9
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	9



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	25
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	25
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	28
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	26
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	27
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	27
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	9
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	6,349



	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,019
OVC_SERV_DSD	Age/Sex: 15-17 Male	651
OVC_SERV_DSD	By: Age/sex: Male 18-24	482
OVC_SERV_DSD	By: Age/sex: Male 25+	2
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,166
OVC_SERV_DSD	Age/Sex: 15-17 Female	825
OVC_SERV_DSD	By: Age/sex: 18-24 Female	564
OVC_SERV_DSD	By: Age/sex: 25+ Female	3
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,661
OVC_SERV_DSD	Age/Sex: <1	20
OVC_SERV_DSD	Age/Sex: 1-9	1,614
OVC_SERV_DSD	Program Completion: Active	6,338
OVC_SERV_DSD	Program Completion: Graduation	11
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	5,296
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,349
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,299
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	725
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	574
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	233
PMTCT_EID_DSD	By infants who received their first virologic HIV test	233



	between 2 and 12 months of age	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	233
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	59,524
TX_CURR_DSD	Age/Sex: 15-19 Male	853
TX_CURR_DSD	Age/Sex: 15-19 Female	1,425
TX_CURR_DSD	Sum of age/sex disaggregates	2,278
TX_CURR_DSD	Age/Sex: <1	41
TX_CURR_DSD	Age/Sex: <1-9	1,680
TX_CURR_DSD	Age/Sex: 10-14 Male	1,057
TX_CURR_DSD	Age/Sex: 10-14 Female	1,060
TX_CURR_DSD	Age/Sex: 20-24 Male	1,137
TX_CURR_DSD	Age/Sex: 50+ Male	1,206
TX_CURR_DSD	Age/Sex: 20-24 Female	3,965
TX_CURR_DSD	Age/Sex: 50+ Female	4,195
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	10,138
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,134
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,689
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,335
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	7,690
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,335
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,243
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,335
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,381



TX_NEW_DSD	By Age/Sex: <1	75
TX_NEW_DSD	By Age/Sex: 1-9	121
TX_NEW_DSD	By Age/Sex: 10-14 Male	32
TX_NEW_DSD	By Age/Sex: 15-19 Male	388
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,242
TX_NEW_DSD	By Age/Sex: 50+ Male	36
TX_NEW_DSD	By Age/Sex: 10-14 Female	46
TX_NEW_DSD	By Age/Sex: 15-19 Female	734
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,524
TX_NEW_DSD	By Age/Sex: 50+ Female	122
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,124
TX_NEW_DSD	Pregnancy status	563
TX_NEW_DSD	Breastfeeding status	99
TX_NEW_DSD	FSW	87
TX_NEW_DSD	MSM	31
TX_NEW_DSD	People in prisons and other enclosed settings	69
TX_NEW_DSD	TG	2
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	852
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	196
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	970
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	251
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	239
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	233
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	237
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male,	77



	Positive	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	60,201
TX_PVLS_DSD	Denominator: Indication: Routine	51,173
TX_PVLS_DSD	Denominator: Indication: Targeted	9,030
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	162
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,411
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	168
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	6,284
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	937
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,655
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	939
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	35,641
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,732
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,953
TX_RET_DSD	Numerator by Status: Breastfeeding	68
TX_RET_DSD	Denominator by Status: Pregnant	565
TX_RET_DSD	Denominator by Status: Breastfeeding	76
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,910



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,822
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,008
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,945
HTS_SELF_DSD	HTS_SELF_N_DSD	1,078
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	59



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	17



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	539
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	539
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	54
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	269
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	217
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	723
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	162
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	65
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	14,265
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	14,976
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	660
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	624
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	9,308
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,372
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	579
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	557
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,883



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	4,246
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	15,521
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	59,519
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,111
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,264
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	37,656
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	17,489
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,510
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	220
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,204

Implementing Mechanism Details

Mechanism ID: 18512	Mechanism Name: UON COE Niche
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,682,803	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,682,803	
Funding Source	Funding Amount
GHP-State	2,682,803



Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	41,500
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	41,500
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	610,158
Renovation	148,000

Budget Code Information

Mechanism ID: 18512



Mechanism Name: UON COE Niche		
Prime Partner Name: University of Nairobi		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	150,683
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	99,625
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	639,809
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	77,480
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,523,564
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	91,642

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	316
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,907
PMTCT_ART_DSD	New on ART	54
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	262



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,907
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,907
PMTCT_STAT_DSD	By Age (Denominator): 10-14	3
PMTCT_STAT_DSD	By Age (Denominator): <15-19	407
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,638
PMTCT_STAT_DSD	By Number of known positives: 15-19	8
PMTCT_STAT_DSD	By Number of known positives: 20-24	51
PMTCT_STAT_DSD	By Number of new positives: 15-19	4
PMTCT_STAT_DSD	By Number of new positives: 20-24	20
PMTCT_STAT_DSD	By Number of new negative: 10-14	3
PMTCT_STAT_DSD	By Number of new negative: 15-19	395
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,567
PMTCT_STAT_DSD	By Age (Numerator): 10-14	3
PMTCT_STAT_DSD	By Age (Numerator): 15-19	407
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,638
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	715
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	715
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	715
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	714
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	650
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	650
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	9



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	650
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	649
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	715
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	715
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	715
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	714
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	175
PrEP_NEW_DSD	Male 15-19	2
PrEP_NEW_DSD	Male 20-24	10
PrEP_NEW_DSD	Male 50+	3
PrEP_NEW_DSD	Female 15-19	21
PrEP_NEW_DSD	Female 20-24	72
PrEP_NEW_DSD	Female 50+	3
PrEP_NEW_DSD	FSW	24
PrEP_NEW_DSD	MSM	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	7



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	5
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	82,809
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,949
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	928
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	6,712
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	135
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,970
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	28



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,175
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,180
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,494
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	277
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,431
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	7



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,091
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	149
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	182
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	149
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	182
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	212
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	358
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	350
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	353
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,571
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	4,535
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,160
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	15,621
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	170
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	6,912
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	135

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	394
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	6



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	404
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,016
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,016
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	2



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	339
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	330
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	693
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	378
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	831
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	831
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49,	277



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	646
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	646
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	646
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	646
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male,	3



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	142
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	129
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	202
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	282
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	6



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	258
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	939
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,970
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,074
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,364
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,364
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	787



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	9
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,093
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,093
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	42
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	609
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	35
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	407
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	42
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	609
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	35
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	407
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	654
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The	368



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	290
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	56
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	56
PMTCT_EID_DSD	Sum of Infant Age disaggregates	56
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	17,150
TX_CURR_DSD	Age/Sex: 15-19 Male	227
TX_CURR_DSD	Age/Sex: 15-19 Female	421
TX_CURR_DSD	Sum of age/sex disaggregates	648
TX_CURR_DSD	Age/Sex: <1	11
TX_CURR_DSD	Age/Sex: <1-9	371
TX_CURR_DSD	Age/Sex: 10-14 Male	186
TX_CURR_DSD	Age/Sex: 10-14 Female	199
TX_CURR_DSD	Age/Sex: 20-24 Male	303
TX_CURR_DSD	Age/Sex: 50+ Male	465
TX_CURR_DSD	Age/Sex: 20-24 Female	1,172
TX_CURR_DSD	Age/Sex: 50+ Female	1,095
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,641
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	824
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,005
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,288



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,005
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,287
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,367
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,287
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,278
TX_NEW_DSD	By Age/Sex: <1	16
TX_NEW_DSD	By Age/Sex: 1-9	10
TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	68
TX_NEW_DSD	By Age/Sex: 20-24 Male	218
TX_NEW_DSD	By Age/Sex: 50+ Male	13
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	143
TX_NEW_DSD	By Age/Sex: 20-24 Female	490
TX_NEW_DSD	By Age/Sex: 50+ Female	5
TX_NEW_DSD	Sum of Age/Sex disaggregates	940
TX_NEW_DSD	Pregnancy status	153
TX_NEW_DSD	Breastfeeding status	10
TX_NEW_DSD	FSW	30
TX_NEW_DSD	MSM	13
TX_NEW_DSD	People in prisons and other enclosed settings	7
TX_NEW_DSD	TG	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	30
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	62
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	33



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	74
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	74
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	23
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,479
TX_PVLS_DSD	Denominator: Indication: Routine	16,428
TX_PVLS_DSD	Denominator: Indication: Targeted	1,051
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	49
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	259
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	49
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	694
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	416
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,273
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	410
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	10,329
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,426
TX_RET_DSD	Total number of adults and children who initiated ART	2,879



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Breastfeeding	46
TX_RET_DSD	Denominator by Status: Pregnant	242
TX_RET_DSD	Denominator by Status: Breastfeeding	43
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	714
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,662
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	884
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	1,912



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	112
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	2



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	6
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	28
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	22



HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	75
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	7
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	431
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	484
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	17
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	18
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	286
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	163
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	15
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	16
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	256
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	144
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	484
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	17,150
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	391
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	378
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	10,703
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	5,678
TX_TB_DSD	Denominator: Number of ART patients who had a	561



	specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	171
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	390

Implementing Mechanism Details

Mechanism ID: 18513	Mechanism Name: LVCT Steps
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,727,557	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,727,557	
Funding Source	Funding Amount
GHP-State	5,727,557

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	157,100
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	157,109
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention



Focus Area:	Training of health workers and community outreach workers
Gender: GBV	197,483
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	246,854
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Renovation	112,244
Motor Vehicles: Purchased	102,041
Adolescent Girls and Young Women (AGYW)	3,263,522
Human Resources for Health	772,148

Budget Code Information

Mechanism ID: 18513		
Mechanism Name: LVCT Steps		
Prime Partner Name: Liverpool VCT and Care		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	831,523
Strategic Area	Budget Code	Planned Amount



Care	HVTB	51,123
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	59,097
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	627,397
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	3,594,597
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	46,905



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	516,915
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,057
PrEP_NEW_DSD	Male 15-19	11
PrEP_NEW_DSD	Male 20-24	64
PrEP_NEW_DSD	Male 50+	21
PrEP_NEW_DSD	Female 15-19	126
PrEP_NEW_DSD	Female 20-24	433
PrEP_NEW_DSD	Female 50+	21
PrEP_NEW_DSD	FSW	147
PrEP_NEW_DSD	MSM	75
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	75
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	54



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	31
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	45,754
PP_PREV_DSD	Age/sex: 10-14 Male	215
PP_PREV_DSD	Age/sex: 15-19 Male	1,814
PP_PREV_DSD	Age/sex: 20-24 Male	4,150
PP_PREV_DSD	Age/sex: 50+ Male	1,211
PP_PREV_DSD	Age/sex: 10-14 Female	1,502
PP_PREV_DSD	Age/sex: 15-19 Female	7,698
PP_PREV_DSD	Age/sex: 20-24 Female	7,197
PP_PREV_DSD	Age/sex: 50+ Female	1,175
PP_PREV_DSD	Sum of Age/Sex disaggregates	24,962
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,312
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,885
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	2,312
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,885
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	2,312
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,885
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	2,312
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	2,885
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,504
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,278
KP_PREV_DSD	By key population type: Female sex workers (FSW)	12,810



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	375
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	41
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	74,407
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,274
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	754
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	4,388
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,415
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	238



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	By Key Population: FSW, Negative	15,724
HTC_TST_DSD	By Key Population: FSW, Positive	585
HTC_TST_DSD	By Key Population: MSM, Negative	1,198
HTC_TST_DSD	By Key Population: MSM, Positive	27
HTC_TST_DSD	By Key Population: PWID, Negative	200



HTC_TST_DSD	By Key Population: PWID, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	580
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	108
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,996
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	348
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	58
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	583
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,162
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	4,766
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male,	2,139



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	16,420
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	255
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	6,843
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	126
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,007
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	253
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	40



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,191
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,430
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,430
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	290



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	348
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	348
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	5,038
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	280

	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	6,045
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	6,045
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2,016
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	38
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	16
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	16
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	1



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
GEND_GBV_DSD	Number of people receiving post-GBV care	21,239
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	10,622
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	10,620
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	6,297
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	213
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	213
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	213
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	213
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	637
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	637
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	213
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	213
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	2,123
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	2,125
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	212



GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	213
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	2,973
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,972
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	214
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	213
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	211
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	214
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	213
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	214
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	637
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	637
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	212
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	212
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	637
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	637
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	212
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	212
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	637
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	637
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	212
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	212



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	637
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	637
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	212
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	212
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,402
OVC_SERVDSD	Age/Sex: 10-14 Male	2,655
OVC_SERVDSD	Age/Sex: 15-17 Male	1,685
OVC_SERVDSD	By: Age/sex: Male 18-24	1,095
OVC_SERVDSD	By: Age/sex: Male 25+	4
OVC_SERVDSD	Age/Sex: 10-14 Female	3,335
OVC_SERVDSD	Age/Sex: 15-17 Female	4,609
OVC_SERVDSD	By: Age/sex: 18-24 Female	2,739
OVC_SERVDSD	By: Age/sex: 25+ Female	2
OVC_SERVDSD	Sum of Age/Sex disaggregates	12,284
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,406
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	5,279
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	3,339
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	327
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	213
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	122
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	277



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	28
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	83
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	52
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	414
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	448
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	242
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	544
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	157
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	71
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	254
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	556
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,091
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	221
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	137
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	94



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,876
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	11,585
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	7,530
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	332
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	212
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	135
OVC_SERV_DSD	Age/Sex: <1	20
OVC_SERV_DSD	Age/Sex: 1-9	4,255
OVC_SERV_DSD	Program Completion: Active	20,348
OVC_SERV_DSD	Program Completion: Graduation	54
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	16,560
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,402
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	17
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TX_CURR_DSD	Number of adults and children receiving antiretroviral	4,272



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	68
TX_CURR_DSD	Age/Sex: 15-19 Female	152
TX_CURR_DSD	Sum of age/sex disaggregates	220
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	67
TX_CURR_DSD	Age/Sex: 10-14 Male	24
TX_CURR_DSD	Age/Sex: 10-14 Female	26
TX_CURR_DSD	Age/Sex: 20-24 Male	92
TX_CURR_DSD	Age/Sex: 50+ Male	124
TX_CURR_DSD	Age/Sex: 20-24 Female	419
TX_CURR_DSD	Age/Sex: 50+ Female	249
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	599
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	218
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	454
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	338
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	454
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	338
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	311
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	338
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,012
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	2
TX_NEW_DSD	By Age/Sex: 10-14 Male	1



TX_NEW_DSD	By Age/Sex: 15-19 Male	41
TX_NEW_DSD	By Age/Sex: 20-24 Male	133
TX_NEW_DSD	By Age/Sex: 50+ Male	22
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	38
TX_NEW_DSD	By Age/Sex: 20-24 Female	385
TX_NEW_DSD	Sum of Age/Sex disaggregates	621
TX_NEW_DSD	Pregnancy status	86
TX_NEW_DSD	Breastfeeding status	24
TX_NEW_DSD	FSW	11
TX_NEW_DSD	MSM	2
TX_NEW_DSD	People in prisons and other enclosed settings	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	100
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	119
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	119
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	39
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,458
TX_PVLS_DSD	Denominator: Indication: Routine	3,275
TX_PVLS_DSD	Denominator: Indication: Targeted	183
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	5
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	66



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	5
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	107
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	46
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,100
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	48
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,081
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	75
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	129
TX_RET_DSD	Numerator by Status: Breastfeeding	3
TX_RET_DSD	Denominator by Status: Pregnant	10
TX_RET_DSD	Denominator by Status: Breastfeeding	4
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	87



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	21,511
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	63
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,149



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	1,149
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	10,787
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	10,724
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	1,073
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	5,362

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	4,289
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	14,372
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	3,218
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	1,287
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	257
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	261
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	11
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	16
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	143
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	90
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	11
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	11
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	141
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	93
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	261
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	257
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	4,195
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	185



TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	230
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	2,510
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,271
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	219
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	12
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	200

Implementing Mechanism Details

Mechanism ID: 18514	Mechanism Name: HWWK Nairobi Eastern
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,598,213	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,598,213	
Funding Source	Funding Amount
GHP-State	3,598,213

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	34,880
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance



Key Populations: FSW	229,895
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	21,900
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: Gender Equality	574,523
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	1,431,855
Human Resources for Health	628,809

Budget Code Information

Mechanism ID: 18514		
Mechanism Name: HWWK Nairobi Eastern		
Prime Partner Name: Hope Worldwide		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	318,957
Strategic Area	Budget Code	Planned Amount



Care	HVTB	10,368
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	280,535
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	447,068
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	2,436,447
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	103,485
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,353

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	403
PrEP_NEW_DSD	Male 15-19	3
PrEP_NEW_DSD	Male 20-24	24
PrEP_NEW_DSD	Male 50+	7
PrEP_NEW_DSD	Female 15-19	49
PrEP_NEW_DSD	Female 20-24	166
PrEP_NEW_DSD	Female 50+	7
PrEP_NEW_DSD	FSW	56
PrEP_NEW_DSD	MSM	27
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	27
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	17
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	17



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	17
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	10
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,792
PP_PREV_DSD	Age/sex: 10-14 Male	157
PP_PREV_DSD	Age/sex: 15-19 Male	1,187
PP_PREV_DSD	Age/sex: 20-24 Male	1,130
PP_PREV_DSD	Age/sex: 50+ Male	111
PP_PREV_DSD	Age/sex: 10-14 Female	1,342
PP_PREV_DSD	Age/sex: 15-19 Female	3,456
PP_PREV_DSD	Age/sex: 20-24 Female	3,055
PP_PREV_DSD	Age/sex: 50+ Female	57
PP_PREV_DSD	Sum of Age/Sex disaggregates	10,495
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	264
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	524
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	264
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	669
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	264
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	524
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	264
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	524
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	30,850
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,092
KP_PREV_DSD	By key population type: Female sex workers (FSW)	27,104



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	589
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	65
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	67,054
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	623
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	313
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,145
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	999
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	35



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	294
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	140
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,016
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	449
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	24



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	137
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	589
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	571
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	94
HTC_TST_DSD	By Key Population: FSW, Negative	29,704
HTC_TST_DSD	By Key Population: FSW, Positive	728
HTC_TST_DSD	By Key Population: MSM, Negative	1,532
HTC_TST_DSD	By Key Population: MSM, Positive	56
HTC_TST_DSD	By Key Population: PWID, Negative	122



HTC_TST_DSD	By Key Population: PWID, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	139
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	73
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	445
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	233
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female,	4,740



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4,073
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	16,330
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	296
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	13,031
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	219
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	530
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	241
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	2



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	249
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	286
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	2

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	303
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	71
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	303
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	71
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	101
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	9



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	29



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	3,713
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,210
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	4,246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,450
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,060
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	18

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,450
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,060
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	484
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	8
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	10
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	10
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
GEND_GBV_DSD	Number of people receiving post-GBV care	18,050
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	9,025
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	9,026
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	7,039



GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	181
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	<10, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	<10, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	543
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	542
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	1,674
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,806
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	2,530
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,527
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	181
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	542
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	542
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	603
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	593
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3	181



	30-34, Male, Physical and/or Emotional Violence	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	542
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	542
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	181
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	542
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	542
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	181
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	181
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,063
OVC_SERVDSD	Age/Sex: 10-14 Male	895
OVC_SERVDSD	Age/Sex: 15-17 Male	459
OVC_SERVDSD	By: Age/sex: Male 18-24	262
OVC_SERVDSD	By: Age/sex: Male 25+	4
OVC_SERVDSD	Age/Sex: 10-14 Female	1,684
OVC_SERVDSD	Age/Sex: 15-17 Female	1,221
OVC_SERVDSD	By: Age/sex: 18-24 Female	808
OVC_SERVDSD	By: Age/sex: 25+ Female	15
OVC_SERVDSD	Sum of Age/Sex disaggregates	4,259
OVC_SERVDSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,891



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,175
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	698
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	85
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	116
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	35
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	797
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	230
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	435
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	186
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	156
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	75
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	396
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	444



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	181
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	467
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	606
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,001
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	4,255
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	3,675
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	151
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	282
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	236
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	29
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	3



OVC_SERV_DSD	Age/Sex: <1	94
OVC_SERV_DSD	Age/Sex: 1-9	2,623
OVC_SERV_DSD	Program Completion: Active	8,036
OVC_SERV_DSD	Program Completion: Graduation	27
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	6,976
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,063
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	11
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	921
TX_CURR_DSD	Age/Sex: 15-19 Male	17
TX_CURR_DSD	Age/Sex: 15-19 Female	27
TX_CURR_DSD	Sum of age/sex disaggregates	44
TX_CURR_DSD	Age/Sex: 20-24 Male	20
TX_CURR_DSD	Age/Sex: 50+ Male	20
TX_CURR_DSD	Age/Sex: 20-24 Female	75
TX_CURR_DSD	Age/Sex: 50+ Female	68
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	163
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	36



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	124
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	54
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	124
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	54
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	85
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	54
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	433
TX_NEW_DSD	By Age/Sex: 15-19 Male	25
TX_NEW_DSD	By Age/Sex: 20-24 Male	99
TX_NEW_DSD	By Age/Sex: 50+ Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	47
TX_NEW_DSD	By Age/Sex: 20-24 Female	146
TX_NEW_DSD	By Age/Sex: 50+ Female	2
TX_NEW_DSD	Sum of Age/Sex disaggregates	320
TX_NEW_DSD	Pregnancy status	28
TX_NEW_DSD	Breastfeeding status	4
TX_NEW_DSD	FSW	5
TX_NEW_DSD	MSM	1
TX_NEW_DSD	People in prisons and other enclosed settings	5
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	27
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	10
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	34
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male,	12



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	12
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	707
TX_PVLS_DSD	Denominator: Indication: Routine	707
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	130
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	577
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	134
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	158
TX_RET_DSD	Numerator by Status: Pregnant	12
TX_RET_DSD	Numerator by Status: Breastfeeding	1
TX_RET_DSD	Denominator by Status: Pregnant	12
TX_RET_DSD	Denominator by Status: Breastfeeding	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	92
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	50



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	108
HTS_SELF_DSD	HTS_SELF_N_DSD	52,466
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	935



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	2,814
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	2,814
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	949
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	949
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	2,810
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	26,233
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	26,233

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	2,623
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	13,117
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	10,493
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	35,153
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	7,868
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	3,149
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	80
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	85
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	3
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	54
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	26
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	3
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	15
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	50
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	12
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	85
TX_TB_DSD	Number of ART patients who were screened for TB at	4,186



	least once during the reporting period	
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	202
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	201
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	2,763
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,019
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	46
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	6
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	37

Implementing Mechanism Details

Mechanism ID: 18515	Mechanism Name: Faith-Based Sites in the Eastern Slums of Nairobi
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Deanery AIDS Relief Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,737,135	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,737,135	
Funding Source	Funding Amount
GHP-State	5,737,135

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	30,937
Focus Area:	Training of health workers and community outreach



	workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	72,238
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	89,149
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	689,796
Motor Vehicles: Purchased	58,100
Renovation	25,200

Budget Code Information

Mechanism ID: 18515		
Mechanism Name: Faith-Based Sites in the Eastern Slums of Nairobi		
Prime Partner Name: Eastern Deanery AIDS Relief Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	271,263
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,004,916
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,047,448
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	293,973
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,949,995
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	169,540

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,000
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,741
PMTCT_ART_DSD	New on ART	511
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,489
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,741
PMTCT_STAT_DSD	Number of new ANC and L&D clients	17,273
PMTCT_STAT_DSD	By Age (Denominator): 10-14	10
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,423



PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,709
PMTCT_STAT_DSD	By Age (Denominator): 50+	1
PMTCT_STAT_DSD	By Number of known positives: 15-19	47
PMTCT_STAT_DSD	By Number of known positives: 20-24	278
PMTCT_STAT_DSD	By Number of new positives: 15-19	40
PMTCT_STAT_DSD	By Number of new positives: 20-24	188
PMTCT_STAT_DSD	By Number of new negative: 10-14	10
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,143
PMTCT_STAT_DSD	By Number of new negative: 20-24	5,089
PMTCT_STAT_DSD	By Number of new negative: 50+	1
PMTCT_STAT_DSD	By Age (Numerator): 10-14	10
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,230
PMTCT_STAT_DSD	By Age (Numerator): 20-24	5,555
PMTCT_STAT_DSD	By Age (Numerator): 50+	1
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,484
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,678
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,484
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2,484
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	307
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	2,095
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	75
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	307
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,132
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	75
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	307
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	2,095



	35-39, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	75
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	307
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,095
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	75
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,477
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,514
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,477
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,477
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	21,836
VMMC_CIRC_DSD	By Age: 10-14	13,066
VMMC_CIRC_DSD	By Age: 15-19	6,683
VMMC_CIRC_DSD	By Age: 20-24	1,128
VMMC_CIRC_DSD	By Age: 25-29	924
VMMC_CIRC_DSD	By Age: 50+	35
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	20,912
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	21,836
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	21,345
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	494
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	525
PrEP_NEW_DSD	Male 15-19	6
PrEP_NEW_DSD	Male 20-24	31
PrEP_NEW_DSD	Male 50+	10
PrEP_NEW_DSD	Female 15-19	63
PrEP_NEW_DSD	Female 20-24	215



PrEP_NEW_DSD	Female 50+	10
PrEP_NEW_DSD	FSW	73
PrEP_NEW_DSD	MSM	37
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	38
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	16
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	21
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	21
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	16
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	122,646
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	540
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	542
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,523
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,117
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	18



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,520
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	10



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,665
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	3,993
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,993
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	390
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	186
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	36



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,344
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	240
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,310
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	119
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	234
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	632
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,159
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	5,165
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,705
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	153



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4,146
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	29,977
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	526
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	13,261
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	233
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	258
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	755
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	231
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	627
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	17



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	153
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	316
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	382
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	43



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	382
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,127
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	349
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,127
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,127
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,127
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	13



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,804
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	3,783
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,061
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,538
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	515



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	4,538
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	515
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,512
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,664
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	20
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,569
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,578
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	60
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	875
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	584



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	61
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	876
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	57
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	584
GEND_GBV_DSD	Number of people receiving post-GBV care	1,463
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	732
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	731
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	179
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	15
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	44
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	14
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	146
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	148
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	204
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	207
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	15



GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	16
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	45
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	44
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	15



	40-49, Male, Physical and/or Emotional Violence	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	14
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	629
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	351
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	278
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	70
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	70
PMTCT_EID_DSD	Sum of Infant Age disaggregates	70
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	32,674
TX_CURR_DSD	Age/Sex: 15-19 Male	430
TX_CURR_DSD	Age/Sex: 15-19 Female	801
TX_CURR_DSD	Sum of age/sex disaggregates	1,231
TX_CURR_DSD	Age/Sex: <1	24
TX_CURR_DSD	Age/Sex: <1-9	706
TX_CURR_DSD	Age/Sex: 10-14 Male	355
TX_CURR_DSD	Age/Sex: 10-14 Female	379
TX_CURR_DSD	Age/Sex: 20-24 Male	578
TX_CURR_DSD	Age/Sex: 50+ Male	883
TX_CURR_DSD	Age/Sex: 20-24 Female	2,232
TX_CURR_DSD	Age/Sex: 50+ Female	2,085
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,032



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,569
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,823
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,451
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,820
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,451
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,604
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,451
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,835
TX_NEW_DSD	By Age/Sex: <1	48
TX_NEW_DSD	By Age/Sex: 1-9	26
TX_NEW_DSD	By Age/Sex: 10-14 Male	4
TX_NEW_DSD	By Age/Sex: 15-19 Male	203
TX_NEW_DSD	By Age/Sex: 20-24 Male	654
TX_NEW_DSD	By Age/Sex: 50+ Male	38
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	427
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,474
TX_NEW_DSD	By Age/Sex: 50+ Female	15
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,817
TX_NEW_DSD	Pregnancy status	458
TX_NEW_DSD	Breastfeeding status	32
TX_NEW_DSD	FSW	89
TX_NEW_DSD	MSM	40
TX_NEW_DSD	People in prisons and other enclosed settings	22
TX_NEW_DSD	TG	8



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	89
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	186
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	102
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	24
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	24
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	75
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	34,448
TX_PVLS_DSD	Denominator: Indication: Routine	32,037
TX_PVLS_DSD	Denominator: Indication: Targeted	2,411
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	53
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	799
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	53
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,506
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	707
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,604
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	732



	Female Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	19,994
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,113
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,051
TX_RET_DSD	Numerator by Status: Breastfeeding	116
TX_RET_DSD	Denominator by Status: Pregnant	592
TX_RET_DSD	Denominator by Status: Breastfeeding	133
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,552
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,433
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	77
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,943
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	73



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,958
HTS_SELF_DSD	HTS_SELF_N_DSD	1,060
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	19



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	530
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	530



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	53
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	265
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	212
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	710
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	159
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	64
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,499
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,985
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	72
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	72
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,175
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	667
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	48
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	57
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	889
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	504
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,984
TX_TB_DSD	Number of ART patients who were screened for TB at	32,586



	least once during the reporting period	
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	745
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	719
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	20,336
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	10,786
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,065
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	322
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	706

Implementing Mechanism Details

Mechanism ID: 18516	Mechanism Name: Bomu Hospital Affiliated Sites
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mkomani Society Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,162,707	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,162,707	
Funding Source	Funding Amount
GHP-State	4,162,707

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	87,409
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	94,610
Adolescent Girls and Young Women (AGYW)	1,158,754

Budget Code Information

Mechanism ID: 18516		
Mechanism Name: Bomu Hospital Affiliated Sites		
Prime Partner Name: Mkomani Society Clinic		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	431,519
Strategic Area	Budget Code	Planned Amount
Care	HVTB	205,240
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	72,724
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	246,615
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	654,511
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	202,840
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	112,926
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,006,360
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	229,972

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	896
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,635
PMTCT_ART_DSD	New on ART	137
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	759
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,635
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,561
PMTCT_STAT_DSD	By Age (Denominator): 10-14	5
PMTCT_STAT_DSD	By Age (Denominator): <15-19	196
PMTCT_STAT_DSD	By Age (Denominator): 20-24	886
PMTCT_STAT_DSD	By Age (Denominator): 50+	38
PMTCT_STAT_DSD	By Number of known positives: 15-19	21
PMTCT_STAT_DSD	By Number of known positives: 20-24	164
PMTCT_STAT_DSD	By Number of new positives: 15-19	15
PMTCT_STAT_DSD	By Number of new positives: 20-24	48
PMTCT_STAT_DSD	By Number of new negative: 15-19	140
PMTCT_STAT_DSD	By Number of new negative: 20-24	719
PMTCT_STAT_DSD	By Number of new negative: 50+	7
PMTCT_STAT_DSD	By Age (Numerator): 15-19	171
PMTCT_STAT_DSD	By Age (Numerator): 20-24	902
PMTCT_STAT_DSD	By Age (Numerator): 50+	8
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	359
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	359
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	359



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	359
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	130
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	224
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	21
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	130
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	224
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	21
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	130
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	235
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	21
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	130
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	234
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	21
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	435
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	249
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	435
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	435
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	488
PrEP_NEW_DSD	Male 15-19	5
PrEP_NEW_DSD	Male 20-24	29



PrEP_NEW_DSD	Male 50+	10
PrEP_NEW_DSD	Female 15-19	58
PrEP_NEW_DSD	Female 20-24	204
PrEP_NEW_DSD	Female 50+	10
PrEP_NEW_DSD	FSW	68
PrEP_NEW_DSD	MSM	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	15
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	24
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	19
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	24
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	19
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	24
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	15
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,454
PP_PREV_DSD	Age/sex: 10-14 Male	4
PP_PREV_DSD	Age/sex: 15-19 Male	16
PP_PREV_DSD	Age/sex: 20-24 Male	24
PP_PREV_DSD	Age/sex: 50+ Male	11
PP_PREV_DSD	Age/sex: 10-14 Female	758
PP_PREV_DSD	Age/sex: 15-19 Female	2,303
PP_PREV_DSD	Age/sex: 20-24 Female	1,113
PP_PREV_DSD	Age/sex: 50+ Female	4
PP_PREV_DSD	Sum of Age/Sex disaggregates	4,233
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	36
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	36
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	36



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	36
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	437
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	417
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	20
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,495
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	204



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	619
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	491
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	328
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	864
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,137
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,756
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	103
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	151



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,427
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	806
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	66



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	188
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	31
HTC_TST_DSD	By Key Population: FSW, Negative	109
HTC_TST_DSD	By Key Population: FSW, Positive	2
HTC_TST_DSD	By Key Population: MSM, Negative	16
HTC_TST_DSD	By Key Population: PWID, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,467
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,979
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	135
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	360
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	464
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	142
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	8



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	4

HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	12



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	714
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	531
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	656
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	304
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	215

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	304
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,813
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,813
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,813
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,813
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	159



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	6



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	408
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	468
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	73



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	3
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	643
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	633
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	384
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	217



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	373
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	218
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,720
OVC_SERV_DSD	Age/Sex: 10-14 Male	841
OVC_SERV_DSD	Age/Sex: 15-17 Male	426
OVC_SERV_DSD	By: Age/sex: Male 18-24	233
OVC_SERV_DSD	By: Age/sex: Male 25+	5
OVC_SERV_DSD	Age/Sex: 10-14 Female	850
OVC_SERV_DSD	Age/Sex: 15-17 Female	450
OVC_SERV_DSD	By: Age/sex: 18-24 Female	208
OVC_SERV_DSD	By: Age/sex: 25+ Female	5
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,567
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	226
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,371
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,642
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	904
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	274



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	409
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	274
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	328
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	821
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,507
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,742
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	3,284
OVC_SERV_DSD	Age/Sex: <1	25
OVC_SERV_DSD	Age/Sex: 1-9	1,677
OVC_SERV_DSD	Program Completion: Active	4,717
OVC_SERV_DSD	Program Completion: Graduation	3
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	4,309
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,720
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	451
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	270
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	181



	TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	264
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	264
PMTCT_EID_DSD	Sum of Infant Age disaggregates	264
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	25,504
TX_CURR_DSD	Age/Sex: 15-19 Male	809
TX_CURR_DSD	Age/Sex: 15-19 Female	884
TX_CURR_DSD	Sum of age/sex disaggregates	1,693
TX_CURR_DSD	Age/Sex: <1	13
TX_CURR_DSD	Age/Sex: <1-9	641
TX_CURR_DSD	Age/Sex: 10-14 Male	691
TX_CURR_DSD	Age/Sex: 10-14 Female	689
TX_CURR_DSD	Age/Sex: 20-24 Male	1,078
TX_CURR_DSD	Age/Sex: 50+ Male	493
TX_CURR_DSD	Age/Sex: 20-24 Female	2,466
TX_CURR_DSD	Age/Sex: 50+ Female	1,533
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,691
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	882
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,809
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,371
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,809
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,365
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,915



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,365
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,069
TX_NEW_DSD	By Age/Sex: <1	18
TX_NEW_DSD	By Age/Sex: 1-9	154
TX_NEW_DSD	By Age/Sex: 10-14 Male	53
TX_NEW_DSD	By Age/Sex: 15-19 Male	186
TX_NEW_DSD	By Age/Sex: 20-24 Male	596
TX_NEW_DSD	By Age/Sex: 50+ Male	6
TX_NEW_DSD	By Age/Sex: 10-14 Female	66
TX_NEW_DSD	By Age/Sex: 15-19 Female	71
TX_NEW_DSD	By Age/Sex: 20-24 Female	244
TX_NEW_DSD	By Age/Sex: 50+ Female	28
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,250
TX_NEW_DSD	Pregnancy status	166
TX_NEW_DSD	Breastfeeding status	17
TX_NEW_DSD	FSW	5
TX_NEW_DSD	People in prisons and other enclosed settings	29
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	196
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	30
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	226
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	36
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	56
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	36
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49,	56



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	12
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	26,919
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	35
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	93
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	398
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	248
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	226
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,970
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	215
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,180
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	510
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,337
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	480
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	12,227
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,937
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,967
TX_RET_DSD	Numerator by Status: Breastfeeding	9
TX_RET_DSD	Denominator by Status: Pregnant	256



TX_RET_DSD	Denominator by Status: Breastfeeding	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	511
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,426
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	689
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,278
HTS_SELF_DSD	HTS_SELF_N_DSD	288
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	5



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	16



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	144
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	144
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	15
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	72
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	58
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	193
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	17
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	108
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,028
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	99
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	72
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,820



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,039
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	3
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	2
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	69
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	33
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,028
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	22,297
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	938
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	924
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	11,681
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	8,753
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	788
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	109
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	601

Implementing Mechanism Details

Mechanism ID: 18517	Mechanism Name: UOW Training
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	



Funding Source	Funding Amount
GHP-State	250,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	12,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	43,000

Budget Code Information

Mechanism ID: 18517		
Mechanism Name: UOW Training		
Prime Partner Name: University of Washington		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	22,500
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	227,500
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18670	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18678	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70108	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70109	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 70110	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70111	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70112	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70150	Mechanism Name: OPTIMIZE
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Reproductive Health& HIV Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70150 Mechanism Name: OPTIMIZE Prime Partner Name: Wits Reproductive Health& HIV Institute		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	500,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 80036	Mechanism Name: FELTP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Task Force for Global Health Inc.	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 259,680	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 259,680	
Funding Source	Funding Amount
GHP-State	259,680

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	80036	
Mechanism Name:	FELTP	
Prime Partner Name:	Task Force for Global Health Inc.	
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	259,680

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		209,947		209,947	0	209,947
Computers/IT Services		731,500		731,500	0	731,500
ICASS		1,291,069		1,291,069	0	1,291,069
Management Meetings/Professional Development		598,294		598,294	0	598,294
Non-ICASS Administrative Costs		641,721		641,721	0	641,721
Staff Program Travel		2,364,120		2,364,120	0	2,364,120
USG Staff Salaries and Benefits - Internationally Recruited		1,182,290		1,182,290	468,196	1,650,486
USG Staff Salaries and Benefits - Locally Recruited		5,239,532		5,239,532	0	5,239,532



Total	0	12,258,473	0	12,258,473	468,196	12,726,669
--------------	----------	-------------------	----------	-------------------	----------------	-------------------

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		16,823		16,823	38,647	55,470
ICASS		12,770		12,770	29,336	42,106
Institutional Contractors		463,299		463,299	1,064,308	1,527,607
Management Meetings/Professional Development		20,655		20,655	47,449	68,104
Non-ICASS Administrative Costs		160,016		160,016	367,632	527,648
Non-ICASS Motor Vehicles		53,622		53,622	123,183	176,805
Staff Program Travel		141,281		141,281	324,557	465,838
USG Staff Salaries and Benefits - Internationally Recruited		25,894		25,894	59,486	85,380
USG Staff Salaries and Benefits -		108,280		108,280	248,747	357,027



Locally Recruited						
Total	0	1,002,640	0	1,002,640	2,303,345	3,305,985

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		975,179		975,179	739,542	1,714,721
Computers/IT Services		0		0	822,192	822,192
ICASS		1,400,000		1,400,000	0	1,400,000
Institutional Contractors				0	60,000	60,000
Management Meetings/Professional Development		0		0	139,479	139,479
Non-ICASS Administrative Costs		98,372		98,372	506,800	605,172
Staff Program Travel		0		0	1,502,913	1,502,913
USG Staff Salaries and Benefits - Internationally Recruited	3,320,000	1,479,050		4,799,050	0	4,799,050



USG Staff Salaries and Benefits - Locally Recruited	0	7,223,535		7,223,535	0	7,223,535
Total	3,320,000	11,176,136	0	14,496,136	3,770,926	18,267,062

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		425,833		425,833	0	425,833
Institutional Contractors				0	0	0
Management Meetings/Professional Development		0		0	286,000	286,000
Non-ICASS Administrative Costs		0		0	54,000	54,000
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel				0	89,999	89,999
USG Staff Salaries and Benefits - Internationally Recruited		443,723		443,723	0	443,723

Approved



USG Staff Salaries and Benefits - Locally Recruited				0	676,682	676,682
Total	0	869,556	0	869,556	1,106,681	1,976,237